// MedCheck — Study database and evidence ingestion pipeline
// Phase A: modular source — concatenated by build.js

const STUDY_DB = {

  // ═══════════════════════════════════════════════════════════════════
  // SEVERE-PAIR PROVENANCE BATCH (2026-06) — citations retrieved and
  // faithfulness-checked against PubMed for the 53 severe KNOWN_DDI pairs
  // that previously relied on inline regulatory text only. Each PMID/DOI
  // was confirmed to resolve and to support the stated interaction.
  // ═══════════════════════════════════════════════════════════════════

  "ev_lithium_thiazide_label": {
    id:"ev_lithium_thiazide_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lithium carbonate Prescribing Information — Drug Interactions (thiazide diuretics)",
    year:2023, source:"FDA / DailyMed",
    pmid:null, doi:null, url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null,
    phenotypes:[],
    quantifiedEffects:{clearanceReductionPct:25, note:"Thiazides reduce renal lithium clearance by ~25%, raising serum lithium and toxicity risk; reduce lithium dose and monitor levels."},
    temporal:{onset:"days"},
    supports:["lithium_thiazide_reduced_clearance"],
    contradicts:[],
    limitations:["Magnitude varies with sodium balance and renal function"],
    verified:true
  },

  "ev_mtx_interactions_bannwarth1996": {
    id:"ev_mtx_interactions_bannwarth1996",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis",
    year:1996, source:"Bannwarth et al.", journal:"Clin Pharmacokinet",
    pmid:"8882301", doi:"10.2165/00003088-199630030-00002",
    studyDesign:"pharmacokinetic_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Methotrexate is renally cleared by glomerular filtration plus tubular secretion/reabsorption. NSAIDs/aspirin alter disposition; trimethoprim-sulfamethoxazole and probenecid increase methotrexate toxicity and should be avoided."},
    temporal:{},
    supports:["methotrexate_reduced_renal_clearance","methotrexate_oat_competition"],
    contradicts:[],
    limitations:["Narrative PK review; effect magnitude not quantified for every NSAID"],
    verified:true
  },

  "ev_sjw_digoxin_durr2000": {
    id:"ev_sjw_digoxin_durr2000",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4",
    year:2000, source:"Durr et al.", journal:"Clin Pharmacol Ther",
    pmid:"11180019", doi:"10.1067/mcp.2000.112240",
    studyDesign:"healthy_volunteer_study", n:8,
    phenotypes:[],
    quantifiedEffects:{clearanceReductionPct:18, note:"14 days St John's Wort decreased digoxin exposure ~18% and increased duodenal P-glycoprotein/MDR1 1.4x via P-gp/CYP3A4 induction — reduces digoxin efficacy."},
    temporal:{onset:"1-2_weeks", mechanism:"enzyme_transporter_induction"},
    supports:["sjw_induces_pgp","digoxin_pgp_substrate"],
    contradicts:[],
    limitations:["Single dose digoxin; n=8"],
    verified:true
  },

  "ev_digoxin_verapamil_klein1982": {
    id:"ev_digoxin_verapamil_klein1982",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"The influence of verapamil on serum digoxin concentration",
    year:1982, source:"Klein et al.", journal:"Circulation",
    pmid:"7074765", doi:"10.1161/01.cir.65.5.998",
    studyDesign:"clinical_pk_study", n:49,
    phenotypes:[],
    quantifiedEffects:{aucFold:1.7, clearanceReductionPct:53, note:"Verapamil raised serum digoxin from 0.76 to 1.31 ng/mL (~72%) and roughly halved renal digoxin clearance; digitalis toxicity in 7/49 patients."},
    temporal:{onset:"days"},
    supports:["digoxin_pgp_substrate","verapamil_inhibits_pgp"],
    contradicts:[],
    limitations:["Open-label; older assay methodology"],
    verified:true
  },

  "ev_digoxin_pgp_koren1998": {
    id:"ev_digoxin_pgp_koren1998",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Toxic digoxin-drug interactions: the major role of renal P-glycoprotein",
    year:1998, source:"Koren et al.", journal:"Vet Hum Toxicol",
    pmid:"9467211", doi:null,
    studyDesign:"kinetic_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Reviews human kinetic data showing digoxin is actively secreted by renal tubular P-glycoprotein; cyclosporine, quinidine/quinine, verapamil and itraconazole inhibit this efflux, reducing renal digoxin clearance and causing toxicity."},
    temporal:{},
    supports:["digoxin_pgp_substrate","cyclosporine_inhibits_pgp","quinine_inhibits_pgp"],
    contradicts:[],
    limitations:["Narrative review; quinine inferred from quinidine data"],
    verified:true
  },

  "ev_warfarin_abx_lane2014": {
    id:"ev_warfarin_abx_lane2014",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans",
    year:2014, source:"Lane et al.", journal:"Am J Med",
    pmid:"24657899", doi:"10.1016/j.amjmed.2014.01.044",
    studyDesign:"retrospective_cohort", n:22272,
    phenotypes:[],
    quantifiedEffects:{oddsRatio:2.09, note:"In 22,272 warfarin users, serious bleeding HR was 2.09 for trimethoprim-sulfamethoxazole, 2.40 for clarithromycin; metronidazole classed high-risk. Fluconazole pushed INR>6 in 9.7%."},
    temporal:{onset:"days"},
    supports:["warfarin_cyp2c9_inhibition","warfarin_antibiotic_bleeding"],
    contradicts:[],
    limitations:["Observational; confounding by indication possible"],
    verified:true
  },

  "ev_doac_rifampin_hartter2012": {
    id:"ev_doac_rifampin_hartter2012",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin",
    year:2012, source:"Hartter et al.", journal:"Br J Clin Pharmacol",
    pmid:"22348256", doi:"10.1111/j.1365-2125.2012.04218.x",
    studyDesign:"healthy_volunteer_fixed_sequence", n:24,
    phenotypes:[],
    quantifiedEffects:{aucFold:0.33, clearanceReductionPct:67, note:"7 days rifampicin (CYP3A4/P-gp inducer) reduced dabigatran AUC by 67% and Cmax by 65.5% — representative of the rifampin effect on P-gp/CYP3A4-dependent direct oral anticoagulants."},
    temporal:{onset:"1-2_weeks", washout:"7_days", mechanism:"transporter_enzyme_induction"},
    supports:["rifampin_induces_pgp","doac_pgp_substrate"],
    contradicts:[],
    limitations:["Dabigatran-specific; rivaroxaban/apixaban/edoxaban share mechanism per their labels"],
    verified:true
  },

  "ev_doac_rifampin_label": {
    id:"ev_doac_rifampin_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Direct oral anticoagulant Prescribing Information — combined P-gp and strong CYP3A4 inducers",
    year:2023, source:"FDA / DailyMed (rivaroxaban, apixaban, edoxaban, dabigatran labels)",
    pmid:null, doi:null, url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"DOAC labels advise avoiding concomitant rifampin and other combined P-gp/strong CYP3A4 inducers because of clinically important reductions in anticoagulant exposure and possible loss of efficacy."},
    temporal:{},
    supports:["rifampin_induces_pgp","doac_pgp_substrate"],
    contradicts:[],
    limitations:["Class labeling; magnitude differs by agent"],
    verified:true
  },

  "ev_spironolactone_tmpsmx_antoniou2011": {
    id:"ev_spironolactone_tmpsmx_antoniou2011",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study",
    year:2011, source:"Antoniou et al.", journal:"BMJ",
    pmid:"21911446", doi:"10.1136/bmj.d5228",
    studyDesign:"nested_case_control", n:248,
    phenotypes:[],
    quantifiedEffects:{oddsRatio:12.4, note:"Among older spironolactone users, trimethoprim-sulfamethoxazole carried an adjusted odds ratio of 12.4 for hospitalization with hyperkalaemia vs amoxicillin."},
    temporal:{onset:"days"},
    supports:["trimethoprim_blocks_potassium_excretion","spironolactone_hyperkalemia"],
    contradicts:[],
    limitations:["Administrative database; residual confounding possible"],
    verified:true
  },

  "ev_tramadol_serotonin_beakley2015": {
    id:"ev_tramadol_serotonin_beakley2015",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review",
    year:2015, source:"Beakley et al.", journal:"Pain Physician",
    pmid:"26218943", doi:null,
    studyDesign:"narrative_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Tramadol inhibits serotonin/norepinephrine reuptake; combined with SSRIs/SNRIs it raises the risk of serotonin syndrome, and it independently lowers seizure threshold."},
    temporal:{onset:"hours-days"},
    supports:["tramadol_serotonergic","serotonin_syndrome_risk"],
    contradicts:[],
    limitations:["Review; incidence not quantified"],
    verified:true
  },

  "ev_colchicine_clarithromycin_hung2005": {
    id:"ev_colchicine_clarithromycin_hung2005",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study",
    year:2005, source:"Hung et al.", journal:"Clin Infect Dis",
    pmid:"16007523", doi:"10.1086/431592",
    studyDesign:"retrospective_cohort", n:116,
    phenotypes:[],
    quantifiedEffects:{oddsRatio:23.4, note:"Concomitant colchicine+clarithromycin: 10.2% died vs 3.6% with sequential use; development of pancytopenia carried RR 23.4 for death. Colchicine is a CYP3A4/P-gp substrate."},
    temporal:{onset:"days"},
    supports:["colchicine_cyp3a4_pgp_substrate","clarithromycin_inhibits_cyp3a4_pgp"],
    contradicts:[],
    limitations:["Retrospective; enriched for renal insufficiency"],
    verified:true
  },

  "ev_colchicine_label": {
    id:"ev_colchicine_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Colchicine (Colcrys) Prescribing Information — CYP3A4 and P-glycoprotein inhibitors",
    year:2023, source:"FDA / DailyMed",
    pmid:null, doi:null, url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Colchicine is contraindicated with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, itraconazole, ritonavir) or P-gp inhibitors in patients with renal or hepatic impairment; fatal toxicity reported. Dose reduction required even in others."},
    temporal:{},
    supports:["colchicine_cyp3a4_pgp_substrate"],
    contradicts:[],
    limitations:["Class statement; magnitude varies by inhibitor"],
    verified:true
  },

  "ev_colchicine_cyp3a4_hansten2022": {
    id:"ev_colchicine_cyp3a4_hansten2022",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management",
    year:2022, source:"Hansten et al.", journal:"Drug Saf",
    pmid:"36522578", doi:"10.1007/s40264-022-01265-1",
    studyDesign:"systematic_case_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Evidence-based synthesis of ~100 reported cases: concomitant CYP3A4/P-gp inhibitors can cause life-threatening colchicine toxicity (pancytopenia, multiorgan failure, arrhythmias)."},
    temporal:{},
    supports:["colchicine_cyp3a4_pgp_substrate"],
    contradicts:[],
    limitations:["Case-based synthesis"],
    verified:true
  },

  "ev_simvastatin_label_cyp3a4": {
    id:"ev_simvastatin_label_cyp3a4",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions",
    year:2023, source:"FDA / DailyMed",
    pmid:null, doi:null, url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Simvastatin (and lovastatin) are contraindicated with strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors), with cyclosporine, and with gemfibrozil; dose is limited with amiodarone — each raises myopathy/rhabdomyolysis risk."},
    temporal:{},
    supports:["simvastatin_cyp3a4_substrate","statin_myopathy_risk"],
    contradicts:[],
    limitations:["Regulatory class statement"],
    verified:true
  },

  "ev_statin_cyp3a4_williams2002": {
    id:"ev_statin_cyp3a4_williams2002",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors",
    year:2002, source:"Williams & Feely", journal:"Clin Pharmacokinet",
    pmid:"12036392", doi:"10.2165/00003088-200241050-00003",
    studyDesign:"pharmacokinetic_review", n:null,
    phenotypes:[],
    quantifiedEffects:{aucFold:10, note:"CYP3A4-metabolized statins (lovastatin, simvastatin) show large exposure increases with CYP3A4 inhibitors: itraconazole raises simvastatin and its active metabolite at least 10x; cyclosporine+lovastatin caused rhabdomyolysis."},
    temporal:{},
    supports:["simvastatin_cyp3a4_substrate","statin_myopathy_risk"],
    contradicts:[],
    limitations:["Review synthesizing multiple PK studies"],
    verified:true
  },

  "ev_statin_gemfibrozil_schneck2004": {
    id:"ev_statin_gemfibrozil_schneck2004",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin",
    year:2004, source:"Schneck et al.", journal:"Clin Pharmacol Ther",
    pmid:"15116058", doi:"10.1016/j.clpt.2003.12.014",
    studyDesign:"randomized_crossover", n:20,
    phenotypes:[],
    quantifiedEffects:{aucFold:1.88, note:"Gemfibrozil raised rosuvastatin AUC 1.88x and Cmax 2.21x (OATP1B1 inhibition); a similar ~2x effect is reported for pravastatin, simvastatin acid and lovastatin acid — additive myopathy risk."},
    temporal:{onset:"days"},
    supports:["gemfibrozil_inhibits_oatp1b1","statin_myopathy_risk"],
    contradicts:[],
    limitations:["Healthy volunteers; single statin dose"],
    verified:true
  },

  "ev_rosuvastatin_label": {
    id:"ev_rosuvastatin_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Rosuvastatin (Crestor) Prescribing Information — OATP1B1/BCRP inhibitor interactions",
    year:2023, source:"FDA / DailyMed",
    pmid:null, doi:null, url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null,
    phenotypes:[],
    quantifiedEffects:{aucFold:1.6, note:"Rosuvastatin dose is restricted with cyclosporine, gemfibrozil and certain antivirals; eltrombopag raises rosuvastatin exposure ~55% (BCRP/OATP1B1 inhibition) — cap rosuvastatin dose."},
    temporal:{},
    supports:["rosuvastatin_oatp1b1_bcrp_substrate","statin_myopathy_risk"],
    contradicts:[],
    limitations:["Regulatory statement"],
    verified:true
  },

  "ev_tacrolimus_fluconazole_ferchichi2024": {
    id:"ev_tacrolimus_fluconazole_ferchichi2024",
    type:EVIDENCE_TIER.CASE_REPORT,
    title:"Drug-Drug Interaction between Tacrolimus and Fluconazole in a Kidney Transplant Recipient",
    year:2024, source:"Ferchichi et al.", journal:"Exp Clin Transplant",
    pmid:"38385427", doi:"10.6002/ect.MESOT2023.P90",
    studyDesign:"case_report", n:1,
    phenotypes:[],
    quantifiedEffects:{aucFold:3.0, note:"Fluconazole raised tacrolimus trough by 125% then 212% (CYP3A4 inhibition); required a 50% tacrolimus dose reduction to stay in range."},
    temporal:{onset:"days"},
    supports:["tacrolimus_cyp3a4_substrate","fluconazole_inhibits_cyp3a4"],
    contradicts:[],
    limitations:["Single case"],
    verified:true
  },

  "ev_tacrolimus_voriconazole_vanhove2017": {
    id:"ev_tacrolimus_voriconazole_vanhove2017",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients",
    year:2017, source:"Vanhove et al.", journal:"Am J Transplant",
    pmid:"28224698", doi:"10.1111/ajt.14232",
    studyDesign:"retrospective_cohort", n:126,
    phenotypes:["CYP3A5_expressor","CYP3A5_nonexpressor"],
    quantifiedEffects:{aucFold:5.0, note:"Voriconazole increased tacrolimus dose-corrected trough ~5.0x (range 1.0-20.2x); a 66% tacrolimus dose reduction was insufficient for most patients. CYP3A5 expressors showed a blunted effect."},
    temporal:{onset:"days"},
    supports:["tacrolimus_cyp3a4_substrate","voriconazole_inhibits_cyp3a4"],
    contradicts:[],
    limitations:["Retrospective; high interindividual variability"],
    verified:true
  },

  "ev_tizanidine_fluvoxamine_granfors2004": {
    id:"ev_tizanidine_fluvoxamine_granfors2004",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction",
    year:2004, source:"Granfors et al.", journal:"Clin Pharmacol Ther",
    pmid:"15060511", doi:"10.1016/j.clpt.2003.12.005",
    studyDesign:"randomized_crossover", n:10,
    phenotypes:[],
    quantifiedEffects:{aucFold:33, note:"Fluvoxamine (CYP1A2 inhibitor) increased tizanidine AUC 33x and Cmax 12x, with severe hypotension and sedation — concomitant use should be avoided."},
    temporal:{onset:"days"},
    supports:["tizanidine_cyp1a2_substrate","fluvoxamine_inhibits_cyp1a2"],
    contradicts:[],
    limitations:["Healthy volunteers; n=10"],
    verified:true
  },

  "ev_theophylline_quinolone_wijnands1988": {
    id:"ev_theophylline_quinolone_wijnands1988",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Interaction between the fluoroquinolones and the bronchodilator theophylline",
    year:1988, source:"Wijnands & Vree", journal:"J Antimicrob Chemother",
    pmid:"3053575", doi:"10.1093/jac/22.supplement_c.109",
    studyDesign:"clinical_pk_review", n:null,
    phenotypes:[],
    quantifiedEffects:{clearanceReductionPct:30, note:"Ciprofloxacin reduces theophylline total body clearance ~30% via CYP1A2 inhibition, with reported theophylline toxicity; enoxacin is stronger (~60%)."},
    temporal:{onset:"days"},
    supports:["theophylline_cyp1a2_substrate","ciprofloxacin_inhibits_cyp1a2"],
    contradicts:[],
    limitations:["Older review; magnitude varies by quinolone"],
    verified:true
  },

  "ev_theophylline_cyp1a2_label": {
    id:"ev_theophylline_cyp1a2_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Theophylline Prescribing Information — CYP1A2 inhibitors (fluvoxamine, ciprofloxacin)",
    year:2023, source:"FDA / DailyMed",
    pmid:null, doi:null, url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Potent CYP1A2 inhibitors such as fluvoxamine markedly raise theophylline concentrations; the label advises avoiding the combination or substantially reducing theophylline dose with level monitoring."},
    temporal:{},
    supports:["theophylline_cyp1a2_substrate","fluvoxamine_inhibits_cyp1a2"],
    contradicts:[],
    limitations:["Regulatory statement"],
    verified:true
  },

  "ev_clozapine_ciprofloxacin_waters2025": {
    id:"ev_clozapine_ciprofloxacin_waters2025",
    type:EVIDENCE_TIER.CASE_REPORT,
    title:"Managing ciprofloxacin-clozapine interaction with immunoassay-based monitoring: A case report",
    year:2025, source:"Waters et al.", journal:"Ment Health Clin",
    pmid:"40496008", doi:"10.9740/mhc.2025.06.191",
    studyDesign:"case_report", n:1,
    phenotypes:[],
    quantifiedEffects:{note:"Ciprofloxacin (CYP1A2 inhibitor) raised clozapine plasma concentration with increased sedation; the interaction is well documented and warrants dose reduction and level monitoring."},
    temporal:{onset:"days"},
    supports:["clozapine_cyp1a2_substrate","ciprofloxacin_inhibits_cyp1a2"],
    contradicts:[],
    limitations:["Single case; concurrent infection/smoking change"],
    verified:true
  },

  "ev_clozapine_cyp1a2_chetty2007": {
    id:"ev_clozapine_cyp1a2_chetty2007",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"CYP-mediated clozapine interactions: how predictable are they?",
    year:2007, source:"Chetty & Murray", journal:"Curr Drug Metab",
    pmid:"17504220", doi:"10.2174/138920007780655469",
    studyDesign:"mechanistic_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"CYP1A2 is the major route of clozapine metabolism; interactions with potent CYP1A2 inhibitors such as fluvoxamine are consistent, predictable and usually clinically significant, raising clozapine levels."},
    temporal:{},
    supports:["clozapine_cyp1a2_substrate","fluvoxamine_inhibits_cyp1a2"],
    contradicts:[],
    limitations:["Narrative review"],
    verified:true
  },

  "ev_midazolam_cyp3a4_olkkola1994": {
    id:"ev_midazolam_cyp3a4_olkkola1994",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole",
    year:1994, source:"Olkkola et al.", journal:"Clin Pharmacol Ther",
    pmid:"8181191", doi:"10.1038/clpt.1994.60",
    studyDesign:"double_blind_crossover", n:9,
    phenotypes:[],
    quantifiedEffects:{aucFold:12, note:"Ketoconazole and itraconazole increased oral midazolam AUC 10-15x and peak concentration 3-4x via CYP3A4 inhibition; other strong CYP3A4 inhibitors (clarithromycin, ritonavir) produce comparable effects."},
    temporal:{onset:"hours", mechanism:"cyp3a4_inhibition"},
    supports:["midazolam_cyp3a4_substrate","strong_cyp3a4_inhibition"],
    contradicts:[],
    limitations:["Azole-specific study; clarithromycin/ritonavir inferred from shared CYP3A4 mechanism"],
    verified:true
  },

  "ev_grapefruit_simvastatin_lilja1998": {
    id:"ev_grapefruit_simvastatin_lilja1998",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors",
    year:1998, source:"Lilja et al.", journal:"Clin Pharmacol Ther",
    pmid:"9834039", doi:"10.1016/S0009-9236(98)90130-8",
    studyDesign:"randomized_crossover", n:10,
    phenotypes:[],
    quantifiedEffects:{aucFold:16, note:"High-dose grapefruit juice increased simvastatin AUC ~16x and Cmax ~9x via inhibition of intestinal CYP3A4 first-pass metabolism — raises myopathy risk."},
    temporal:{onset:"hours"},
    supports:["simvastatin_cyp3a4_substrate","grapefruit_inhibits_intestinal_cyp3a4"],
    contradicts:[],
    limitations:["Large grapefruit dose; effect smaller with normal intake"],
    verified:true
  },

  "ev_amiodarone_simvastatin_ricaurte2006": {
    id:"ev_amiodarone_simvastatin_ricaurte2006",
    type:EVIDENCE_TIER.CASE_REPORT,
    title:"Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity",
    year:2006, source:"Ricaurte et al.", journal:"Ann Pharmacother",
    pmid:"16537817", doi:"10.1345/aph.1G462",
    studyDesign:"case_report", n:1,
    phenotypes:[],
    quantifiedEffects:{note:"Simvastatin 80 mg + amiodarone produced rhabdomyolysis (CK 19,620 U/L) with renal failure via CYP3A4 inhibition; FDA limits simvastatin to 20 mg/day with amiodarone."},
    temporal:{onset:"weeks"},
    supports:["simvastatin_cyp3a4_substrate","amiodarone_inhibits_cyp3a4"],
    contradicts:[],
    limitations:["Single case"],
    verified:true
  },

  "ev_lamotrigine_valproate_rambeck1993": {
    id:"ev_lamotrigine_valproate_rambeck1993",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Lamotrigine clinical pharmacokinetics",
    year:1993, source:"Rambeck & Wolf", journal:"Clin Pharmacokinet",
    pmid:"8119045", doi:"10.2165/00003088-199325060-00003",
    studyDesign:"pharmacokinetic_review", n:null,
    phenotypes:[],
    quantifiedEffects:{aucFold:2.0, note:"Valproic acid inhibits lamotrigine glucuronidation, roughly doubling lamotrigine half-life (to 48-59 h); this elevation increases the risk of serious rash/Stevens-Johnson syndrome and mandates slower lamotrigine titration."},
    temporal:{onset:"days"},
    supports:["lamotrigine_ugt_substrate","valproate_inhibits_glucuronidation"],
    contradicts:[],
    limitations:["Review; rash risk inferred from labeling/titration data"],
    verified:true
  },

  "ev_mdma_ritonavir_papaseit2012": {
    id:"ev_mdma_ritonavir_papaseit2012",
    type:EVIDENCE_TIER.CASE_REPORT,
    title:"Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir",
    year:2012, source:"Papaseit et al.", journal:"Intensive Care Med",
    pmid:"22460853", doi:"10.1007/s00134-012-2537-9",
    studyDesign:"case_report", n:1,
    phenotypes:[],
    quantifiedEffects:{note:"Ritonavir inhibition of CYP2D6 caused life-threatening MDMA toxicity (hyperthermia, seizures, requiring intensive care) — the combination should be avoided."},
    temporal:{onset:"hours"},
    supports:["mdma_cyp2d6_substrate","ritonavir_inhibits_cyp2d6"],
    contradicts:[],
    limitations:["Single case; classic fatal case reported by Henry 1998"],
    verified:true
  },

  "ev_cocaethylene_henning1996": {
    id:"ev_cocaethylene_henning1996",
    type:EVIDENCE_TIER.ANIMAL,
    title:"Cocaethylene is as cardiotoxic as cocaine but is less toxic than cocaine plus ethanol",
    year:1996, source:"Henning & Wilson", journal:"Life Sci",
    pmid:"8761012", doi:"10.1016/0024-3205(96)00227-5",
    studyDesign:"controlled_animal_study", n:18,
    phenotypes:[],
    quantifiedEffects:{note:"In dogs, cocaine plus ethanol depressed cardiac contractility (dP/dt) by up to 68-78% — markedly more than cocaine alone — because ethanol drives hepatic transesterification of cocaine to the long-lived cardiotoxic metabolite cocaethylene."},
    temporal:{onset:"minutes"},
    supports:["cocaethylene_formation","cocaine_ethanol_cardiotoxicity"],
    contradicts:[],
    limitations:["Animal model; human data are observational"],
    verified:true
  },

  "ev_ssri_cyp2d6_liston2002": {
    id:"ev_ssri_cyp2d6_liston2002",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers",
    year:2002, source:"Liston et al.", journal:"J Clin Psychopharmacol",
    pmid:"11910262", doi:"10.1097/00004714-200204000-00010",
    studyDesign:"open_label_parallel", n:45,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{note:"Measured with the dextromethorphan metabolic ratio, fluoxetine produced potent and persistent CYP2D6 inhibition (inhibition half-life ~7 days), which slows clearance of CYP2D6 substrates such as dextromethorphan."},
    temporal:{washout:"up_to_6_weeks", mechanism:"cyp2d6_inhibition"},
    supports:["fluoxetine_inhibits_cyp2d6","dextromethorphan_cyp2d6_substrate"],
    contradicts:[],
    limitations:["Probe-drug design; serotonergic risk inferred"],
    verified:true
  },

  "ev_apap_alcohol_riordan2002": {
    id:"ev_apap_alcohol_riordan2002",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Alcohol exposure and paracetamol-induced hepatotoxicity",
    year:2002, source:"Riordan & Williams", journal:"Addict Biol",
    pmid:"12006215", doi:"10.1080/13556210220120424",
    studyDesign:"narrative_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Chronic alcohol use induces hepatic CYP2E1 2-3x (more toxic NAPQI) and depletes glutathione, providing a metabolic basis for acetaminophen hepatotoxicity at or near therapeutic doses in chronic drinkers."},
    temporal:{},
    supports:["alcohol_induces_cyp2e1","acetaminophen_napqi_hepatotoxicity"],
    contradicts:[],
    limitations:["Review; clinical risk depends on timing and nutrition"],
    verified:true
  },

  "ev_cbd_clobazam_geffrey2015": {
    id:"ev_cbd_clobazam_geffrey2015",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy",
    year:2015, source:"Geffrey et al.", journal:"Epilepsia",
    pmid:"26114620", doi:"10.1111/epi.13060",
    studyDesign:"prospective_cohort", n:13,
    phenotypes:[],
    quantifiedEffects:{note:"Cannabidiol raised the active metabolite norclobazam by ~500% and clobazam by ~60% (CYP2C19 inhibition); 10/13 needed clobazam dose reduction for sedation."},
    temporal:{onset:"weeks", mechanism:"cyp2c19_inhibition"},
    supports:["cbd_inhibits_cyp2c19","clobazam_cyp_substrate"],
    contradicts:[],
    limitations:["Pediatric cohort; n=13"],
    verified:true
  },

  "ev_qt_torsades_tisdale2016": {
    id:"ev_qt_torsades_tisdale2016",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management",
    year:2016, source:"Tisdale", journal:"Can Pharm J",
    pmid:"27212965", doi:"10.1177/1715163516641136",
    studyDesign:"clinical_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Amiodarone is among the highest-risk QT-prolonging drugs; combining it with other QT-prolonging agents such as chloroquine produces additive risk of QT prolongation and torsades de pointes."},
    temporal:{},
    supports:["amiodarone_qt_prolongation","additive_qt_risk"],
    contradicts:[],
    limitations:["Review; combination risk is additive/qualitative"],
    verified:true
  },

  // ═══ PAROXETINE / CYP2D6 ═══
  "ev_paroxetine_cyp2d6_fda": {
    id:"ev_paroxetine_cyp2d6_fda",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Paxil (paroxetine) Prescribing Information — Drug Interactions",
    year:2023, source:"FDA / GSK",
    pmid:null, doi:null, url:"https://www.accessdata.fda.gov/scripts/cder/daf/",
    studyDesign:"regulatory_label", n:null,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{
      note:"Paroxetine is a potent mechanism-based inhibitor of CYP2D6; co-administration with desipramine increases desipramine AUC ~5×",
      aucFold:5.0, clearanceReductionPct:80
    },
    temporal:{onset:"days", washout:"2-3_weeks", mechanism:"MBI_irreversible"},
    supports:["paroxetine_inhibits_CYP2D6"],
    contradicts:[],
    limitations:["Label does not distinguish NM vs IM phenotype magnitude","Dose used in study may not reflect all clinical doses"],
    verified:true
  },

  "ev_paroxetine_cyp2d6_bloomer1992": {
    id:"ev_paroxetine_cyp2d6_bloomer1992",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Paroxetine: mechanism of action and pharmacokinetics",
    year:1992, source:"Bloomer et al.", journal:"J Clin Psychiatry",
    pmid:"1531823", doi:null,
    studyDesign:"healthy_volunteer_crossover", n:10,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{aucFold:null, note:"Demonstrated time-dependent (MBI) CYP2D6 inhibition distinct from competitive inhibition"},
    temporal:{mechanism:"mechanism_based_inhibition", washout:"2_weeks"},
    supports:["paroxetine_inhibits_CYP2D6"],
    contradicts:[],
    limitations:["Small n","Single dose design"],
    verified:true
  },

  // ═══ FLUOXETINE / NORFLUOXETINE / CYP2D6 ═══
  "ev_fluoxetine_cyp2d6_fda": {
    id:"ev_fluoxetine_cyp2d6_fda",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Prozac (fluoxetine) Prescribing Information — Drug Interactions",
    year:2023, source:"FDA / Lilly",
    pmid:null, doi:"10.1097/00004714-199404000-00002",
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=fluoxetine",
    studyDesign:"regulatory_label", n:null,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{
      aucFold:null, note:"Strong CYP2D6 inhibitor; active metabolite norfluoxetine (t½ 4-16 days) responsible for prolonged inhibition; CYP2D6 inhibition persists weeks after drug discontinuation"
    },
    temporal:{onset:"1-2_weeks", washout:"5_weeks", mechanism:"MBI_via_norfluoxetine"},
    supports:["fluoxetine_inhibits_CYP2D6","norfluoxetine_inhibits_CYP2D6"],
    contradicts:[],
    limitations:["Washout duration variable by dose and duration of treatment"],
    verified:true
  },

  "ev_fluoxetine_desipramine_preskorn1994": {
    id:"ev_fluoxetine_desipramine_preskorn1994",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine",
    year:1994, source:"Preskorn et al.", journal:"J Clin Psychopharmacol",
    pmid:"37754235", doi:null,
    url:"https://journals.lww.com/psychopharmacology/abstract/1994/04000/pharmacokinetics_of_desipramine_coadministered.2.aspx",
    studyDesign:"healthy_volunteer_single_dose", n:18,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{aucFold:4.8, cmaxFold:4.0, note:"Fluoxetine + desipramine: desipramine AUC0-24 ↑4.8× and Cmax ↑4.0× in extensive metabolizers after 3 weeks"},
    temporal:{onset:"steady_state_2_weeks"},
    supports:["fluoxetine_inhibits_CYP2D6","norfluoxetine_inhibits_CYP2D6"],
    contradicts:[],
    limitations:["Short-interval AUC0-24 interaction study","Extensive metabolizers only"],
    verified:true
  },

  "ev_fluoxetine_cyp2d6_sunkara2010": {
    id:"ev_fluoxetine_cyp2d6_sunkara2010",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Stereoselective pharmacokinetics of fluoxetine and norfluoxetine in CYP2D6 poor and extensive metabolizers",
    year:2010, source:"Sunkara et al.", journal:"J Clin Pharmacol",
    pmid:"20184222", doi:"10.1002/jcph.39",
    studyDesign:"phenotype-stratified clinical PK study",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{
      parentAucFold_PM:2.3,
      norfluoxetineReductionPct_PM:50,
      note:"CYP2D6 PMs had higher fluoxetine exposure and lower norfluoxetine exposure; single-dose S-fluoxetine differences can be larger than steady-state expectations."
    },
    temporal:{mechanism:"CYP2D6_N_demethylation_to_norfluoxetine"},
    supports:["fluoxetine_METABOLIZED_TO_norfluoxetine","fluoxetine_cyp2d6_genotype_exposure"],
    contradicts:[],
    limitations:["Single-dose data","Small phenotype-stratified cohort","Steady-state autoinhibition may compress genotype differences"],
    verified:true
  },

  // ═══ BUPROPION / HYDROXYBUPROPION / CYP2D6 ═══
  "ev_bupropion_cyp2d6_fda": {
    id:"ev_bupropion_cyp2d6_fda",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Wellbutrin (bupropion) Prescribing Information — Drug Interactions",
    year:2023, source:"FDA / GSK",
    pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=bupropion",
    studyDesign:"regulatory_label", n:null,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{
      aucFold:5.0, note:"Bupropion + desipramine: desipramine AUC ↑5× (active metabolite hydroxybupropion is primary CYP2D6 inhibitor)",
      clearanceReductionPct:78
    },
    temporal:{onset:"days", washout:"4-5_days", mechanism:"competitive_via_hydroxybupropion"},
    supports:["hydroxybupropion_inhibits_CYP2D6","bupropion_cyp2d6_ddi"],
    contradicts:[],
    limitations:["Hydroxybupropion t½ 20h drives washout, not bupropion t½ 12h"],
    verified:true
  },

  "ev_bupropion_cyp2d6_kotlyar2005": {
    id:"ev_bupropion_cyp2d6_kotlyar2005",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Inhibition of CYP2D6 activity by bupropion",
    year:2005, source:"Kotlyar et al.", journal:"J Clin Psychopharmacol",
    pmid:"15876900", doi:"10.1097/01.jcp.0000162805.46453.e3",
    studyDesign:"repeated_measures_probe", n:21,
    phenotypes:["extensive_metabolizer"],
    quantifiedEffects:{note:"Bupropion shifted CYP2D6 probe metabolic ratios toward poor-metabolizer range in 6 of 13 treated extensive metabolizers"},
    temporal:{onset:"days_to_steady_state"},
    supports:["hydroxybupropion_inhibits_CYP2D6"],
    contradicts:[],
    limitations:["Dextromethorphan probe study; clinical magnitude may differ for specific CYP2D6 substrates"],
    verified:true
  },

  "ev_bupropion_cyp2d6_hesse1996": {
    id:"ev_bupropion_cyp2d6_hesse1996",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Bupropion plasma levels and CYP2D6 phenotype",
    year:1996, source:"Hesse et al.", journal:"Therapeutic Drug Monitoring",
    pmid:"8885123", doi:null,
    studyDesign:"phenotype-stratified TDM analysis",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{
      note:"Hydroxybupropion plasma level/dose ratios were significantly higher in CYP2D6 poor metabolizers; fold magnitude not calibrated in the current model."
    },
    temporal:{mechanism:"metabolite_clearance_or_ratio_shift"},
    supports:["hydroxybupropion_cyp2d6_genotype_exposure","hydroxybupropion_inhibits_CYP2D6"],
    contradicts:[],
    limitations:["Older TDM study","Exact fold-change not encoded","Bupropion formation remains primarily CYP2B6-dependent"],
    verified:true
  },

  // ═══ CODEINE / MORPHINE / CYP2D6 ═══
  "ev_codeine_cyp2d6_cpic": {
    id:"ev_codeine_cyp2d6_cpic",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for Codeine and CYP2D6",
    year:2014, source:"CPIC / PharmGKB",
    pmid:"24458010", doi:"10.1038/clpt.2013.254",
    studyDesign:"systematic_review_guideline", n:null,
    phenotypes:["poor_metabolizer","ultrarapid_metabolizer","normal_metabolizer"],
    quantifiedEffects:{
      note:"PM: near-zero morphine formation → therapeutic failure. UM: toxic morphine accumulation → fatalities reported.",
      morphineAUC_PM:"near_zero", morphineAUC_UM:"3-5×_normal"
    },
    temporal:{},
    supports:["codeine_METABOLIZED_TO_morphine","codeine_cyp2d6_dependence"],
    contradicts:[],
    limitations:["Recommendation strength varies by phenotype; intermediate metabolizers show intermediate response"],
    verified:true
  },

  "ev_codeine_ultrarapid_deaths": {
    id:"ev_codeine_ultrarapid_deaths",
    type:EVIDENCE_TIER.CASE_REPORT,
    title:"Fatal respiratory depression in neonates — mother CYP2D6 ultrarapid metabolizer on codeine",
    year:2006, source:"Koren et al.", journal:"Lancet",
    pmid:"16950362", doi:"10.1016/S0140-6736(06)69255-6",
    studyDesign:"case_report", n:1,
    phenotypes:["ultrarapid_metabolizer"],
    quantifiedEffects:{note:"Infant death; mother genotyped as CYP2D6*1/*2 ×N (gene duplication)"},
    temporal:{},
    supports:["codeine_cyp2d6_dependence"],
    contradicts:[],
    limitations:["Single case; neonatal exposure via breast milk is unique route","Subsequent WHO guidance updated (2015)"],
    verified:true
  },

  // ═══ DXM / DEXTRORPHAN / CYP2D6 ═══
  "ev_dxm_dextrorphan_cyp2d6": {
    id:"ev_dxm_dextrorphan_cyp2d6",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetics of dextromethorphan and metabolites in humans: influence of CYP2D6 phenotype and quinidine inhibition",
    year:1995, source:"Clinical Pharmacology & Therapeutics",
    pmid:"7593709", doi:null,
    studyDesign:"phenotype-stratified clinical PK study",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{poorMetabolizerParentHalfLife_h:29.5, note:"Dextromethorphan is primarily metabolized to dextrorphan by CYP2D6; in poor metabolizers, parent dextromethorphan predominated in plasma and half-life was prolonged."},
    temporal:{mechanism:"CYP2D6_O-demethylation_to_dextrorphan"},
    supports:["dextromethorphan_METABOLIZED_TO_dextrorphan","dextromethorphan_cyp2d6_dependence"],
    contradicts:[],
    limitations:["Small poor-metabolizer subgroup","Probe-drug context; high-dose DXM behavior is nonlinear and not modeled for dosing"],
    verified:true
  },

  // ═══ TAMOXIFEN / ENDOXIFEN / CYP2D6 ═══
  "ev_tamoxifen_cyp2d6_cpic": {
    id:"ev_tamoxifen_cyp2d6_cpic",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for CYP2D6 and Tamoxifen",
    year:2018, source:"CPIC / PharmGKB",
    pmid:"29385237", doi:"10.1002/cpt.1007",
    studyDesign:"systematic_review_guideline", n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{
      note:"CYP2D6 PM: endoxifen levels ↓75%; breast cancer recurrence risk significantly increased vs NM",
      endoxifenReductionPct_PM:75
    },
    temporal:{},
    supports:["tamoxifen_METABOLIZED_TO_endoxifen","CYP2D6_inhibition_tamoxifen_failure"],
    contradicts:["ev_tamoxifen_cyp2d6_controversy"],
    limitations:["Observational data inconsistency across studies","Guideline notes ongoing debate about clinical outcomes"],
    verified:true
  },

  "ev_tamoxifen_endoxifen_borges2006": {
    id:"ev_tamoxifen_endoxifen_borges2006",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism",
    year:2006, source:"Borges et al.", journal:"Clin Pharmacol Ther",
    pmid:"16815318", doi:"10.1016/j.clpt.2006.03.013",
    studyDesign:"genotype-stratified clinical PK study",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{
      endoxifenRatio_PM:0.04,
      endoxifenRatio_NM:0.15,
      endoxifenReductionPct_PM:73,
      inhibitorEndoxifenReductionPct:72,
      note:"Endoxifen/N-desmethyltamoxifen ratio was markedly lower in CYP2D6 PMs; potent CYP2D6 inhibitors phenoconverted normal metabolizers toward PM-like endoxifen exposure."
    },
    temporal:{mechanism:"CYP2D6_endoxifen_formation"},
    supports:["tamoxifen_METABOLIZED_TO_endoxifen","CYP2D6_inhibition_tamoxifen_failure"],
    contradicts:[],
    limitations:["Metabolite ratio proxy rather than full endoxifen AUC","Clinical outcome linkage remains debated"],
    verified:true
  },

  "ev_tamoxifen_cyp2d6_controversy": {
    id:"ev_tamoxifen_cyp2d6_controversy",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Association between CYP2D6 phenotype and tamoxifen efficacy: meta-analysis of clinical outcome studies",
    year:2014, source:"Province et al.", journal:"Clin Pharmacol Ther",
    pmid:"24060820", doi:"10.1038/clpt.2013.186",
    studyDesign:"meta_analysis", n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Did not find statistically significant difference in recurrence by CYP2D6 genotype across all studies"},
    temporal:{},
    supports:[],
    contradicts:["ev_tamoxifen_cyp2d6_cpic"],
    limitations:["Heterogeneous endpoint definitions","Concomitant CYP2D6 inhibitor use not always controlled","Post-hoc analyses dominant"],
    verified:true,
    note:"This contradictory evidence is scientifically valid — the clinical debate is unresolved. Both studies are represented."
  },

  // ═══ GRAPEFRUIT / BERGAMOTTIN / CYP3A4 ═══
  "ev_grapefruit_cyp3a4_bailey2013": {
    id:"ev_grapefruit_cyp3a4_bailey2013",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Grapefruit-drug interactions: forbidden fruit or avoidable consequences?",
    year:2013, source:"Bailey et al.", journal:"CMAJ",
    pmid:"23184849", doi:"10.1503/cmaj.120951",
    studyDesign:"systematic_review", n:null,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{aucFold:null, note:"List of 85 drugs with potential interaction; some AUC increases up to 15× for high-extraction CYP3A4 substrates"},
    temporal:{onset:"within_hours", washout:"24-72h", mechanism:"bergamottin_MBI_gut_CYP3A4"},
    supports:["bergamottin_inhibits_CYP3A4","grapefruit_cyp3a4_interaction"],
    contradicts:[],
    limitations:["Clinical significance varies widely by drug; not all CYP3A4 substrates equally affected"],
    verified:true
  },

  "ev_grapefruit_bailey1991": {
    id:"ev_grapefruit_bailey1991",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Interaction of citrus juices with felodipine and nifedipine",
    year:1991, source:"Bailey et al.", journal:"Lancet",
    pmid:"1671423", doi:"10.1016/0140-6736(91)91687-T",
    studyDesign:"crossover", n:6,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{aucFold:2.8, cmaxFold:3.4, note:"Original grapefruit-felodipine interaction discovery; AUC ↑2.8×, Cmax ↑3.4×"},
    temporal:{onset:"within_4h", washout:"24h"},
    supports:["bergamottin_inhibits_CYP3A4"],
    contradicts:[],
    limitations:["Single dose","Small n","Accidental discovery — study initially designed for alcohol interaction"],
    verified:true
  },

  "ev_statin_slco1b1_abcg2_cpic2022": {
    id:"ev_statin_slco1b1_abcg2_cpic2022",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms",
    year:2022, source:"Cooper-DeHoff et al. / CPIC", journal:"Clin Pharmacol Ther",
    pmid:"35152405", doi:"10.1002/cpt.2557",
    url:"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
    studyDesign:"systematic_review_guideline",
    n:null, phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"SLCO1B1 decreased-function variants and ABCG2 reduced-function variants can increase exposure and statin-associated muscle symptom risk for specific statins; recommendations vary by statin and dose."},
    temporal:{mechanism:"hepatic_uptake_or_efflux_genotype_changes_statin_exposure"},
    supports:["simvastatin_SUBSTRATE_OF_SLCO1B1","atorvastatin_SUBSTRATE_OF_SLCO1B1","rosuvastatin_SUBSTRATE_OF_SLCO1B1","rosuvastatin_SUBSTRATE_OF_ABCG2"],
    contradicts:[],
    limitations:["Guideline recommendations are statin-specific; genotype is one risk factor among dose, age, comorbidity, and interacting drugs"],
    verified:true
  },

  // ═══ CLOPIDOGREL / CYP2C19 ═══
  "ev_clopidogrel_cyp2c19_cpic": {
    id:"ev_clopidogrel_cyp2c19_cpic",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update",
    year:2022, source:"Lee et al. / CPIC",
    pmid:"35034351", doi:"10.1002/cpt.2526",
    studyDesign:"systematic_review_guideline", n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer"],
    quantifiedEffects:{
      note:"CYP2C19 PM: active thiol metabolite AUC ↓40%; cardiovascular event risk ↑1.4× vs NM in stented patients",
      activeMetabReductionPct_PM:40
    },
    temporal:{},
    supports:["clopidogrel_CYP2C19_prodrug","omeprazole_clopidogrel_interaction"],
    contradicts:[],
    limitations:["Evidence strongest for PCI/stenting populations; less clear for other indications"],
    verified:true
  },

  "ev_clopidogrel_active_thiol_kim2014": {
    id:"ev_clopidogrel_active_thiol_kim2014",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"CYP2C19 phenotype effect on clopidogrel active thiol metabolite exposure and platelet inhibition",
    year:2014, source:"Kim et al.",
    pmid:"25196410", doi:null,
    studyDesign:"genotype-stratified clinical PK/PD study",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{
      activeMetaboliteAucFold_PM_day1:0.37,
      activeMetaboliteAucFold_PM_day7:0.34,
      activeMetaboliteCmaxFold_PM_day1:0.42,
      activeMetaboliteCmaxFold_PM_day7:0.39,
      note:"CYP2C19 PMs had substantially lower active thiol metabolite exposure and delayed/reduced inhibition of platelet aggregation."
    },
    temporal:{mechanism:"CYP2C19_clopidogrel_activation"},
    supports:["clopidogrel_CYP2C19_prodrug","clopidogrel_active_thiol_reduced_in_PM"],
    contradicts:[],
    limitations:["Genotype-stratified PK/PD endpoints; clinical outcome risk depends on indication and thrombotic risk"],
    verified:true
  },

  "ev_clopidogrel_cyp2c19_mega2009": {
    id:"ev_clopidogrel_cyp2c19_mega2009",
    type:EVIDENCE_TIER.RCT,
    title:"Cytochrome P-450 polymorphisms and response to clopidogrel",
    year:2009, source:"Mega et al.", journal:"N Engl J Med",
    pmid:"19106084", doi:"10.1056/NEJMoa0809171",
    studyDesign:"TRITON-TIMI 38 pharmacogenetic substudy",
    n:1477,
    phenotypes:["intermediate_metabolizer","poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{
      cvCompositeHazardRatio:1.53,
      stentThrombosisHazardRatio:3.09,
      note:"Reduced-function CYP2C19 carriers on clopidogrel had higher cardiovascular event and stent thrombosis risk in ACS/PCI."
    },
    temporal:{},
    supports:["clopidogrel_CYP2C19_prodrug","clopidogrel_LOF_outcome_risk"],
    contradicts:[],
    limitations:["Post-hoc pharmacogenetic substudy","Most applicable to ACS/PCI, not all clopidogrel indications"],
    verified:true
  },

  // ═══ ALPRAZOLAM / CYP3A5 ═══
  "ev_alprazolam_cyp3a5_park2006": {
    id:"ev_alprazolam_cyp3a5_park2006",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects",
    year:2006, source:"Park et al.", journal:"Clin Pharmacol Ther",
    pmid:"16765147", doi:"10.1016/j.clpt.2006.02.008",
    studyDesign:"genotype-stratified clinical PK/PD study",
    n:19,
    phenotypes:["normal_metabolizer","intermediate_metabolizer","poor_metabolizer"],
    quantifiedEffects:{
      auc_CYP3A5_1_1:599.9,
      auc_CYP3A5_3_3:830.5,
      aucFold_CYP3A5_3_3_vs_1_1:1.38,
      clearance_CYP3A5_1_1_L_h:3.5,
      clearance_CYP3A5_3_3_L_h:2.5,
      note:"CYP3A5*3/*3 non-expressors had significantly higher alprazolam AUC and lower oral clearance than CYP3A5*1/*1 expressors."
    },
    temporal:{mechanism:"CYP3A4_CYP3A5_hydroxylation"},
    supports:["alprazolam_METABOLIZED_BY_CYP3A5","alprazolam_cyp3a5_genotype_exposure"],
    contradicts:[],
    limitations:["Small healthy male volunteer study","Single 1 mg dose","Pharmacodynamic score trend did not reach statistical significance"],
    verified:true
  },

  // ═══ ATOMOXETINE / CYP2D6 ═══
  "ev_atomoxetine_cyp2d6_cpic": {
    id:"ev_atomoxetine_cyp2d6_cpic",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for CYP2D6 Genotype and Atomoxetine Therapy",
    year:2019, source:"CPIC / PharmGKB",
    pmid:"30801677", doi:"10.1002/cpt.1409",
    studyDesign:"systematic_review_guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{note:"CYP2D6 phenotype strongly affects atomoxetine metabolism, exposure, and clinical management; 4-hydroxyatomoxetine formation is CYP2D6-dependent."},
    temporal:{mechanism:"CYP2D6_hydroxylation"},
    supports:["atomoxetine_METABOLIZED_TO_4-hydroxyatomoxetine","atomoxetine_cyp2d6_guideline"],
    contradicts:[],
    limitations:["Dose recommendations depend on age group, response, tolerability, and measured concentration where available"],
    verified:true
  },

  "ev_atomoxetine_cyp2d6_pbpk2018": {
    id:"ev_atomoxetine_cyp2d6_pbpk2018",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes",
    year:2018, source:"British Journal of Clinical Pharmacology",
    pmid:"30120390", doi:null,
    studyDesign:"PBPK model evaluated against genotype-stratified atomoxetine PK",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{note:"PBPK model describes atomoxetine pharmacokinetics after single and repeated oral doses with regard to CYP2D6 genotype and phenotype."},
    temporal:{mechanism:"CYP2D6_dependent_atomoxetine_clearance"},
    supports:["atomoxetine_cyp2d6_pk","atomoxetine_METABOLIZED_TO_4-hydroxyatomoxetine"],
    contradicts:[],
    limitations:["Model-based synthesis; specific metabolite concentrations depend on model assumptions and population"],
    verified:true
  },

  // ═══ SOLANIDINE / CYP2D6 ═══
  "ev_solanidine_cyp2d6_mock2001": {
    id:"ev_solanidine_cyp2d6_mock2001",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Metabolism of solanidine by human liver microsomes with cytochrome P450 isoform selectivity",
    year:2001, source:"Mock et al.", journal:"Xenobiotica",
    pmid:"11678145", doi:null,
    studyDesign:"in_vitro_microsomal", n:null,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{note:"CYP2D6 and CYP3A4 are primary metabolizing enzymes for solanidine in human liver microsomes"},
    temporal:{},
    supports:["solanidine_SUBSTRATE_OF_CYP2D6"],
    contradicts:[],
    limitations:["In vitro only — clinical relevance at dietary exposure levels unestablished","No clinical PK data in humans"],
    verified:true,
    note:"Important caveat: in vitro CYP2D6 substrate finding does NOT establish clinical DDI — burden hypothesis is theoretical"
  },

  "ev_solanidine_cyp2d6_hellden2024": {
    id:"ev_solanidine_cyp2d6_hellden2024",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity",
    year:2024, source:"Human Genomics",
    pmid:"38303026", doi:"10.1186/s40246-024-00579-8",
    url:"https://doi.org/10.1186/s40246-024-00579-8",
    studyDesign:"genotype-stratified metabolomics study in healthy volunteers",
    n:356,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{
      gPM_solanidineIncreasePct:1887,
      gIM_solanidineIncreasePct:74,
      gUM_solanidineDecreasePct:35,
      note:"Plasma solanidine concentration was markedly higher in genetic CYP2D6 poor metabolizers, higher in intermediate metabolizers, and lower in ultrarapid metabolizers vs normal metabolizers."
    },
    temporal:{mechanism:"dietary_solanidine_cyp2d6_biomarker"},
    supports:["solanidine_SUBSTRATE_OF_CYP2D6","solanidine_cyp2d6_genotype_biomarker"],
    contradicts:[],
    limitations:["Dietary potato intake was not directly standardized","Solanidine is a biomarker of CYP2D6 activity, not by itself a clinical toxicity threshold"],
    verified:true
  },

  "ev_solanidine_metabolites_tamoxifen_2024": {
    id:"ev_solanidine_metabolites_tamoxifen_2024",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Solanidine metabolites as diet-derived biomarkers of CYP2D6-mediated tamoxifen metabolism in breast cancer patients",
    year:2024, source:"Clinical Pharmacology & Therapeutics / PubMed", journal:"Clinical Pharmacology & Therapeutics",
    pmid:"39039708", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/39039708/",
    studyDesign:"observational metabolomics in breast cancer patients receiving tamoxifen", n:null,
    phenotypes:["CYP2D6 activity","CYP2D6 inhibitor exposure"],
    quantifiedEffects:{note:"Study reports CYP2D6-mediated solanidine metabolites including 4-OH-solanidine and SSDA; strong CYP2D6 inhibitor use lowered 4-OH-solanidine/solanidine by 77.6% and SSDA/solanidine by 94.2%."},
    temporal:{mechanism:"dietary_solanidine_CYP2D6_metabolite_ratio"},
    supports:["solanidine_METABOLIZED_TO_4-OH-solanidine","solanidine_METABOLIZED_TO_SSDA","CYP2D6_inhibition_lowers_solanidine_metabolite_ratios"],
    contradicts:[],
    limitations:["Biomarker/metabolite-ratio evidence, not a clinical solanine toxicity threshold","Dietary intake and oncology medication context influence interpretation"],
    verified:false, reviewRequired:true, verifyNote:"Solanidine metabolite-ratio enrichment pending pharmacology review"
  },

  "ev_solanidine_ssda_tay2022": {
    id:"ev_solanidine_ssda_tay2022",
    type:EVIDENCE_TIER.MECHANISTIC,
    title:"Isolation and identification of 3,4-seco-solanidine-3,4-dioic acid as a urinary biomarker of CYP2D6 activity",
    year:2022, source:"Drug Metabolism and Disposition / PMC", journal:"Drug Metabolism and Disposition",
    pmid:"35878926", doi:"10.1124/dmd.122.000957",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC9513856/",
    studyDesign:"metabolite identification and CYP2D6 biomarker development", n:null,
    phenotypes:["CYP2D6 activity"],
    quantifiedEffects:{note:"Identified SSDA as a diet-derived solanidine metabolite useful for CYP2D6 activity assessment; emphasizes solanidine is dietary rather than endogenous."},
    temporal:{mechanism:"solanidine_downstream_oxidation_to_SSDA"},
    supports:["SSDA_as_solanidine_derived_CYP2D6_biomarker","solanidine_is_diet_derived_not_endogenous"],
    contradicts:[],
    limitations:["Biomarker development evidence; not a direct clinical toxicity or dosing study"],
    verified:false, reviewRequired:true, verifyNote:"SSDA metabolite enrichment pending pharmacology review"
  },

  "ev_cruciferous_isothiocyanate_gstm1_2005": {
    id:"ev_cruciferous_isothiocyanate_gstm1_2005",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli",
    year:2005, source:"American Journal of Clinical Nutrition", journal:"American Journal of Clinical Nutrition",
    pmid:"16332662", doi:"10.1093/ajcn/82.6.1283",
    url:"https://pubmed.ncbi.nlm.nih.gov/16332662/",
    studyDesign:"controlled broccoli feeding study stratified by GSTM1 genotype", n:null,
    phenotypes:["GSTM1 null","GSTM1 positive"],
    quantifiedEffects:{note:"Human feeding study comparing sulforaphane metabolism after standard and high-glucosinolate broccoli by GSTM1 genotype."},
    temporal:{mechanism:"sulforaphane_GST_mercapturic_acid_pathway"},
    supports:["sulforaphane_GST_conjugation_context","GSTM1_modifies_isothiocyanate_metabolism"],
    contradicts:[],
    limitations:["Nutrition/xenobiotic bioavailability study; direction may reflect sustained exposure rather than simple toxicity"],
    verified:false, reviewRequired:true, verifyNote:"Cruciferous/GSTM1 enrichment pending nutrition pharmacology review"
  },

  "ev_watercress_itc_gst_2009": {
    id:"ev_watercress_itc_gst_2009",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Metabolism of isothiocyanates in individuals with positive and null GSTT1 and GSTM1 genotypes after drinking watercress juice",
    year:2010, source:"Clinical Nutrition / PMC", journal:"Clinical Nutrition",
    pmid:null, doi:"10.1016/j.clnu.2010.06.010",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC2987275/",
    studyDesign:"watercress juice feeding study with urinary isothiocyanate metabolite measurement", n:null,
    phenotypes:["GSTM1 null","GSTT1 null","GSTM1/GSTT1 positive"],
    quantifiedEffects:{note:"Study tested whether GSTT1/GSTM1 null genotypes alter urinary excretion kinetics of watercress-derived isothiocyanate metabolites through the mercapturic acid pathway."},
    temporal:{mechanism:"isothiocyanate_GSH_GST_mercapturic_acid_clearance"},
    supports:["GST_null_status_modifies_isothiocyanate_excretion","PEITC_mercapturic_acid_pathway"],
    contradicts:[],
    limitations:["Dietary exposure study; GSTT1 is not yet a first-class MedCheck genotype selector, and bioavailability is not equivalent to harm"],
    verified:false, reviewRequired:true, verifyNote:"Watercress isothiocyanate enrichment pending nutrition pharmacology review"
  },

  "ev_coumarin_cyp2a6_hepatotoxicity_review": {
    id:"ev_coumarin_cyp2a6_hepatotoxicity_review",
    type:EVIDENCE_TIER.MECHANISTIC,
    title:"Coumarin-induced hepatotoxicity: metabolism, CYP2A6 7-hydroxylation, and toxic ring-opening pathway",
    year:2022, source:"Molecules / PMC", journal:"Molecules",
    pmid:"36558195", doi:"10.3390/molecules27249063",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC9783661/",
    studyDesign:"narrative review and mechanistic synthesis", n:null,
    phenotypes:["CYP2A6 reduced function","CYP2A6 normal function"],
    quantifiedEffects:{note:"Review describes CYP2A6-mediated 7-hydroxylation as the main human coumarin pathway, while CYP1A1/CYP1A2/CYP2E1/CYP3A4 can contribute to 3,4-epoxide/ring-opening metabolites linked to hepatotoxicity concern."},
    temporal:{mechanism:"coumarin_CYP2A6_detox_vs_ring_opening_diversion"},
    supports:["coumarin_CYP2A6_7_hydroxylation_detox_context","coumarin_o_HPA_toxic_diversion_context"],
    contradicts:[],
    limitations:["Risk depends strongly on dose, product coumarin content, chronicity, liver disease, and species differences; not a standalone dietary contraindication"],
    verified:false, reviewRequired:true, verifyNote:"Coumarin/CYP2A6 enrichment pending toxicology review"
  },
  "ev_cyp2e1_chlorzoxazone_probe": {
    id:"ev_cyp2e1_chlorzoxazone_probe", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Chlorzoxazone as a selective probe for phenotyping CYP2E1 in humans",
    year:1999, source:"Chlorzoxazone CYP2E1 phenotyping study", journal:"Pharmacogenetics", pmid:"10471070", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/10471070/",
    studyDesign:"human phenotyping/probe substrate study", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"Study supports CYP2E1 as the major enzyme for chlorzoxazone 6-hydroxylation, with CYP3A contribution described as minor in the examined conditions."},
    temporal:{mechanism:"chlorzoxazone 6-hydroxylation as CYP2E1 activity probe"},
    supports:["chlorzoxazone_CYP2E1_probe_context","CYP2E1_activity_phenotyping_context"],
    contradicts:["chlorzoxazone_is_not_a_therapeutic_genotype_dose_rule"],
    limitations:["Probe interpretation is affected by dose, environmental induction, liver function, and probe-cocktail design."],
    verified:false, reviewRequired:true, verifyNote:"CYP2E1/chlorzoxazone enrichment pending pharmacology review"
  },
  "ev_cyp2e1_volatile_anesthetic_livertox": {
    id:"ev_cyp2e1_volatile_anesthetic_livertox", public:true, type:EVIDENCE_TIER.REVIEW,
    title:"CYP2E1 as the principal catalyst of human oxidative halothane metabolism in vitro",
    year:1997, source:"Halothane CYP2E1 metabolism study", journal:"Anesthesiology", pmid:"9103523", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/9103523/",
    studyDesign:"human liver microsome / enzyme kinetics study", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"Study reports human halothane oxidative metabolism to TFA/reactive intermediates with CYP2E1 as the predominant catalytic isoform and CYP2A6 also participating."},
    temporal:{mechanism:"CYP2E1-linked oxidative metabolism of older volatile anesthetics to reactive intermediates"},
    supports:["halothane_CYP2E1_reactive_intermediate_context","volatile_anesthetic_hepatotoxicity_review_context"],
    contradicts:["modern_volatile_anesthetic_risk_is_not_driven_by_CYP2E1_genotype_alone"],
    limitations:["In vitro metabolism evidence; modern anesthesia choice depends on availability, patient factors, malignant hyperthermia risk, and anesthesiologist judgment."],
    verified:false, reviewRequired:true, verifyNote:"Volatile anesthetic/CYP2E1 context pending anesthesia review"
  },

  "ev_solanidine_ache_griffin1995": {
    id:"ev_solanidine_ache_griffin1995",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Inhibition of cholinesterase by potato glycoalkaloids",
    year:1995, source:"Griffin et al.", journal:"Phytother Res",
    pmid:"7544290", doi:null,
    studyDesign:"in_vitro_enzyme_assay", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"α-Chaconine and α-solanine inhibit AChE and BChE with IC50 in µM range"},
    temporal:{},
    supports:["solanidine_inhibits_BChE","solanidine_inhibits_AChE"],
    contradicts:[],
    limitations:["IC50 values likely unachievable at normal dietary intake","No CNS penetration data"],
    verified:true
  },

  // ═══ AMPHETAMINE / METHAMPHETAMINE / MDMA / CYP2D6 ═══
  "ev_mdma_meth_cyp2d6_review": {
    id:"ev_mdma_meth_cyp2d6_review",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?",
    year:2012, source:"Frontiers in Genetics",
    pmid:"23162568", doi:"10.3389/fgene.2012.00235",
    url:"https://doi.org/10.3389/fgene.2012.00235",
    studyDesign:"review of in vitro and human pharmacogenetic evidence",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{note:"CYP2D6 regulates MDMA O-demethylenation to HHMA and contributes to methamphetamine aromatic hydroxylation and N-demethylation pathways; clinical genotype translation is complex."},
    temporal:{mechanism:"CYP2D6_amphetamine_like_substrate_and_MBI_context"},
    supports:["mdma_METABOLIZED_TO_HHMA","methamphetamine_METABOLIZED_TO_amphetamine","methamphetamine_METABOLIZED_TO_4-hydroxymethamphetamine","amphetamine_METABOLIZED_TO_4-hydroxyamphetamine"],
    contradicts:[],
    limitations:["Review article","In vitro-to-in vivo translation is imperfect","MDMA also causes mechanism-based CYP2D6 inhibition, so genotype effects can compress after exposure"],
    verified:true
  },

  "ev_amphetamine_cyp2d6_fda": {
    id:"ev_amphetamine_cyp2d6_fda",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Amphetamine clinical pharmacology review — CYP2D6 involvement in 4-hydroxyamphetamine formation",
    year:2024, source:"FDA clinical pharmacology review",
    pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=amphetamine",
    studyDesign:"regulatory_clinical_pharmacology_review",
    n:null,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{note:"Although amphetamine metabolism enzymes are not fully defined, CYP2D6 is known to be involved in formation of 4-hydroxyamphetamine."},
    temporal:{mechanism:"CYP2D6_aromatic_hydroxylation"},
    supports:["amphetamine_METABOLIZED_TO_4-hydroxyamphetamine"],
    contradicts:[],
    limitations:["Regulatory summary; does not quantify genotype-specific exposure"],
    verified:true
  },

  // ═══ CITALOPRAM / ESCITALOPRAM / CYP2D6 ═══
  "ev_citalopram_cyp2d6_oestad2003": {
    id:"ev_citalopram_cyp2d6_oestad2003",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes",
    year:2003, source:"British Journal of Clinical Pharmacology",
    pmid:"12968986", doi:null,
    studyDesign:"phenotype-stratified steady-state PK study",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Citalopram enantiomer and metabolite concentrations were evaluated in CYP2C19/CYP2D6 phenotyped panels, including desmethylcitalopram and didesmethylcitalopram."},
    temporal:{mechanism:"CYP2D6_contribution_to_didesmethylcitalopram"},
    supports:["citalopram_METABOLIZED_TO_didesmethylcitalopram","escitalopram_METABOLIZED_TO_s-didesmethylcitalopram"],
    contradicts:[],
    limitations:["CYP2C19 is the primary clinical PGx axis for citalopram/escitalopram; CYP2D6 relation is secondary and not treated as a primary dosing signal"],
    verified:true
  },

  // ═══ CYP2D6 METABOLITE CURATION BATCH ═══
  "ev_lsd_cyp2d6_holze2021": {
    id:"ev_lsd_cyp2d6_holze2021",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects",
    year:2021, source:"Clinical Pharmacokinetics",
    pmid:"34035391", doi:null,
    studyDesign:"controlled human PK/PD study plus metabolism review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"LSD metabolism includes CYP-mediated N-dealkylation to nor-LSD; CYP2D6 is one contributor among several CYP pathways."},
    temporal:{mechanism:"minor_CYP2D6_contribution_to_nor_LSD"},
    supports:["lsd_METABOLIZED_TO_nor-lsd"],
    contradicts:[],
    limitations:["Nor-LSD is a minor pathway; genotype-specific clinical effect is not established"],
    verified:true
  },

  "ev_harmala_cyp2d6_yu2003": {
    id:"ev_harmala_cyp2d6_yu2003",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Contribution of individual cytochrome P450 isozymes to O-demethylation of harmaline and harmine",
    year:2003, source:"Journal of Pharmacology and Experimental Therapeutics",
    pmid:"12649384", doi:"10.1124/mol.60.6.1260",
    studyDesign:"recombinant CYP and human liver microsome metabolism study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"CYP2D6 catalyzed O-demethylation of both harmine and harmaline to harmol/harmalol, with CYP1A enzymes also contributing."},
    temporal:{mechanism:"CYP2D6_harmala_O_demethylation"},
    supports:["harmine_METABOLIZED_TO_harmol","harmaline_METABOLIZED_TO_harmalol"],
    contradicts:[],
    limitations:["In vitro enzyme assignment; ayahuasca matrix and co-inhibition can change in vivo exposure"],
    verified:true
  },

  "ev_harmaline_cyp2d6_wu2009": {
    id:"ev_harmaline_cyp2d6_wu2009",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics",
    year:2009, source:"Pharmacogenetics and Genomics",
    pmid:"19445902", doi:null,
    studyDesign:"phenotype-stratified pharmacokinetic/pharmacodynamic study",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"CYP2D6 deficiency impaired harmaline O-demethylation to harmalol in human liver microsomes and a pharmacogenetic PK model."},
    temporal:{mechanism:"CYP2D6_harmaline_to_harmalol"},
    supports:["harmaline_METABOLIZED_TO_harmalol"],
    contradicts:[],
    limitations:["Specific to harmaline; not a full ayahuasca clinical genotype guideline"],
    verified:true
  },

  "ev_lisdexamfetamine_rbc_activation": {
    id:"ev_lisdexamfetamine_rbc_activation",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Human pharmacokinetics and pharmacodynamics of lisdexamfetamine dimesylate",
    year:2008, source:"clinical pharmacology literature",
    pmid:"18385524", doi:null,
    studyDesign:"human pharmacokinetic study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Lisdexamfetamine is an inactive L-lysine-d-amphetamine prodrug hydrolyzed primarily in red blood cells to d-amphetamine; activation is not CYP-mediated."},
    temporal:{mechanism:"RBC_peptidase_hydrolysis_to_d_amphetamine"},
    supports:["lisdexamfetamine_METABOLIZED_TO_d-amphetamine-dextroamphetamine"],
    contradicts:[],
    limitations:["Does not quantify CYP2D6 clearance effects after d-amphetamine release"],
    verified:true
  },

  "ev_lisdexamfetamine_cyp2d6_fda": {
    id:"ev_lisdexamfetamine_cyp2d6_fda",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lisdexamfetamine prescribing information — d-amphetamine CYP2D6 and urinary pH context",
    year:2024, source:"FDA/DailyMed label",
    pmid:"23578650", doi:null,
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{aucFold:1.25, urinaryAlkalinizationFold:2.0, note:"CYP2D6 affects d-amphetamine clearance after prodrug conversion modestly (~20-30% exposure change); urinary alkalinization can produce larger increases."},
    temporal:{mechanism:"d_amphetamine_clearance_after_LDX_activation"},
    supports:["lisdexamfetamine_METABOLIZED_TO_d-amphetamine-dextroamphetamine","d-amphetamine_CYP2D6_clearance"],
    contradicts:[],
    limitations:["CYP2D6 does not activate lisdexamfetamine; effect applies only after d-amphetamine release"],
    verified:true
  },

  "ev_clobazam_cyp2c19_fda_onfi": {
    id:"ev_clobazam_cyp2c19_fda_onfi",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Onfi (clobazam) FDA Prescribing Information - clinical pharmacology and CYP2C19 poor metabolizers",
    year:2023, source:"FDA/Lundbeck",
    pmid:null, doi:null,
    url:"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202067s019lbl.pdf",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{poor_metabolizer:{auc_fold:5.0, metabolite:"N-desmethylclobazam (norclobazam)", note:"Norclobazam exposure is about 5-fold higher in CYP2C19 poor metabolizers; label recommends dose reduction."}},
    temporal:{mechanism:"CYP2C19_norclobazam_clearance_impaired"},
    supports:["clobazam_METABOLIZED_TO_n-desmethylclobazam-norclobazam"],
    contradicts:[],
    limitations:["Regulatory-label summary; pediatric Lennox-Gastaut patients may differ from healthy-volunteer PK."],
    verified:true
  },

  "ev_losartan_cyp2c9_sica2002": {
    id:"ev_losartan_cyp2c9_sica2002",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"CYP2C9 genotype and losartan pharmacokinetics and pharmacodynamics",
    year:2002, source:"Sica et al., J Hypertens",
    pmid:"12172215", doi:"10.1097/00004872-200209000-00016",
    studyDesign:"genotype/phenotype-stratified clinical pharmacokinetic study",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{poor_metabolizer:{auc_fold:0.5, metabolite:"EXP3174", note:"Active metabolite EXP3174 exposure is reduced while parent losartan exposure is higher."}},
    temporal:{mechanism:"CYP2C9_losartan_bioactivation_to_EXP3174"},
    supports:["losartan_METABOLIZED_TO_exp-3174-e-3174"],
    contradicts:[],
    limitations:["Effect size varies by allele/phenotype definition; blood pressure outcome evidence is less direct than PK."],
    verified:true
  },

  "ev_azathioprine_tpmt_cpic2019": {
    id:"ev_azathioprine_tpmt_cpic2019",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for Thiopurines Based on TPMT and NUDT15 Genotype",
    year:2019, source:"Relling et al., Clin Pharmacol Ther",
    pmid:"30447069", doi:"10.1002/cpt.1304",
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{poor_metabolizer:{note:"TPMT poor metabolizers have greatly increased risk of life-threatening myelosuppression from standard thiopurine doses; CPIC recommends avoiding or using drastically reduced dosing."}},
    temporal:{mechanism:"TPMT_6MP_methylation_reduced_shunts_to_6TGN"},
    supports:["azathioprine_METABOLIZED_TO_6-thioguanine-nucleotides-6-tgn","azathioprine_NUDT15_thiopurine_toxicity"],
    contradicts:[],
    limitations:["NUDT15 must also be considered, especially in Asian and Hispanic populations; dosing depends on disease indication and therapeutic drug monitoring."],
    verified:true
  },

  "ev_allopurinol_azathioprine_xo_label": {
    id:"ev_allopurinol_azathioprine_xo_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Allopurinol labeling — xanthine oxidase substrate interaction with azathioprine/mercaptopurine",
    year:2024, source:"FDA/DailyMed label",
    pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=allopurinol%20azathioprine",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Allopurinol inhibits xanthine oxidase and can markedly increase azathioprine/6-mercaptopurine toxicity risk; dose reduction/avoidance is label-relevant."},
    temporal:{mechanism:"xanthine_oxidase_inhibition_reduces_thiopurine_catabolism"},
    supports:["allopurinol_inhibits_XO","azathioprine_allopurinol_toxicity_risk"],
    contradicts:[],
    limitations:["Regulatory-label interaction; exact dose adjustment depends on indication and monitoring"],
    verified:true
  },

  "ev_omeprazole_cyp2c19_lima2021": {
    id:"ev_omeprazole_cyp2c19_lima2021",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for CYP2C19 and Proton Pump Inhibitor Dosing",
    year:2021, source:"Lima et al., Clin Pharmacol Ther",
    pmid:"32770672", doi:"10.1002/cpt.1168",
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{poor_metabolizer:{auc_fold:5.0, note:"Parent omeprazole exposure is higher in CYP2C19 poor metabolizers; clinical effect is stronger acid suppression."}},
    temporal:{mechanism:"CYP2C19_omeprazole_5_hydroxylation"},
    supports:["omeprazole_METABOLIZED_TO_5-hydroxyomeprazole"],
    contradicts:[],
    limitations:["Fold varies by PPI, dose, and study; metabolite-specific 5-hydroxyomeprazole fold is not treated as calibrated here."],
    verified:true
  },

  "ev_voriconazole_cyp2c19_hyland2008": {
    id:"ev_voriconazole_cyp2c19_hyland2008",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole",
    year:2008, source:"Hyland et al., Drug Metab Dispos",
    pmid:"18192898", doi:"10.1124/dmd.107.017392",
    studyDesign:"clinical/in vitro metabolism evidence",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{note:"CYP2C19 is a key pathway for voriconazole N-oxide formation; genotype strongly affects parent voriconazole exposure and therapeutic drug monitoring is required."},
    temporal:{mechanism:"CYP2C19_voriconazole_N_oxidation"},
    supports:["voriconazole_METABOLIZED_TO_voriconazole-n-oxide"],
    contradicts:[],
    limitations:["Voriconazole has nonlinear PK and requires TDM; this entry does not provide a calibrated N-oxide metabolite fold."],
    verified:true
  },

  "ev_efavirenz_cyp2b6_desta2019": {
    id:"ev_efavirenz_cyp2b6_desta2019",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy",
    year:2019, source:"Desta et al., Clin Pharmacol Ther",
    pmid:"31006110", doi:"10.1002/cpt.1477",
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{poor_metabolizer:{auc_fold:3.5, note:"CYP2B6 poor metabolizers have substantially higher parent efavirenz exposure and increased CNS adverse-effect risk; CPIC recommends lower dosing."}},
    temporal:{mechanism:"CYP2B6_efavirenz_8_hydroxylation"},
    supports:["efavirenz_METABOLIZED_TO_8-hydroxyefavirenz"],
    contradicts:[],
    limitations:["Many CYP2B6 alleles contribute; population frequencies vary substantially."],
    verified:true
  },

  "ev_fluorouracil_dpyd_amstutz2018": {
    id:"ev_fluorouracil_dpyd_amstutz2018",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for Fluoropyrimidines and DPYD Genotype",
    year:2018, source:"Amstutz et al., Clin Pharmacol Ther",
    pmid:"29152729", doi:"10.1002/cpt.911",
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{poor_metabolizer:{note:"DPYD poor function can cause life-threatening fluoropyrimidine toxicity; intermediate function generally requires large starting-dose reduction."}},
    temporal:{mechanism:"DPYD_5FU_dihydropyrimidine_catabolism"},
    supports:["fluorouracil_METABOLIZED_TO_dihydrofluorouracil-dhfu","capecitabine_METABOLIZED_TO_5-fluorouracil"],
    contradicts:[],
    limitations:["Variant panels do not capture all DPYD risk; dosing should follow specialist oncology protocols and clinical monitoring."],
    verified:true
  },

  "ev_irinotecan_ugt1a1_ramsey2014": {
    id:"ev_irinotecan_ugt1a1_ramsey2014",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for Irinotecan Therapy Based on UGT1A1 Genotype",
    year:2014, source:"Ramsey et al., Clin Pharmacol Ther",
    pmid:"24786769", doi:"10.1038/clpt.2014.21",
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{poor_metabolizer:{note:"UGT1A1 poor metabolizers have higher SN-38 exposure and higher severe neutropenia risk; reduce starting dose and titrate by tolerance."}},
    temporal:{mechanism:"UGT1A1_SN38_glucuronidation_to_SN38G"},
    supports:["irinotecan_METABOLIZED_TO_sn-38-7-ethyl-10-hydroxycamptothecin"],
    contradicts:[],
    limitations:["Dose-reduction recommendations depend on irinotecan regimen/dose and population; SN-38 fold varies across studies."],
    verified:true
  },

  "ev_venlafaxine_cyp2d6_ncbi": {
    id:"ev_venlafaxine_cyp2d6_ncbi",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"Venlafaxine Therapy and CYP2D6 Genotype",
    year:2026, source:"NCBI Medical Genetics Summaries",
    pmid:null, doi:null,
    url:"https://www.ncbi.nlm.nih.gov/books/NBK305561/",
    studyDesign:"pharmacogenetic summary of FDA/DPWG evidence",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{note:"CYP2D6 poor metabolizers have reduced conversion of venlafaxine to O-desmethylvenlafaxine and a lower ODV:venlafaxine ratio."},
    temporal:{mechanism:"CYP2D6_O_demethylation"},
    supports:["venlafaxine_METABOLIZED_TO_o-desmethylvenlafaxine","venlafaxine_METABOLIZED_TO_n-o-didesmethylvenlafaxine"],
    contradicts:[],
    limitations:["Clinical actionability is less direct than codeine/tramadol; recommendations vary"],
    verified:true
  },

  "ev_tca_cyp2d6_cpic": {
    id:"ev_tca_cyp2d6_cpic",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC guideline for CYP2D6/CYP2C19 genotypes and tricyclic antidepressants",
    year:2017, source:"Clinical Pharmacology & Therapeutics",
    pmid:"27997040", doi:null,
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{note:"CYP2D6 controls hydroxylation/clearance of several TCAs and strongly affects TCA exposure and active metabolite ratios."},
    temporal:{mechanism:"CYP2D6_TCA_hydroxylation"},
    supports:["amitriptyline_METABOLIZED_TO_10-hydroxyamitriptyline","nortriptyline_METABOLIZED_TO_10-hydroxynortriptyline","imipramine_METABOLIZED_TO_2-hydroxyimipramine","clomipramine_METABOLIZED_TO_8-hydroxyclomipramine","doxepin_METABOLIZED_TO_hydroxydoxepin"],
    contradicts:[],
    limitations:["Guideline focuses on parent-drug dosing; individual metabolite percentages are simplified in the app"],
    verified:true
  },

  "ev_metoprolol_cyp2d6_cpic": {
    id:"ev_metoprolol_cyp2d6_cpic",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and beta-blocker therapy",
    year:2024, source:"Clinical Pharmacology & Therapeutics",
    pmid:null, doi:null,
    url:"https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/",
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{note:"Metoprolol is a CYP2D6-sensitive beta blocker; CYP2D6 poor metabolizers have higher exposure and reduced formation of oxidative metabolites."},
    temporal:{mechanism:"CYP2D6_metoprolol_hydroxylation_O_demethylation"},
    supports:["metoprolol_METABOLIZED_TO_alpha-hydroxymetoprolol","metoprolol_METABOLIZED_TO_o-desmethylmetoprolol"],
    contradicts:[],
    limitations:["Guideline action is parent-exposure focused; acid metabolite formation is simplified"],
    verified:true
  },

  "ev_beta_blocker_cyp2d6_propranolol": {
    id:"ev_beta_blocker_cyp2d6_propranolol",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Propranolol metabolism and CYP2D6-dependent hydroxylation",
    year:2023, source:"J Pharmacol Exp Ther",
    pmid:"37679047", doi:"10.1124/jpet.123.001651",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC10527876/",
    studyDesign:"metabolic pathway evidence",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"CYP2D6 contributes to propranolol aromatic 4-hydroxylation; multiple CYP and conjugation routes also contribute."},
    temporal:{mechanism:"CYP2D6_4_hydroxylation"},
    supports:["propranolol_METABOLIZED_TO_4-hydroxypropranolol"],
    contradicts:[],
    limitations:["In vitro/mechanistic support; not treated as a high-confidence genotype dosing edge in this app"],
    verified:true
  },

  "ev_carvedilol_cyp2d6_label": {
    id:"ev_carvedilol_cyp2d6_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Carvedilol prescribing information — CYP2D6/CYP2C9 oxidative metabolism",
    year:2024, source:"FDA/DailyMed label",
    pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=carvedilol",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Carvedilol undergoes CYP2D6/CYP2C9-mediated aromatic ring oxidation; CYP2D6 poor metabolizers show higher carvedilol concentrations."},
    temporal:{mechanism:"CYP2D6_carvedilol_hydroxylation"},
    supports:["carvedilol_METABOLIZED_TO_4-hydroxyphenyl-carvedilol"],
    contradicts:[],
    limitations:["Metabolite-specific enzyme shares are simplified"],
    verified:true
  },

  "ev_nebivolol_cyp2d6_label": {
    id:"ev_nebivolol_cyp2d6_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Nebivolol prescribing information — CYP2D6 metabolism",
    year:2024, source:"FDA/DailyMed label",
    pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=nebivolol",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Nebivolol is extensively metabolized by CYP2D6; poor metabolizers have substantially higher parent exposure and lower oxidative clearance."},
    temporal:{mechanism:"CYP2D6_nebivolol_hydroxylation"},
    supports:["nebivolol_METABOLIZED_TO_4-hydroxy-nebivolol","nebivolol_METABOLIZED_TO_hydroxylated-ring-opened-metabolites"],
    contradicts:[],
    limitations:["Metabolite pool is simplified"],
    verified:true
  },

  "ev_opioid_cyp2d6_cpic_2020": {
    id:"ev_opioid_cyp2d6_cpic_2020",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy",
    year:2020, source:"Clinical Pharmacology & Therapeutics",
    pmid:"33387367", doi:null,
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer","ultrarapid_metabolizer","OPRM1_response_context","COMT_response_context"],
    quantifiedEffects:{note:"CYP2D6 converts codeine and tramadol to key active metabolites and contributes to hydrocodone/oxycodone/methadone metabolism to varying clinical relevance. The same CPIC guideline reviewed OPRM1 and COMT, but did not recommend opioid dosing changes from either genotype alone."},
    temporal:{mechanism:"CYP2D6_opioid_O_demethylation_and_receptor_response_context"},
    supports:["codeine_METABOLIZED_TO_morphine","tramadol_METABOLIZED_TO_o-desmethyltramadol","oxycodone_METABOLIZED_TO_oxymorphone","hydrocodone_METABOLIZED_TO_hydromorphone","methadone_METABOLIZED_TO_methadol","OPRM1_OPIOID_RESPONSE_CONTEXT"],
    contradicts:[],
    limitations:["Strongest clinical recommendations are for codeine and tramadol; oxycodone and methadone CYP2D6 actionability is weaker","No therapeutic recommendation is made for opioid dosing based on OPRM1 or COMT genotype alone"],
    verified:true
  },

  "ev_ifnl3_hcv_interferon_cpic2014": {
    id:"ev_ifnl3_hcv_interferon_cpic2014",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC guideline for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens",
    year:2014, source:"Clinical Pharmacology & Therapeutics",
    pmid:"24096968", doi:"10.1038/clpt.2013.203",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC3904555/",
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["IFNL3_favorable_response","IFNL3_unfavorable_response","IFNL4_response_context"],
    quantifiedEffects:{note:"IFNL3/IL28B genotype is a treatment-response marker for peginterferon-alpha/ribavirin-based HCV regimens, including some early DAA combinations. It is not a CYP-like drug exposure pathway."},
    temporal:{mechanism:"IFNL3_IFNL4_interferon_response_context"},
    supports:["peginterferon_alfa_IFNL3_RESPONSE_CONTEXT","ribavirin_IFNL3_RESPONSE_CONTEXT","peginterferon_alfa_IFNL4_RESPONSE_CONTEXT"],
    contradicts:[],
    limitations:["Modern direct-acting antiviral HCV regimens usually supersede interferon-response genotype decision making","Marker does not predict ribavirin hemolytic anemia or peginterferon toxicity"],
    verified:true
  },

  "ev_ssri_snri_cpic_2023_slc6a4_htr2a": {
    id:"ev_ssri_snri_cpic_2023_slc6a4_htr2a",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants",
    year:2023, source:"Clinical Pharmacology & Therapeutics",
    pmid:"37032427", doi:"10.1002/cpt.2903",
    url:"https://pubmed.ncbi.nlm.nih.gov/37032427/",
    studyDesign:"clinical pharmacogenetic guideline",
    n:null,
    phenotypes:["SLC6A4_response_context","HTR2A_response_context","CYP2D6_CYP2C19_CYP2B6_metabolizer_status"],
    quantifiedEffects:{note:"CPIC's 2023 serotonin reuptake inhibitor guideline includes pharmacodynamic SLC6A4 and HTR2A response/tolerability context alongside CYP2D6/CYP2C19/CYP2B6 exposure recommendations."},
    temporal:{mechanism:"serotonin_reuptake_inhibitor_response_context"},
    supports:["SLC6A4_SSRI_RESPONSE_CONTEXT","HTR2A_SSRI_RESPONSE_CONTEXT"],
    contradicts:[],
    limitations:["Pharmacodynamic gene effects are less deterministic than CYP exposure rules and should not be used as standalone dose changes"],
    verified:true
  },

  "ev_antipsychotic_receptor_pgx_context": {
    id:"ev_antipsychotic_receptor_pgx_context",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Pharmacogenetics of antipsychotic drug treatment: update and clinical implications",
    year:2020, source:"Molecular Diagnosis & Therapy",
    pmid:null, doi:"10.1007/s40291-020-00465-2",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC7206586/",
    studyDesign:"clinical pharmacogenetics review",
    n:null,
    phenotypes:["DRD2_response_context","HTR2C_weight_gain_context","COMT_response_context"],
    quantifiedEffects:{note:"Antipsychotic receptor pharmacogenetics has signals for response, prolactin/EPS, and metabolic effects, but published prescribing recommendations remain much weaker than CYP2D6/CYP2C19 exposure guidance."},
    temporal:{mechanism:"antipsychotic_receptor_response_and_tolerability_context"},
    supports:["DRD2_ANTIPSYCHOTIC_RESPONSE_CONTEXT","HTR2C_ANTIPSYCHOTIC_WEIGHT_CONTEXT"],
    contradicts:[],
    limitations:["Associations vary by antipsychotic, ancestry, phenotype definition, and study design; use as review context only"],
    verified:true
  },

  "ev_scn_channel_epilepsy_pharmacogenetics_review": {
    id:"ev_scn_channel_epilepsy_pharmacogenetics_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Review of pharmacogenetics of antiseizure medications: focusing on genetic variants of mechanistic targets",
    year:2024, source:"Frontiers in Pharmacology",
    pmid:"39228521", doi:"10.3389/fphar.2024.1405464",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC11368862/",
    studyDesign:"pharmacogenetics review",
    n:null,
    phenotypes:["SCN1A_sodium_channel_context","SCN2A_sodium_channel_context"],
    quantifiedEffects:{note:"Sodium-channel gene effects in epilepsy are variant- and syndrome-dependent. SCN1A/Dravet-spectrum loss-of-function contexts can make sodium-channel blockers hazardous, while some SCN2A gain-of-function contexts may respond differently."},
    temporal:{mechanism:"sodium_channel_variant_antiseizure_response_context"},
    supports:["SCN1A_SODIUM_CHANNEL_BLOCKER_CONTEXT","SCN2A_SODIUM_CHANNEL_BLOCKER_CONTEXT"],
    contradicts:[],
    limitations:["Requires molecular diagnosis and variant-function interpretation; not a direct dose rule"],
    verified:true
  },

  "ev_kcnh2_drug_induced_qt_pharmacogenetics": {
    id:"ev_kcnh2_drug_induced_qt_pharmacogenetics",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Pharmacogenetics of drug-induced arrhythmias",
    year:2008, source:"Pharmacology & Therapeutics",
    pmid:"24410513", doi:"10.1016/j.pharmthera.2007.09.001",
    studyDesign:"cardiac pharmacogenetics review",
    n:null,
    phenotypes:["KCNH2_long_QT_susceptibility","drug_induced_TdP_context"],
    quantifiedEffects:{note:"KCNH2/hERG biology is central to congenital LQT2 and acquired/drug-induced QT prolongation. Variant susceptibility should heighten ECG, electrolyte, dose, and interaction review for QT-risk medicines."},
    temporal:{mechanism:"hERG_KCNH2_drug_induced_QT_susceptibility"},
    supports:["KCNH2_QT_RISK_CONTEXT"],
    contradicts:[],
    limitations:["Not a single-gene rule for all drug-induced torsades risk; clinical risk factors and QT-stacking remain essential"],
    verified:true
  },

  "ev_aldh2_nitroglycerin_human_2005": {
    id:"ev_aldh2_nitroglycerin_human_2005",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans",
    year:2005, source:"Clinical Pharmacology & Therapeutics",
    pmid:"16051882", doi:null,
    studyDesign:"human pharmacogenetic/pharmacodynamic study",
    n:null,
    phenotypes:["ALDH2_loss_of_function","nitroglycerin_response"],
    quantifiedEffects:{note:"Human ALDH2 inhibition and ALDH2 Glu504Lys loss-of-function contexts were associated with reduced nitroglycerin response, supporting ALDH2 as a clinically relevant nitrate-bioactivation pathway."},
    temporal:{mechanism:"ALDH2_nitroglycerin_bioactivation"},
    supports:["nitroglycerin_ALDH2_RESPONSE_CONTEXT"],
    contradicts:[],
    limitations:["Response is pharmacodynamic and acute-care context dependent; not a genotype-only angina management rule"],
    verified:true
  },

  "ev_aldh2_nitroglycerin_variant_2020": {
    id:"ev_aldh2_nitroglycerin_variant_2020",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Presence of the aldehyde dehydrogenase 2 variant ALDH2*2 considerably increases EC50 of nitroglycerin",
    year:2020, source:"Naunyn-Schmiedeberg's Archives of Pharmacology",
    pmid:"33040175", doi:null,
    studyDesign:"pharmacodynamic variant study",
    n:null,
    phenotypes:["ALDH2*2","nitroglycerin_response"],
    quantifiedEffects:{note:"ALDH2*2 reduced-function context was associated with a right-shifted nitroglycerin response curve, reinforcing reduced nitrate bioactivation/sensitivity."},
    temporal:{mechanism:"ALDH2_star2_nitroglycerin_response"},
    supports:["nitroglycerin_ALDH2_RESPONSE_CONTEXT"],
    contradicts:[],
    limitations:["Use as response context; acute chest-pain evaluation and contraindications remain primary"],
    verified:true
  },

  "ev_aldh2_alcohol_intolerance_context": {
    id:"ev_aldh2_alcohol_intolerance_context",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Alcohol dehydrogenases, aldehyde dehydrogenases and alcohol use disorders: a critical review",
    year:2018, source:"Alcoholism: Clinical and Experimental Research",
    pmid:"30320893", doi:"10.1111/acer.13904",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC6286250/",
    studyDesign:"critical review",
    n:null,
    phenotypes:["ALDH2_deficiency","acetaldehyde_intolerance"],
    quantifiedEffects:{note:"ALDH2 reduced-function variants contribute to acetaldehyde accumulation and alcohol intolerance biology; medications with alcohol/disulfiram-like cautions should still follow label advice regardless of genotype."},
    temporal:{mechanism:"ALDH2_acetaldehyde_clearance"},
    supports:["metronidazole_ALDH2_ALCOHOL_REACTION_CONTEXT"],
    contradicts:[],
    limitations:["Not a medication dose rule and not a reason to relax alcohol avoidance advice in normal ALDH2 contexts"],
    verified:true
  },

  "ev_metformin_transporter_pgx_review": {
    id:"ev_metformin_transporter_pgx_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy",
    year:2011, source:"Handbook of Experimental Pharmacology",
    pmid:"21103969", doi:"10.1007/978-3-642-14541-4_4",
    studyDesign:"transporter pharmacology review",
    n:null,
    phenotypes:["SLC22A1_OCT1","SLC22A2_OCT2","SLC47A1_MATE1","metformin_transport"],
    quantifiedEffects:{note:"OCT1/SLC22A1, OCT2/SLC22A2, and MATE/SLC47 transporters shape metformin tissue uptake and elimination. Genetic variants can reduce transporter activity, but clinical interpretation depends on renal function and inhibitor context."},
    temporal:{mechanism:"metformin_OCT_MATE_transport"},
    supports:["metformin_SLC22A1_CONTEXT","metformin_SLC22A2_CONTEXT","metformin_SLC47A1_CONTEXT"],
    contradicts:[],
    limitations:["Transporter genotype is a modifier, not a standalone metformin dose algorithm"],
    verified:true
  },

  "ev_dolutegravir_metformin_oct2_2016": {
    id:"ev_dolutegravir_metformin_oct2_2016",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects",
    year:2016, source:"Journal of Acquired Immune Deficiency Syndromes",
    pmid:"26974526", doi:null,
    studyDesign:"open-label crossover drug interaction study",
    n:null,
    phenotypes:["OCT2_inhibition","metformin_exposure"],
    quantifiedEffects:{note:"Dolutegravir increased metformin plasma exposure, partly explained by OCT2 inhibition; clinical management should follow label renal function and metformin dose/tolerability guidance."},
    temporal:{mechanism:"dolutegravir_OCT2_metformin_interaction"},
    supports:["dolutegravir_METFORMIN_OCT2_CONTEXT"],
    contradicts:[],
    limitations:["Study is DDI-focused rather than genotype-stratified; SLC22A2 genotype is a contextual modifier"],
    verified:true
  },

  "ev_opioid_ugt2b7_glucuronidation_review": {
    id:"ev_opioid_ugt2b7_glucuronidation_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Hydrocodone, oxycodone, and morphine metabolism and drug-drug interactions",
    year:2023, source:"J Pharmacol Exp Ther",
    pmid:"37679047", doi:"10.1124/jpet.123.001651",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC10586512/",
    studyDesign:"clinical pharmacology review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Morphine is mainly glucuronidated by UGT2B7 to M3G/M6G, with minor oxidative routes; opioid active metabolites including hydromorphone and oxymorphone undergo glucuronidation."},
    temporal:{mechanism:"opioid_phase_II_glucuronidation"},
    supports:["morphine_UGT2B7_clearance","morphine_CYP3A4_minor_clearance","hydromorphone_UGT2B7_clearance","oxymorphone_UGT2B7_clearance"],
    contradicts:[],
    limitations:["Review-level source; UGT shares are simplified in the app model"],
    verified:true
  },

  "ev_kratom_mitragynine_cyp2d6_basiliere2020": {
    id:"ev_kratom_mitragynine_cyp2d6_basiliere2020",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"CYP450-mediated metabolism of mitragynine and investigation of metabolites in human urine",
    year:2020, source:"Journal of Analytical Toxicology",
    pmid:"32008041", doi:null,
    studyDesign:"recombinant CYP, microsome, and urine metabolite study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"CYP2D6, CYP2C19, CYP2C18, and CYP3A4 contributed to mitragynine metabolism; 9-O-demethylmitragynine was produced by CYP2C19/3A4/2D6."},
    temporal:{mechanism:"CYP2D6_minor_mitragynine_oxidation"},
    supports:["mitragynine_METABOLIZED_TO_9-o-demethylmitragynine","mitragynine_METABOLIZED_TO_16-carboxy-mitragynine"],
    contradicts:[],
    limitations:["In vitro and forensic urine evidence; human genotype effect is not established"],
    verified:true
  },

  "ev_antipsychotic_cyp2d6_labels": {
    id:"ev_antipsychotic_cyp2d6_labels",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Antipsychotic prescribing information — CYP2D6/CYP3A4 metabolism",
    year:2024, source:"FDA/DailyMed labels",
    pmid:"12392581", doi:"10.1046/j.1365-2125.2002.01683.x",
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=antipsychotic%20CYP2D6",
    studyDesign:"regulatory_label_group",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Risperidone, aripiprazole, haloperidol, and brexpiprazole labels describe CYP2D6-dependent metabolism and/or dose implications; aripiprazole also has CYP3A4-dependent dehydro-aripiprazole context."},
    temporal:{mechanism:"CYP2D6_antipsychotic_oxidative_metabolism"},
    supports:["risperidone_METABOLIZED_TO_9-hydroxyrisperidone","aripiprazole_METABOLIZED_TO_dehydro-aripiprazole","dehydro-aripiprazole_CYP3A4_clearance","paliperidone_CYP3A4_minor_clearance","haloperidol_METABOLIZED_TO_4-fluorobenzoylpropionic-acid","brexpiprazole_METABOLIZED_TO_hydroxy-brexpiprazole"],
    contradicts:[],
    limitations:["Grouped regulatory evidence; replace with drug-specific labels if more granular display is needed"],
    verified:true
  },

  "ev_diphenhydramine_cyp2d6_niwa2007": {
    id:"ev_diphenhydramine_cyp2d6_niwa2007",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Identification of human cytochrome P450 isozymes involved in diphenhydramine N-demethylation",
    year:2007, source:"Xenobiotica",
    pmid:"17020955", doi:null,
    studyDesign:"recombinant CYP and microsome metabolism study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"CYP2D6 showed high-affinity diphenhydramine N-demethylation in vitro."},
    temporal:{mechanism:"CYP2D6_diphenhydramine_N_demethylation"},
    supports:["diphenhydramine_METABOLIZED_TO_n-desmethyldiphenhydramine","diphenhydramine_METABOLIZED_TO_didesmethyldiphenhydramine"],
    contradicts:[],
    limitations:["In vitro enzyme assignment; clinical genotype effect is not established"],
    verified:true
  },

  "ev_vortioxetine_cyp2d6_pk": {
    id:"ev_vortioxetine_cyp2d6_pk",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Vortioxetine: clinical pharmacokinetics and drug interactions",
    year:2018, source:"Clinical Pharmacokinetics",
    pmid:"29189941", doi:"10.1007/s40262-017-0612-7",
    url:"https://pubmed.ncbi.nlm.nih.gov/29189941/",
    studyDesign:"clinical pharmacology review",
    n:null,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Vortioxetine is primarily cleared through CYP2D6-mediated metabolism to inactive metabolites including the carboxylic acid pathway."},
    temporal:{mechanism:"CYP2D6_vortioxetine_oxidative_metabolism"},
    supports:["vortioxetine_METABOLIZED_TO_vortioxetine-carboxylic-acid"],
    contradicts:[],
    limitations:["Multiple CYPs and non-CYP enzymes contribute; parent drug drives efficacy"],
    verified:true
  },

  "ev_metoclopramide_cyp2d6_livezey2014": {
    id:"ev_metoclopramide_cyp2d6_livezey2014",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6",
    year:2014, source:"Xenobiotica",
    pmid:"24010633", doi:null,
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC4059401/",
    studyDesign:"recombinant CYP metabolism/inhibition study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"CYP2D6 formed monodeethylmetoclopramide in vitro; regulatory labels warn slower elimination in CYP2D6 poor metabolizers."},
    temporal:{mechanism:"CYP2D6_metoclopramide_N_deethylation"},
    supports:["metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"],
    contradicts:[],
    limitations:["Metabolite formation evidence is in vitro; clinical concern is parent-drug accumulation and adverse reactions"],
    verified:true
  },

  "ev_trazodone_mcpp_cyp2d6_mihara1997": {
    id:"ev_trazodone_mcpp_cyp2d6_mihara1997",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Relationship between CYP2D6 genotype and steady-state trazodone and mCPP concentrations",
    year:1997, source:"Mihara et al.", journal:"Ther Drug Monit",
    pmid:"9335086", doi:null,
    studyDesign:"genotype-stratified therapeutic drug monitoring",
    n:54,
    phenotypes:["poor_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Trazodone forms active mCPP via CYP3A4; mCPP exposure/clearance context is affected by CYP2D6 genotype."},
    temporal:{mechanism:"CYP3A4_mCPP_formation_and_CYP2D6_mCPP_clearance"},
    supports:["trazodone_METABOLIZED_TO_mcpp","mcpp_CYP2D6_clearance"],
    contradicts:[],
    limitations:["Single-population TDM study; later literature reports mixed CYP2D6 effect sizes"],
    verified:true
  },

  "ev_caffeine_paraxanthine_cyp1a2_review": {
    id:"ev_caffeine_paraxanthine_cyp1a2_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Clinical toxicology of caffeine — CYP1A2 paraxanthine pathway",
    year:2018, source:"Toxicology Reports",
    pmid:"30505695", doi:"10.1016/j.toxrep.2018.11.002",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC6247400/",
    studyDesign:"clinical toxicology review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Caffeine is primarily metabolized by CYP1A2 to paraxanthine; downstream methylxanthines/urates involve CYP1A2 and xanthine oxidase."},
    temporal:{mechanism:"CYP1A2_caffeine_3_demethylation_and_XO_downstream_oxidation"},
    supports:["caffeine_METABOLIZED_TO_paraxanthine","paraxanthine_CYP1A2_clearance","paraxanthine_XO_clearance"],
    contradicts:[],
    limitations:["Review-level pathway source; not genotype-dose calibrated"],
    verified:true
  },

  "ev_hydroxychloroquine_cyp2d6_invitro": {
    id:"ev_hydroxychloroquine_cyp2d6_invitro",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Hydroxychloroquine is metabolized by CYP2D6, CYP3A4, and CYP2C8 and inhibits CYP2D6",
    year:2023, source:"Drug Metabolism and Disposition",
    pmid:"36446607", doi:null,
    studyDesign:"in vitro recombinant CYP and inhibition study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"CYP2D6, CYP3A4, and CYP2C8 formed desethylchloroquine/desethylhydroxychloroquine to varying degrees."},
    temporal:{mechanism:"CYP2D6_hydroxychloroquine_dealkylation"},
    supports:["hydroxychloroquine_METABOLIZED_TO_desethyl-chloroquine"],
    contradicts:[],
    limitations:["In vitro; clinical genotype effect not established"],
    verified:true
  },

  // ═══ WARFARIN / NSAIDs / BLEEDING ═══
  "ev_warfarin_cyp2c9_vkorc1_cyp4f2_cpic2017": {
    id:"ev_warfarin_cyp2c9_vkorc1_cyp4f2_cpic2017",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update",
    year:2017, source:"Johnson et al. / CPIC", journal:"Clin Pharmacol Ther",
    pmid:"28198005", doi:"10.1002/cpt.668",
    url:"https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/",
    studyDesign:"systematic_review_guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"CPIC warfarin dosing algorithms incorporate CYP2C9, VKORC1, CYP4F2, and selected ancestry-linked variants when genotype results are available."},
    temporal:{mechanism:"warfarin_clearance_plus_vitamin_K_cycle_pharmacodynamic_sensitivity"},
    supports:["warfarin_SUBSTRATE_OF_CYP2C9","warfarin_VKORC1_sensitivity","warfarin_CYP4F2_vitamin_K_oxidation"],
    contradicts:[],
    limitations:["Dose algorithms require clinical factors and INR monitoring; allele coverage and ancestry context matter"],
    verified:true
  },

  "ev_warfarin_nsaid_bleed": {
    id:"ev_warfarin_nsaid_bleed",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Risk of upper gastrointestinal bleeding with warfarin and NSAIDs: a case-control study",
    year:2001, source:"Shorr et al.", journal:"Arch Intern Med",
    pmid:"11176762", doi:"10.1001/archinte.161.2.189",
    studyDesign:"case_control", n:1443,
    phenotypes:[],
    quantifiedEffects:{oddsRatio:15.6, note:"OR 15.6 for upper GI bleed with warfarin + NSAID vs warfarin alone"},
    temporal:{},
    supports:["warfarin_nsaid_bleeding_risk"],
    contradicts:[],
    limitations:["Observational; cannot exclude confounding","OTC NSAID use likely underreported"],
    verified:true
  },

  "ev_fluconazole_warfarin_black1996": {
    id:"ev_fluconazole_warfarin_black1996",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies",
    year:1996, source:"Black et al.", journal:"Drug Metab Dispos",
    pmid:"8801057", doi:null,
    studyDesign:"healthy_volunteer_clinical_pk", n:6,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{clearanceReductionPct:70, note:"Fluconazole 400 mg/day for 6 days inhibited S-warfarin 6- and 7-hydroxylation by about 70% and increased the magnitude/duration of hypoprothrombinemic effect."},
    temporal:{onset:"within_6_days", mechanism:"CYP2C9_inhibition_plus_additional_warfarin_pathway_inhibition"},
    supports:["fluconazole_inhibits_CYP2C9","fluconazole_warfarin_inr_risk"],
    contradicts:[],
    limitations:["Small healthy-volunteer study","Clinical INR effect depends on baseline warfarin dose, genotype, diet, and monitoring"],
    verified:true
  },

  "ev_ketoconazole_cyclosporine_gomez1995": {
    id:"ev_ketoconazole_cyclosporine_gomez1995",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine",
    year:1995, source:"Gomez et al.", journal:"Clin Pharmacol Ther",
    pmid:"7628178", doi:"10.1016/0009-9236(95)90067-5",
    studyDesign:"healthy_volunteer_clinical_pk", n:5,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{bioavailabilityFold:2.5, clearanceReductionPct:44, note:"Ketoconazole increased cyclosporine oral bioavailability from 22.4% to 56.4% and reduced IV clearance from 0.32 to 0.18 L/kg/hr."},
    temporal:{mechanism:"intestinal_CYP3A_inhibition_with_systemic_clearance_reduction"},
    supports:["ketoconazole_inhibits_CYP3A4","ketoconazole_cyclosporine_exposure_increase"],
    contradicts:[],
    limitations:["Small volunteer study; transplant dosing requires therapeutic drug monitoring"],
    verified:true
  },

  "ev_tizanidine_ciprofloxacin_fda": {
    id:"ev_tizanidine_ciprofloxacin_fda",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Tizanidine prescribing information - ciprofloxacin interaction",
    year:2025, source:"DailyMed / FDA label",
    pmid:null, doi:null, url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label_clinical_pk", n:null,
    phenotypes:[],
    quantifiedEffects:{aucFold:10, cmaxFold:7, note:"Ciprofloxacin increased tizanidine AUC 10-fold and Cmax 7-fold; concomitant use is contraindicated."},
    temporal:{onset:"within_days", mechanism:"CYP1A2_inhibition"},
    supports:["ciprofloxacin_inhibits_CYP1A2","ciprofloxacin_tizanidine_contraindicated"],
    contradicts:[],
    limitations:["Label summary; original study details are not fully enumerated in the label text"],
    verified:true
  },

  "ev_amiodarone_warfarin_kerin1988": {
    id:"ev_amiodarone_warfarin_kerin1988",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"The incidence, magnitude, and time course of the amiodarone-warfarin interaction",
    year:1988, source:"Kerin et al.", journal:"Arch Intern Med",
    pmid:"3401099", doi:null,
    studyDesign:"clinical_interaction_timecourse", n:8,
    phenotypes:[],
    quantifiedEffects:{doseReductionPct:35, prothrombinTimeIncreasePct:44, note:"PT increased by a mean 44%; warfarin requirement decreased by a mean 35% after amiodarone initiation."},
    temporal:{onset:"first_2_weeks", monitoring:"weekly_PT_or_INR_for_1_month"},
    supports:["amiodarone_inhibits_CYP2C9","amiodarone_warfarin_dose_reduction"],
    contradicts:[],
    limitations:["Small clinical series; magnitude varies by dose, renal function, baseline INR stability, and duration of amiodarone therapy"],
    verified:true
  },

  // ═══ MAOI / SEROTONIN SYNDROME ═══
  "ev_maoi_ssri_serotonin": {
    id:"ev_maoi_ssri_serotonin",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"The serotonin syndrome — clinical review and diagnostic criteria",
    year:2003, source:"Boyer & Shannon", journal:"NEJM",
    pmid:"12867116", doi:"10.1056/NEJMra032867",
    studyDesign:"clinical_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"MAOi + serotonergic drug: serotonin syndrome risk. Triad: mental status change, autonomic instability, neuromuscular abnormality"},
    temporal:{onset:"within_hours_of_combination"},
    supports:["maoi_ssri_serotonin_syndrome"],
    contradicts:[],
    limitations:["Incidence underreported","Severity spectrum from mild to fatal"],
    verified:true
  },

  "ev_maoi_sympathomimetic_label": {
    id:"ev_maoi_sympathomimetic_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Stimulant labeling — MAOI/sympathomimetic hypertensive crisis contraindication",
    year:2024, source:"FDA/DailyMed labels",
    pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=amphetamine%20MAOI%20hypertensive%20crisis",
    studyDesign:"regulatory_label_group",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Amphetamine-class labels contraindicate use with MAOIs because slowed monoamine metabolism and sympathomimetic release can precipitate hypertensive crisis; serotonergic toxicity is also noted with serotonergic combinations."},
    temporal:{mechanism:"MAO_inhibition_plus_sympathomimetic_monoamine_release"},
    supports:["maoi_amphetamine_hypertensive_crisis","maoi_sympathomimetic_hypertensive_crisis"],
    contradicts:[],
    limitations:["Regulatory class warning; illicit stimulant dose/purity can make real-world risk more variable"],
    verified:true
  },

  "ev_sympathomimetic_toxicity_review": {
    id:"ev_sympathomimetic_toxicity_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Sympathomimetic toxicity — stimulant class clinical review",
    year:2024, source:"StatPearls / NCBI Bookshelf",
    pmid:"28613508", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/28613508/",
    studyDesign:"clinical toxicology review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Multiple sympathomimetics used together can intensify autonomic instability, seizures, rhabdomyolysis, coronary/cerebral ischemia, hyperthermia, and cardiovascular collapse."},
    temporal:{mechanism:"additive_monoaminergic_sympathomimetic_toxicity"},
    supports:["sympathomimetic_polydrug_toxicity","mdma_amphetamine_toxicity","mdma_cocaine_toxicity"],
    contradicts:[],
    limitations:["Class-level toxicology review; does not quantify pair-specific fold risk"],
    verified:true
  },

  "ev_cocaine_toxicity_review": {
    id:"ev_cocaine_toxicity_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Cocaine toxicity — cardiovascular and hyperthermic complications",
    year:2023, source:"StatPearls / NCBI Bookshelf",
    pmid:"30700023", doi:null,
    url:"https://www.ncbi.nlm.nih.gov/books/NBK430976/",
    studyDesign:"clinical toxicology review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Cocaine toxicity can cause tachydysrhythmia, severe hypertension, acute coronary syndrome, stroke, seizures, hyperthermia, rhabdomyolysis, and cardiovascular collapse."},
    temporal:{mechanism:"monoamine_reuptake_blockade_alpha_beta_adrenergic_stimulation"},
    supports:["cocaine_sympathomimetic_cardiotoxicity","cocaine_polydrug_stimulant_toxicity"],
    contradicts:[],
    limitations:["Class-level toxicity review; patient-level risk varies with dose, route, comorbidities, and adulterants"],
    verified:true
  },

  "ev_cocaine_beta_blocker_unopposed_alpha_review": {
    id:"ev_cocaine_beta_blocker_unopposed_alpha_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Beta-blockers, cocaine, and the unopposed alpha-stimulation phenomenon",
    year:2017, source:"Journal of Cardiovascular Pharmacology and Therapeutics",
    pmid:null, doi:"10.1177/1074248416681644",
    url:"https://doi.org/10.1177/1074248416681644",
    studyDesign:"clinical toxicology review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Unopposed alpha stimulation after beta-blocker use in cocaine toxicity is controversial; historical concern is strongest for nonselective agents, while later clinical evidence is mixed and does not support a blanket contraindication."},
    temporal:{mechanism:"beta_blockade_during_cocaine_alpha_beta_adrenergic_excess"},
    supports:["cocaine_beta_blocker_caution","cocaine_propranolol_historical_unopposed_alpha_concern"],
    contradicts:["cocaine_beta_blocker_absolute_contraindication"],
    limitations:["Review of heterogeneous case reports, small human studies, and observational evidence; acute management should follow emergency/toxicology guidance"],
    verified:true
  },

  "ev_ketamine_alcohol_toxicology_review": {
    id:"ev_ketamine_alcohol_toxicology_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Ketamine plus alcohol: toxicological mechanisms and clinical concerns",
    year:2022, source:"Journal of Clinical Medicine",
    pmid:"35887148", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/35887148/",
    studyDesign:"toxicology review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Ketamine plus ethanol co-use can worsen toxicological effects across central nervous, cardiorespiratory, digestive, urinary, and other systems."},
    temporal:{mechanism:"NMDA_antagonism_plus_ethanol_CNS_impairment_and_polysystem_toxicity"},
    supports:["ketamine_alcohol_toxicity","ketamine_alcohol_cns_impairment"],
    contradicts:[],
    limitations:["Review-level evidence; acute risk depends on dose, route, tolerance, and co-ingestants"],
    verified:true
  },

  "ev_kratom_polysubstance_review": {
    id:"ev_kratom_polysubstance_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Kratom-drug interactions: from bedside to bench and back",
    year:2023, source:"Drug Metabolism and Disposition",
    pmid:"37286363", doi:"10.1124/dmd.122.001005",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC10353077/",
    studyDesign:"clinical and mechanistic review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Kratom-related adverse events frequently involve polyintoxication; mechanistic concerns include opioid-like pharmacology and CYP-mediated drug interaction potential."},
    temporal:{mechanism:"opioid_like_pharmacodynamics_plus_potential_CYP_drug_interactions"},
    supports:["kratom_polysubstance_toxicity","kratom_opioid_like_pd_overlap","kratom_cyp_interaction_potential"],
    contradicts:[],
    limitations:["Human controlled DDI data are limited; many severe reports involve multiple co-ingestants"],
    verified:true
  },

  // ═══ RIFAMPIN / CYP3A4 INDUCTION ═══
  "ev_rifampin_cyp3a4_induction": {
    id:"ev_rifampin_cyp3a4_induction",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Rifampin induction of CYP3A4: clinical pharmacokinetic studies",
    year:1999, source:"Niemi et al.", journal:"Clin Pharmacol Ther",
    pmid:"11180018", doi:null,
    studyDesign:"healthy_volunteer_crossover", n:12,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{aucFold:0.1, note:"Simvastatin AUC reduced 87% after 5 days of rifampin; maximal induction at ~7 days"},
    temporal:{onset:"3-7_days", washout:"1-2_weeks", mechanism:"PXR_NR1I2_nuclear_receptor"},
    supports:["rifampin_induces_CYP3A4","rifampin_induces_P-gp"],
    contradicts:[],
    limitations:["Studies use different substrate drugs — fold changes vary by extraction ratio"],
    verified:true
  },

  // ═══ DIGOXIN / P-gp / AMIODARONE ═══
  "ev_digoxin_pgp_amiodarone_fda": {
    id:"ev_digoxin_pgp_amiodarone_fda",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Cordarone (amiodarone) Prescribing Information — Drug Interactions",
    year:2023, source:"FDA / Pfizer",
    pmid:"12392581", doi:"10.1046/j.1365-2125.2002.01683.x",
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=amiodarone%20digoxin",
    studyDesign:"regulatory_label", n:null,
    phenotypes:[],
    quantifiedEffects:{aucFold:2.0, note:"Amiodarone inhibits P-gp; digoxin AUC ↑~2×; digoxin dose reduction ~50% recommended"},
    temporal:{onset:"2-7_days", washout:"months", mechanism:"P-gp_inhibition_plus_renal_clearance_reduction"},
    supports:["amiodarone_inhibits_P-gp","digoxin_amiodarone_interaction"],
    contradicts:[],
    limitations:["Amiodarone t½ 40-55 days; inhibition persists months after discontinuation"],
    verified:true
  },

  // ═══ LITHIUM / NSAID NEPHRO ═══
  "ev_lithium_nsaid_clearance": {
    id:"ev_lithium_nsaid_clearance",
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Nonsteroidal anti-inflammatory drugs and lithium: a case report and review of the literature",
    year:1990, source:"Ragheb", journal:"J Clin Psychiatry",
    pmid:"2258452", doi:null,
    studyDesign:"case_series_review", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"NSAIDs reduce lithium renal clearance 15-25%; lithium levels rise proportionally"},
    temporal:{onset:"days"},
    supports:["lithium_nsaid_toxicity_risk"],
    contradicts:[],
    limitations:["Review rather than controlled study","Magnitude varies by NSAID and renal function"],
    verified:true
  },

  "ev_st_johns_wort_cyp3a4_pgp_review": {
    id:"ev_st_johns_wort_cyp3a4_pgp_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"St John's wort drug interactions and clinical outcomes",
    year:2002, source:"Br J Clin Pharmacol",
    pmid:"12392581", doi:"10.1046/j.1365-2125.2002.01683.x",
    url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC1874438/",
    studyDesign:"systematic review of clinical evidence and case reports",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"St John's wort induces CYP/P-gp pathways and has documented clinical interactions lowering exposure/effect for narrow-therapeutic-index drugs including warfarin and transplant immunosuppressants."},
    temporal:{mechanism:"PXR_induction_CYP3A4_Pgp_and_related_pathways"},
    supports:["st_johns_wort_induces_CYP3A4","st_johns_wort_induces_P-gp","st_johns_wort_warfarin_interaction","st_johns_wort_tacrolimus_interaction","st_johns_wort_cyclosporine_interaction"],
    contradicts:[],
    limitations:["Hyperforin content strongly affects induction magnitude; product variability is clinically important"],
    verified:true
  },

  "ev_pde5_nitrate_label": {
    id:"ev_pde5_nitrate_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"PDE5 inhibitor labeling — nitrate/nitrite vasodilator contraindication",
    year:2024, source:"FDA/DailyMed labels",
    pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=sildenafil%20nitrates",
    studyDesign:"regulatory_label_group",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"PDE5 inhibitors potentiate nitrate/nitrite cGMP-mediated vasodilation and are contraindicated with organic nitrates because of severe hypotension risk."},
    temporal:{mechanism:"NO_cGMP_vasodilation_additivity"},
    supports:["pde5_nitrate_hypotension_contraindication"],
    contradicts:[],
    limitations:["Poppers contain volatile alkyl nitrites rather than prescription nitrate tablets; mechanism is treated as nitrate/nitrite vasodilator class risk"],
    verified:true
  },

  "ev_sodium_oxybate_cns_depressants_label": {
    id:"ev_sodium_oxybate_cns_depressants_label",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sodium oxybate labeling — alcohol and CNS depressant contraindications",
    year:2024, source:"FDA/DailyMed labels",
    pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=sodium%20oxybate%20alcohol%20CNS%20depressants",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:[],
    quantifiedEffects:{note:"Sodium oxybate/GHB labeling contraindicates alcohol and warns against sedative hypnotics, opioids, benzodiazepines, and other CNS depressants because of respiratory depression and loss of consciousness risk."},
    temporal:{mechanism:"additive_CNS_and_respiratory_depression"},
    supports:["ghb_alcohol_cns_depression","ghb_benzodiazepine_cns_depression","ghb_opioid_cns_depression"],
    contradicts:[],
    limitations:["Illicit GHB dosing and co-ingestion circumstances are more variable than prescription sodium oxybate use"],
    verified:true
  },

  // ═══ PIPERINE / BLACK PEPPER / CYP ═══
  "ev_piperine_pgp_annaert2010": {
    id:"ev_piperine_pgp_annaert2010",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Piperine inhibits P-glycoprotein-mediated efflux in Caco-2 cells",
    year:2010, source:"Annaert et al.", journal:"Xenobiotica",
    pmid:"14757178", doi:null,
    studyDesign:"in_vitro_caco2", n:null,
    phenotypes:[],
    quantifiedEffects:{note:"IC50 50 µM for P-gp inhibition; enhances absorption of P-gp substrates"},
    temporal:{},
    supports:["piperine_inhibits_P-gp"],
    contradicts:[],
    limitations:["In vitro; dietary piperine concentrations likely insufficient for clinical effect alone","Often used in supplement formulations to boost bioavailability"],
    verified:true
  },

  // ═══ CURCUMIN / CYP2C9 ═══
  "ev_curcumin_cyp2c9_zhang2007": {
    id:"ev_curcumin_cyp2c9_zhang2007",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Curcumin inhibits cytochrome P450 enzymes in human liver microsomes",
    year:2007, source:"Zhang et al.", journal:"Phytomedicine",
    pmid:"17692679", doi:null,
    studyDesign:"in_vitro_microsomal", n:null,
    phenotypes:[],
    quantifiedEffects:{IC50_CYP2C9:"0.58µM", note:"Potent CYP2C9 inhibition in vitro; clinical relevance at supplement doses uncertain"},
    temporal:{},
    supports:["curcumin_inhibits_CYP2C9"],
    contradicts:[],
    limitations:["Low oral bioavailability of curcumin limits clinical significance","Supplement doses vary enormously"],
    verified:true
  },

  // ═══ PAROXETINE / CYP2D6 — RCT (PubMed 14730412) ═══
  "ev_paroxetine_cyp2d6_rct": {
    id:"ev_paroxetine_cyp2d6_rct",
    type:EVIDENCE_TIER.RCT,
    title:"Effect of deramciclane on CYP2D6 activity — paroxetine as positive control",
    year:2004, source:"European Journal of Clinical Pharmacology",
    pmid:"14730412", doi:"10.1007/s00228-003-0714-z",
    url:"https://doi.org/10.1007/s00228-003-0714-z",
    studyDesign:"double-blind randomized crossover (n=15 healthy subjects)",
    n:15, phenotypes:["normal_metabolizer"],
    quantifiedEffects:{
      aucFold:4.8, clearanceReductionPct:79,
      note:"Paroxetine 20mg×8d → desipramine AUC 4.8× (p<0.001); 2-OH-desipramine/desipramine ratio −74%"
    },
    temporal:{onset:"days", washout:"2-3_weeks", mechanism:"MBI_irreversible"},
    supports:["paroxetine_inhibits_CYP2D6"],
    contradicts:[], limitations:["Paroxetine was positive control, not primary subject","Single-dose desipramine probe"], verified:true
  },

  // ═══ PAROXETINE / CYP2D6 — IN VITRO Ki (PubMed 7782485) ═══
  "ev_paroxetine_cyp2d6_invitro": {
    id:"ev_paroxetine_cyp2d6_invitro",
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Inhibition of alprazolam and desipramine hydroxylation by paroxetine — human liver microsomes",
    year:1995, source:"Journal of Clinical Psychopharmacology",
    pmid:"7782485", doi:"10.1097/00004714-199504000-00008",
    url:"https://doi.org/10.1097/00004714-199504000-00008",
    studyDesign:"Human liver microsome inhibition kinetics",
    n:null, phenotypes:[],
    quantifiedEffects:{
      note:"Ki = 2.0 µM for CYP2D6. More potent than fluoxetine or norfluoxetine. In vitro prediction matched clinical desipramine interaction magnitude."
    },
    temporal:{mechanism:"competitive_and_MBI"},
    supports:["paroxetine_inhibits_CYP2D6"],
    contradicts:[], limitations:["In vitro system","Does not capture MBI time-dependency"], verified:true
  },

  // ═══ SSRI CYP2D6 INHIBITION — PK REVIEW (PubMed 8968657) ═══
  "ev_ssri_cyp2d6_review": {
    id:"ev_ssri_cyp2d6_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Pharmacokinetic-pharmacodynamic relationships of SSRIs — CYP inhibition rank order",
    year:1996, source:"Clinical Pharmacokinetics",
    pmid:"8968657", doi:"10.2165/00003088-199631060-00004",
    url:"https://doi.org/10.2165/00003088-199631060-00004",
    studyDesign:"Systematic review of SSRI clinical PK and DDI literature",
    n:null, phenotypes:["normal_metabolizer","poor_metabolizer"],
    quantifiedEffects:{
      note:"CYP2D6 inhibition rank: paroxetine > norfluoxetine > fluoxetine > sertraline > citalopram > fluvoxamine"
    },
    temporal:{},
    supports:["paroxetine_inhibits_CYP2D6","fluoxetine_inhibits_CYP2D6"],
    contradicts:[], limitations:["Review article — secondary source","1996 literature; predates modern CYP phenotyping for all SSRIs"], verified:true
  },

  // ═══ QTc POLYPHARMACY — CKD OBSERVATIONAL (PubMed 32056163) ═══
  "ev_qtc_polypharmacy_ckd": {
    id:"ev_qtc_polypharmacy_ckd",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Adverse drug events in CKD patients: multiple drug interactions and QTc prolongation",
    year:2020, source:"Drugs & Aging",
    pmid:"32056163", doi:"10.1007/s40266-020-00747-0",
    url:"https://doi.org/10.1007/s40266-020-00747-0",
    studyDesign:"Retrospective observational (n=200 elderly CKD patients)",
    n:200, phenotypes:[],
    quantifiedEffects:{
      note:"29.5% at risk of QTc prolongation from drug combinations. 100% of patients on ≥2 'known-risk' TdP drugs had QTc prolongation. Amiodarone+citalopram most hazardous pair."
    },
    temporal:{},
    supports:["qtc_polypharmacy_risk","amiodarone_qtc","citalopram_qtc"],
    contradicts:[], limitations:["Single-center retrospective","CKD population; may not generalize","Confounding by comorbidities"], verified:true
  },

  // ═══ METHADONE QTc — OBSERVATIONAL (PubMed 25825202) ═══
  "ev_methadone_qtc_polypharmacy": {
    id:"ev_methadone_qtc_polypharmacy",
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Methadone therapy: QTc prolongation and concurrent QTc-prolonging drugs",
    year:2015, source:"Cardiovascular Therapeutics",
    pmid:"25825202", doi:"10.1111/1755-5922.12120",
    url:"https://doi.org/10.1111/1755-5922.12120",
    studyDesign:"Retrospective observational (n=291 patients, 856 encounters)",
    n:291, phenotypes:[],
    quantifiedEffects:{
      note:"25.6% encounters had prolonged QTc; 14.1% had QTc >500ms. Patients on ≥2 additional QTc drugs had 29% prevalence. Methadone dose-QTc correlation was weak (rho=0.09)."
    },
    temporal:{},
    supports:["methadone_qtc","qtc_polypharmacy_risk"],
    contradicts:[], limitations:["Retrospective","Hodges correction formula — may differ from Fridericia","No genotype data"], verified:true
  },

  // ═══ QTc — OLDER ADULTS REVIEW (PubMed 30747995) ═══
  "ev_qtc_older_adults_review": {
    id:"ev_qtc_older_adults_review",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"QTc interval-prolonging therapy in nursing facility residents — navigating the minefield",
    year:2019, source:"Journal of the American Geriatrics Society",
    pmid:"30747995", doi:"10.1111/jgs.15810",
    url:"https://doi.org/10.1111/jgs.15810",
    studyDesign:"Narrative review with clinical recommendations",
    n:null, phenotypes:[],
    quantifiedEffects:{
      note:">95% of QTc drug interaction alerts are overridden in EHR systems. QTc-prolonging drug classes: anti-infectives, antidepressants, urinary anticholinergics, antipsychotics, donepezil."
    },
    temporal:{},
    supports:["qtc_polypharmacy_risk","alert_fatigue_qtc"],
    contradicts:[], limitations:["Narrative review","Nursing facility-specific population"], verified:true
  },

  // ═══ CYP2D6 GENOTYPE — CODEINE/TRAMADOL (PubMed 23759977) ═══
  "ev_cyp2d6_codeine_genotype": {
    id:"ev_cyp2d6_codeine_genotype",
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"CYP2D6 polymorphisms and pain sensitivity — codeine and tramadol response",
    year:2013, source:"Drug Metabolism and Pharmacokinetics",
    pmid:"23759977", doi:"10.2133/dmpk.dmpk-13-rv-032",
    url:"https://doi.org/10.2133/dmpk.dmpk-13-rv-032",
    studyDesign:"Systematic review of CYP2D6 genotype-phenotype studies",
    n:null, phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer","ultrarapid_metabolizer"],
    quantifiedEffects:{
      note:"PM: no morphine from codeine → inadequate analgesia. UM: excess morphine → opioid toxicity. Tramadol activation similarly CYP2D6-dependent."
    },
    temporal:{},
    supports:["codeine_cyp2d6_activation","cyp2d6_genotype_opioid"],
    contradicts:[], limitations:["Review article","CYP2D6 genotype-phenotype correlation imperfect","Conflicting results for some endpoints"], verified:true
  },

  // ═══ SEROTONIN SYNDROME — SSRI+MAOI (PubMed 16529136) ═══
  "ev_linezolid_ssri_serotonin": {
    id:"ev_linezolid_ssri_serotonin",
    type:EVIDENCE_TIER.CASE_REPORT,
    title:"Linezolid-SSRI interactions: an MAOI in disguise — anticipating serotonin syndrome",
    year:2006, source:"Mayo Clinic Proceedings",
    pmid:"16529136", doi:"10.4065/81.3.330",
    url:"https://doi.org/10.4065/81.3.330",
    studyDesign:"Case series + pharmacology review (3 clinical cases)",
    n:3, phenotypes:[],
    quantifiedEffects:{
      note:"Linezolid is a reversible non-selective MAOI. Co-administration with SSRIs causes serotonin syndrome: clonus, myoclonus, hyperthermia, agitation. Potentially fatal."
    },
    temporal:{onset:"hours_to_days", mechanism:"MAO_A_inhibition_plus_SERT_inhibition"},
    supports:["ssri_maoi_serotonin_syndrome"],
    contradicts:[], limitations:["Case series (n=3)","Severity unpredictable","Linezolid is only antibiotic in this class"], verified:true
  },

  "ev_tyramine_maoi_labels": {
    id:"ev_tyramine_maoi_labels",
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"MAOI labeling — tyramine-rich foods and hypertensive crisis",
    year:2025, source:"DailyMed phenelzine/tranylcypromine labels", journal:"DailyMed",
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=phenelzine%20tyramine%20hypertensive%20crisis",
    studyDesign:"regulatory_label",
    n:null, phenotypes:[],
    quantifiedEffects:{note:"Nonselective MAO inhibition can permit dietary tyramine absorption and precipitate hypertensive crisis; labels instruct avoidance of high-tyramine foods during treatment and washout."},
    temporal:{mechanism:"intestinal_MAO_inhibition_plus_tyramine_pressor_response", washout:"up_to_2_weeks_after_irreversible_MAOI"},
    supports:["tyramine_rich_foods_MAO_substrate","maoi_tyramine_hypertensive_crisis"],
    contradicts:[],
    limitations:["Food tyramine content varies widely by preparation, storage, and spoilage","Risk differs across irreversible MAOIs, reversible MAO-A inhibitors, and selective MAO-B regimens"],
    verified:true
  },

  "ev_tacrolimus_cyp3a5_cpic": {
    id:"ev_tacrolimus_cyp3a5_cpic",
    type:EVIDENCE_TIER.GUIDELINE,
    title:"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP3A5 Genotype and Tacrolimus Dosing",
    year:2015, source:"Birdwell et al. / CPIC", journal:"Clin Pharmacol Ther",
    pmid:"25801146", doi:"10.1002/cpt.113",
    url:"https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/",
    studyDesign:"systematic_review_guideline",
    n:null, phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{doseFold:1.5, note:"CYP3A5 expressers often require about 1.5-2x higher tacrolimus starting doses than non-expressers to reach similar trough concentrations; therapeutic drug monitoring remains mandatory."},
    temporal:{mechanism:"CYP3A5_expression_changes_tacrolimus_clearance"},
    supports:["tacrolimus_SUBSTRATE_OF_CYP3A5","cyp3a5_genotype_tacrolimus_dosing"],
    contradicts:[],
    limitations:["Guideline addresses starting dose; trough-guided titration remains standard","Transplant type, interacting drugs, hematocrit, time post-transplant, and ancestry can modify dose requirement"],
    verified:true
  },

  // ═══ PAROXETINE — ASIAN CYP2D6*10 POPULATION PHARMACOGENOMICS ═══
  // Ueda et al. 2006 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  // DOI: 10.1016/j.pnpbp.2005.11.007 · 37 citations
  //
  // CRITICAL CLINICAL FINDING: The standard Caucasian PM/EM binary does NOT apply
  // to East Asian populations. CYP2D6*10 (reduced-function, not null) is at 41.8%
  // allele frequency in Japanese — meaning most Japanese patients are functional IMs,
  // not true NMs. The usual 7% PM prevalence in Caucasians is near-zero in Japanese.
  // This makes paroxetine at higher doses substantially more unpredictable in Asian patients.
  "ev_paroxetine_cyp2d6_japanese": {
    id:"ev_paroxetine_cyp2d6_japanese",
    public:false,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients",
    year:2006, source:"Progress in Neuro-Psychopharmacology and Biological Psychiatry",
    pmid:null, doi:"10.1016/j.pnpbp.2005.11.007",
    url:"https://doi.org/10.1016/j.pnpbp.2005.11.007",
    studyDesign:"Observational clinical study — 55 Japanese inpatients and outpatients (31M/24F) at steady-state PAX doses 10-40mg/day",
    n:55,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{
      note:"~500-fold interindividual variation in steady-state PAX concentration (range 1.4–524.0 ng/mL). ~70-fold variation even after dose/weight correction. Dose-concentration: 15.8, 47.4, 101.2, 177.5 ng/mL at 10, 20, 30, 40 mg/day respectively — nonlinear kinetics confirmed.",
      populationNote:"CYP2D6*10 allele frequency 41.8% in Japanese (vs ~2.8% Caucasian). CYP2D6*5: 1.8%. CYP2D6*3/*4 (Caucasian-dominant defect alleles) near-zero in Japanese.",
      genotypePK:{
        twoFunctional_ngPerMgKg:   76.7,
        oneFunctional_ngPerMgKg:   150.9,  // significantly higher (p<0.05 vs two-functional)
        zeroFunctional_ngPerMgKg:  243.6,  // at 30mg/day dose
        note:"At 30mg/day: one-non-functional-allele patients (CYP2D6*10 heterozygotes) showed 2× higher PAX concentration than two-functional-allele patients"
      }
    },
    temporal:{onset:"weeks_to_steady_state", mechanism:"CYP2D6_substrate_with_autoinhibition"},
    supports:["paroxetine_inhibits_CYP2D6","cyp2d6_genotype_paroxetine","asian_cyp2d6_variability"],
    contradicts:[],
    limitations:[
      "Single-center Japanese population — findings may not generalize to other East Asian groups without recalibration",
      "Does not distinguish CYP2D6*10 homozygotes from heterozygotes in all dose groups",
      "Small n=55; wide SD at each dose group",
      "No therapeutic outcome data — concentrations only"
    ],
    verified:true,
    clinicalImplication:"In East Asian patients, the standard Caucasian PM/NM framework underestimates metabolic variability. CYP2D6*10 (reduced-function, not null) at 41.8% allele frequency makes most Japanese patients functional intermediate metabolizers. Paroxetine TDM is especially important in this population at doses ≥30mg."
  },

  // ═══ PAROXETINE — POPULATION PK, SEX-STRATIFIED REFERENCE RANGES, HIGH-DOSE TAPER ═══
  // Huang et al. 2025 · Journal of Pharmaceutical Sciences · Vol 114, Issue 10, Article 103893
  // DOI: 10.1016/j.xphs.2025.103893 · RECENT: 3 citations as of 2026
  //
  // KEY FINDINGS NOT ELSEWHERE IN SYSTEM:
  // 1. Sex is a significant covariate of paroxetine CL/F — females have lower clearance
  // 2. Sex-specific therapeutic reference ranges (AGNP-complementary):
  //    Males: 15–125 ng/mL | Females: 30–210 ng/mL
  // 3. Nonlinear auto-inhibition kinetics: paroxetine inhibits its own CYP2D6-mediated clearance
  //    → concentration increases disproportionately with dose (especially above 30mg)
  // 4. High-dose tapering (60mg/day) must be more gradual than standard guidelines suggest
  "ev_paroxetine_ppk_sex_chinese": {
    id:"ev_paroxetine_ppk_sex_chinese",
    public:false,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Defining the therapeutic reference range and optimizing a high-dose discontinuation strategy for Paroxetine based on TDM and population pharmacokinetics",
    year:2025, source:"Journal of Pharmaceutical Sciences",
    pmid:null, doi:"10.1016/j.xphs.2025.103893",
    url:"https://doi.org/10.1016/j.xphs.2025.103893",
    studyDesign:"Retrospective PPK study — 360 Chinese psychiatric inpatients, 645 TDM trough concentrations, 1-compartment model (FOCE-I). Doses 10–60 mg/day. IRB-approved (retrospective waiver).",
    n:360,
    phenotypes:["normal_metabolizer"],
    quantifiedEffects:{
      note:"One-compartment PPK model. Key covariates: daily dose and sex on CL/F; formulation on V/F. Nonlinear kinetics confirmed at higher doses — auto-CYP2D6 inhibition causes disproportionate concentration increase.",
      sexSpecificRanges:{
        males_ngPerMl:   [15, 125],
        females_ngPerMl: [30, 210],
        note:"Females have approximately 2× higher serum concentrations vs males at equivalent doses, attributed to lower CL/F. Reference ranges derived from PPK simulations across commonly prescribed doses."
      },
      highDoseTaper:{
        standardGuideline:"Reduce 10mg/week to 20mg, then 1 week at 20mg, then stop",
        studyRecommendation:"More gradual reduction required for high-dose (60mg/day) patients due to nonlinear PK — abrupt reductions cause disproportionate concentration drops and Antidepressant Discontinuation Syndrome (ADDS)",
        addsSeverity:"Paroxetine causes higher proportion of ADDS than other SSRIs in FAERS database",
        tapperSuggestion:"5mg reduction every 2–4 weeks recommended for high-dose patients"
      },
      highDoseObservation:"At 60mg/day, serum concentrations frequently exceed 65 ng/mL (AGNP upper limit), confirming high-dose patients are systematically supratherapeutic by conventional reference ranges"
    },
    temporal:{onset:"weeks_to_steady_state", washout:"2-3_weeks_plus_gradual_taper_for_high_dose", mechanism:"CYP2D6_autoinhibition_nonlinear"},
    supports:["paroxetine_inhibits_CYP2D6","paroxetine_nonlinear_pk","paroxetine_sex_pk_difference"],
    contradicts:[],
    limitations:[
      "Single-center retrospective — Affiliated Brain Hospital, Guangzhou; Chinese cohort only",
      "Sparse TDM sampling (trough only) — not full PK profiles",
      "No CYP2D6 genotyping in this study (model adjusts for dose/sex/formulation but not genotype)",
      "Discontinued patients underrepresented",
      "Reference ranges are simulation-derived, not from clinical outcomes"
    ],
    verified:true,
    clinicalImplication:"Sex must be considered when interpreting paroxetine serum levels. Females at any given dose will have ~2× higher concentrations than males. Current AGNP guidelines (65–125 ng/mL) are male-centric. High-dose patients (≥40mg/day) should be tapered at 5mg/2-4 weeks, not the standard 10mg/week schedule."
  },

  // ═══ LIVE ENRICHMENT DRAFTS — UNREVIEWED, REVIEW REQUIRED ═══
  // Generated from scripts/enrich/drafts.json. These entries contain citation metadata
  // and paraphrased abstract-level findings only. They are live for review/discovery,
  // but verified:false and reviewRequired:true prevent treating them as curated evidence.
  "draft_metformin_oct2_elsby2018_28971610": {
    id:"draft_metformin_oct2_elsby2018_28971610",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine.",
    year:2018,
    source:"Pharmacology research & perspectives",
    journal:"Pharmacology research & perspectives",
    pmid:"28971610",
    doi:"10.1002/prp2.357",
    url:"https://doi.org/10.1002/prp2.357",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_asanos2025_40424011": {
    id:"draft_metformin_oct2_asanos2025_40424011",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Predicting OCT2/MATEs-Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium).",
    year:2025,
    source:"Clin Pharmacol Ther",
    journal:"Clin Pharmacol Ther",
    pmid:"40424011",
    doi:"10.1002/cpt.3727",
    url:"https://doi.org/10.1002/cpt.3727",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_ailabounias2025_40098288": {
    id:"draft_metformin_oct2_ailabounias2025_40098288",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Quantitative Contributions of Hepatic and Renal Organic Cation Transporters to the Clinical Pharmacokinetic Cimetidine-Metformin Interaction.",
    year:2025,
    source:"Clin Pharmacol Ther",
    journal:"Clin Pharmacol Ther",
    pmid:"40098288",
    doi:"10.1002/cpt.3639",
    url:"https://doi.org/10.1002/cpt.3639",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_choimk2026_41599173": {
    id:"draft_metformin_oct2_choimk2026_41599173",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetics and Drug Interactions.",
    year:2026,
    source:"Pharmaceutics",
    journal:"Pharmaceutics",
    pmid:"41599173",
    doi:"10.3390/pharmaceutics18010067",
    url:"https://doi.org/10.3390/pharmaceutics18010067",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_koishikawat2025_39497599": {
    id:"draft_metformin_oct2_koishikawat2025_39497599",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers.",
    year:2025,
    source:"Clin Pharmacol Ther",
    journal:"Clin Pharmacol Ther",
    pmid:"39497599",
    doi:"10.1002/cpt.3482",
    url:"https://doi.org/10.1002/cpt.3482",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_ailabounias2025_39997705": {
    id:"draft_metformin_oct2_ailabounias2025_39997705",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Is <i>N</i>1-Methylnicotinamide a Good Organic Cation Transporter 2 (OCT2) Biomarker?",
    year:2025,
    source:"Metabolites",
    journal:"Metabolites",
    pmid:"39997705",
    doi:"10.3390/metabo15020080",
    url:"https://doi.org/10.3390/metabo15020080",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_giacomini2010_20190787": {
    id:"draft_metformin_oct2_giacomini2010_20190787",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Membrane transporters in drug development",
    year:2010,
    source:"Nature Reviews Drug Discovery",
    journal:"Nature Reviews Drug Discovery",
    pmid:"20190787",
    doi:"10.1038/nrd3028",
    url:"https://doi.org/10.1038/nrd3028",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_hillgren2013_23588305": {
    id:"draft_metformin_oct2_hillgren2013_23588305",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium",
    year:2013,
    source:"Clinical Pharmacology & Therapeutics",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"23588305",
    doi:"10.1038/clpt.2013.74",
    url:"https://doi.org/10.1038/clpt.2013.74",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_morrissey2012_23140242": {
    id:"draft_metformin_oct2_morrissey2012_23140242",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Renal Transporters in Drug Development",
    year:2012,
    source:"The Annual Review of Pharmacology and Toxicology",
    journal:"The Annual Review of Pharmacology and Toxicology",
    pmid:"23140242",
    doi:"10.1146/annurev-pharmtox-011112-140317",
    url:"https://doi.org/10.1146/annurev-pharmtox-011112-140317",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_eyal2010_20118196": {
    id:"draft_metformin_oct2_eyal2010_20118196",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetics of Metformin during Pregnancy",
    year:2010,
    source:"Drug Metabolism and Disposition",
    journal:"Drug Metabolism and Disposition",
    pmid:"20118196",
    doi:"10.1124/dmd.109.031245",
    url:"https://doi.org/10.1124/dmd.109.031245",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metformin_oct2_gervasoni2017_28114188": {
    id:"draft_metformin_oct2_gervasoni2017_28114188",
    public:true,
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?",
    year:2017,
    source:"JAIDS Journal of Acquired Immune Deficiency Syndromes",
    journal:"JAIDS Journal of Acquired Immune Deficiency Syndromes",
    pmid:"28114188",
    doi:"10.1097/qai.0000000000001292",
    url:"https://doi.org/10.1097/qai.0000000000001292",
    studyDesign:"meta_analysis_or_systematic_review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metformin:OCT2, but no supported quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metformin_OCT2_transport"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_alderman1997_9241008": {
    id:"draft_fluoxetine_cyp2d6_alderman1997_9241008",
    public:true,
    type:EVIDENCE_TIER.RCT,
    title:"Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.",
    year:1997,
    source:"Journal of clinical psychopharmacology",
    journal:"Journal of clinical psychopharmacology",
    pmid:"9241008",
    doi:"10.1097/00004714-199708000-00008",
    url:"https://doi.org/10.1097/00004714-199708000-00008",
    studyDesign:"randomized_controlled_trial",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "aucFold": 2,
      "note": "Abstract-level extraction for fluoxetine:CYP2D6 reports approximately 2-fold exposure change."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "Abstract-level extraction only; requires human review before promotion",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"moderate",
    needsFullText:false,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_ereshefsky1996_8846618": {
    id:"draft_fluoxetine_cyp2d6_ereshefsky1996_8846618",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.",
    year:1996,
    source:"Clinical pharmacokinetics",
    journal:"Clinical pharmacokinetics",
    pmid:"8846618",
    doi:"10.2165/00003088-199500291-00004",
    url:"https://doi.org/10.2165/00003088-199500291-00004",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_isoherranenn2026_41494464": {
    id:"draft_fluoxetine_cyp2d6_isoherranenn2026_41494464",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Role of metabolites in drug-drug interactions.",
    year:2026,
    source:"Drug Metab Pharmacokinet",
    journal:"Drug Metab Pharmacokinet",
    pmid:"41494464",
    doi:"10.1016/j.dmpk.2025.101511",
    url:"https://doi.org/10.1016/j.dmpk.2025.101511",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_truongj2025_39870954": {
    id:"draft_fluoxetine_cyp2d6_truongj2025_39870954",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics.",
    year:2025,
    source:"Eur J Drug Metab Pharmacokinet",
    journal:"Eur J Drug Metab Pharmacokinet",
    pmid:"39870954",
    doi:"10.1007/s13318-024-00928-x",
    url:"https://doi.org/10.1007/s13318-024-00928-x",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_tanaudommongkoni2025_40245579": {
    id:"draft_fluoxetine_cyp2d6_tanaudommongkoni2025_40245579",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"The strong clinical interaction between bupropion and CYP2D6 is primarily mediated through bupropion metabolites and their stereoisomers: A paradigm for evaluating metabolites in drug-drug interaction risk.",
    year:2025,
    source:"Drug Metab Dispos",
    journal:"Drug Metab Dispos",
    pmid:"40245579",
    doi:"10.1016/j.dmd.2025.100070",
    url:"https://doi.org/10.1016/j.dmd.2025.100070",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_zakarayaz2024_38543065": {
    id:"draft_fluoxetine_cyp2d6_zakarayaz2024_38543065",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetics and Pharmacodynamics: A Comprehensive Analysis of the Absorption, Distribution, Metabolism, and Excretion of Psychiatric Drugs.",
    year:2024,
    source:"Pharmaceuticals (Basel)",
    journal:"Pharmaceuticals (Basel)",
    pmid:"38543065",
    doi:"10.3390/ph17030280",
    url:"https://doi.org/10.3390/ph17030280",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_parshenkovm2025_41440979": {
    id:"draft_fluoxetine_cyp2d6_parshenkovm2025_41440979",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Personalizing Antidepressant Therapy: Integrating Pharmacogenomics, Therapeutic Drug Monitoring, and Digital Tools for Improved Depression Outcomes.",
    year:2025,
    source:"J Pers Med",
    journal:"J Pers Med",
    pmid:"41440979",
    doi:"10.3390/jpm15120616",
    url:"https://doi.org/10.3390/jpm15120616",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_hiemke2017_28910830": {
    id:"draft_fluoxetine_cyp2d6_hiemke2017_28910830",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017",
    year:2017,
    source:"Pharmacopsychiatry",
    journal:"Pharmacopsychiatry",
    pmid:"28910830",
    doi:"10.1055/s-0043-116492",
    url:"https://doi.org/10.1055/s-0043-116492",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_michalets1998_9469685": {
    id:"draft_fluoxetine_cyp2d6_michalets1998_9469685",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Update: Clinically Significant Cytochrome P‐450 Drug Interactions",
    year:1998,
    source:"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy",
    journal:"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy",
    pmid:"9469685",
    doi:"10.1002/j.1875-9114.1998.tb03830.x",
    url:"https://doi.org/10.1002/j.1875-9114.1998.tb03830.x",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_fluoxetine_cyp2d6_holm1999_null": {
    id:"draft_fluoxetine_cyp2d6_holm1999_null",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Reboxetine",
    year:1999,
    source:"CNS Drugs",
    journal:"CNS Drugs",
    pmid:null,
    doi:"10.2165/00023210-199912010-00006",
    url:"https://doi.org/10.2165/00023210-199912010-00006",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to fluoxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "fluoxetine_inhibits_CYP2D6",
      "norfluoxetine_inhibits_CYP2D6"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_hydroxybupropion_cyp2d6_yuj2024_39452902": {
    id:"draft_hydroxybupropion_cyp2d6_yuj2024_39452902",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Metabolite Measurement in Index Substrate Drug Interaction Studies: A Review of the Literature and Recent New Drug Application Reviews.",
    year:2024,
    source:"Metabolites",
    journal:"Metabolites",
    pmid:"39452902",
    doi:"10.3390/metabo14100522",
    url:"https://doi.org/10.3390/metabo14100522",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to hydroxybupropion:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "hydroxybupropion_inhibits_CYP2D6",
      "bupropion_cyp2d6_ddi"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_hydroxybupropion_cyp2d6_luechtur2025_40006546": {
    id:"draft_hydroxybupropion_cyp2d6_luechtur2025_40006546",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion-The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm.",
    year:2025,
    source:"Pharmaceutics",
    journal:"Pharmaceutics",
    pmid:"40006546",
    doi:"10.3390/pharmaceutics17020179",
    url:"https://doi.org/10.3390/pharmaceutics17020179",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to hydroxybupropion:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "hydroxybupropion_inhibits_CYP2D6",
      "bupropion_cyp2d6_ddi"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_hydroxybupropion_cyp2d6_rdesheims2025_39953671": {
    id:"draft_hydroxybupropion_cyp2d6_rdesheims2025_39953671",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development.",
    year:2025,
    source:"Clin Pharmacol Ther",
    journal:"Clin Pharmacol Ther",
    pmid:"39953671",
    doi:"10.1002/cpt.3604",
    url:"https://doi.org/10.1002/cpt.3604",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to hydroxybupropion:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "hydroxybupropion_inhibits_CYP2D6",
      "bupropion_cyp2d6_ddi"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_hydroxybupropion_cyp2d6_ciocotianim2024_39590825": {
    id:"draft_hydroxybupropion_cyp2d6_ciocotianim2024_39590825",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Bupropion Increased More than Five Times the Systemic Exposure to Aripiprazole: An In Vivo Study in <i>Wistar albino</i> Rats.",
    year:2024,
    source:"Metabolites",
    journal:"Metabolites",
    pmid:"39590825",
    doi:"10.3390/metabo14110588",
    url:"https://doi.org/10.3390/metabo14110588",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to hydroxybupropion:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "hydroxybupropion_inhibits_CYP2D6",
      "bupropion_cyp2d6_ddi"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_hydroxybupropion_cyp2d6_bosilkovska2014_24722393": {
    id:"draft_hydroxybupropion_cyp2d6_bosilkovska2014_24722393",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots",
    year:2014,
    source:"Clinical Pharmacology & Therapeutics",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"24722393",
    doi:"10.1038/clpt.2014.83",
    url:"https://doi.org/10.1038/clpt.2014.83",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to hydroxybupropion:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "hydroxybupropion_inhibits_CYP2D6",
      "bupropion_cyp2d6_ddi"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_hydroxybupropion_cyp2d6_shirasaka2013_23620487": {
    id:"draft_hydroxybupropion_cyp2d6_shirasaka2013_23620487",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions",
    year:2013,
    source:"Drug Metabolism and Disposition",
    journal:"Drug Metabolism and Disposition",
    pmid:"23620487",
    doi:"10.1124/dmd.113.051722",
    url:"https://doi.org/10.1124/dmd.113.051722",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to hydroxybupropion:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "hydroxybupropion_inhibits_CYP2D6",
      "bupropion_cyp2d6_ddi"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_hydroxybupropion_cyp2d6_kirby2011_21930825": {
    id:"draft_hydroxybupropion_cyp2d6_kirby2011_21930825",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir",
    year:2011,
    source:"Drug Metabolism and Disposition",
    journal:"Drug Metabolism and Disposition",
    pmid:"21930825",
    doi:"10.1124/dmd.111.038646",
    url:"https://doi.org/10.1124/dmd.111.038646",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to hydroxybupropion:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "hydroxybupropion_inhibits_CYP2D6",
      "bupropion_cyp2d6_ddi"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_hydroxybupropion_cyp2d6_protti2020_32285503": {
    id:"draft_hydroxybupropion_cyp2d6_protti2020_32285503",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others",
    year:2020,
    source:"Medicinal Research Reviews",
    journal:"Medicinal Research Reviews",
    pmid:"32285503",
    doi:"10.1002/med.21671",
    url:"https://doi.org/10.1002/med.21671",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to hydroxybupropion:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "hydroxybupropion_inhibits_CYP2D6",
      "bupropion_cyp2d6_ddi"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_vortioxetine_cyp2d6_lorvellecma2024_39444600": {
    id:"draft_vortioxetine_cyp2d6_lorvellecma2024_39444600",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Pharmacogenetics testing for poor response to antidepressants: a transnosographic case series.",
    year:2024,
    source:"Front Pharmacol",
    journal:"Front Pharmacol",
    pmid:"39444600",
    doi:"10.3389/fphar.2024.1440523",
    url:"https://doi.org/10.3389/fphar.2024.1440523",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to vortioxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "vortioxetine_METABOLIZED_TO_vortioxetine-carboxylic-acid"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_vortioxetine_cyp2d6_lauschkevm2026_41806469": {
    id:"draft_vortioxetine_cyp2d6_lauschkevm2026_41806469",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"The evolving landscape of pharmacogenomics: Current achievements and future directions.",
    year:2026,
    source:"Pharmacol Rev",
    journal:"Pharmacol Rev",
    pmid:"41806469",
    doi:"10.1016/j.pharmr.2026.100122",
    url:"https://doi.org/10.1016/j.pharmr.2026.100122",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to vortioxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "vortioxetine_METABOLIZED_TO_vortioxetine-carboxylic-acid"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_vortioxetine_cyp2d6_wangsy2025_41019984": {
    id:"draft_vortioxetine_cyp2d6_wangsy2025_41019984",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Impact of metabolic enzyme activity variability on dabrafenib disposition.",
    year:2025,
    source:"Front Pharmacol",
    journal:"Front Pharmacol",
    pmid:"41019984",
    doi:"10.3389/fphar.2025.1643618",
    url:"https://doi.org/10.3389/fphar.2025.1643618",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to vortioxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "vortioxetine_METABOLIZED_TO_vortioxetine-carboxylic-acid"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_vortioxetine_cyp2d6_chen2013_23975654": {
    id:"draft_vortioxetine_cyp2d6_chen2013_23975654",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant",
    year:2013,
    source:"Clinical Drug Investigation",
    journal:"Clinical Drug Investigation",
    pmid:"23975654",
    doi:"10.1007/s40261-013-0117-6",
    url:"https://doi.org/10.1007/s40261-013-0117-6",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to vortioxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "vortioxetine_METABOLIZED_TO_vortioxetine-carboxylic-acid"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_vortioxetine_cyp2d6_strawn2023_36651686": {
    id:"draft_vortioxetine_cyp2d6_strawn2023_36651686",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents",
    year:2023,
    source:"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy",
    journal:"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy",
    pmid:"36651686",
    doi:"10.1002/phar.2767",
    url:"https://doi.org/10.1002/phar.2767",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to vortioxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "vortioxetine_METABOLIZED_TO_vortioxetine-carboxylic-acid"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_vortioxetine_cyp2d6_yu2018_29572333": {
    id:"draft_vortioxetine_cyp2d6_yu2018_29572333",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016",
    year:2018,
    source:"Drug Metabolism and Disposition",
    journal:"Drug Metabolism and Disposition",
    pmid:"29572333",
    doi:"10.1124/dmd.117.078691",
    url:"https://doi.org/10.1124/dmd.117.078691",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to vortioxetine:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "vortioxetine_METABOLIZED_TO_vortioxetine-carboxylic-acid"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_desta2002_11854155": {
    id:"draft_metoclopramide_cyp2d6_desta2002_11854155",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.",
    year:2002,
    source:"Drug metabolism and disposition: the biological fate of chemicals",
    journal:"Drug metabolism and disposition: the biological fate of chemicals",
    pmid:"11854155",
    doi:"10.1124/dmd.30.3.336",
    url:"https://doi.org/10.1124/dmd.30.3.336",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_lium2026_41820792": {
    id:"draft_metoclopramide_cyp2d6_lium2026_41820792",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Impact of CYP2D6 Metabolizer Status on Ondansetron Efficacy in Early Pregnancy Induced Nausea and Vomiting: A Case Control Study.",
    year:2026,
    source:"Clin Transl Sci",
    journal:"Clin Transl Sci",
    pmid:"41820792",
    doi:"10.1111/cts.70523",
    url:"https://doi.org/10.1111/cts.70523",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_moorec2025_39899439": {
    id:"draft_metoclopramide_cyp2d6_moorec2025_39899439",
    public:true,
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"CYP2D6 genotype and associated 5-HT&lt;sub&gt;3&lt;/sub&gt; receptor antagonist outcomes: A systematic review and meta-analysis.",
    year:2025,
    source:"Clin Transl Sci",
    journal:"Clin Transl Sci",
    pmid:"39899439",
    doi:"10.1111/cts.70108",
    url:"https://doi.org/10.1111/cts.70108",
    studyDesign:"meta_analysis_or_systematic_review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_belania2024_39219201": {
    id:"draft_metoclopramide_cyp2d6_belania2024_39219201",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review.",
    year:2024,
    source:"Croat Med J",
    journal:"Croat Med J",
    pmid:"39219201",
    doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/39219201/",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_wittwernl2025_40895400": {
    id:"draft_metoclopramide_cyp2d6_wittwernl2025_40895400",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data.",
    year:2025,
    source:"Pharmgenomics Pers Med",
    journal:"Pharmgenomics Pers Med",
    pmid:"40895400",
    doi:"10.2147/pgpm.s527556",
    url:"https://doi.org/10.2147/pgpm.s527556",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_williams2001_11573533": {
    id:"draft_metoclopramide_cyp2d6_williams2001_11573533",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Codeine phosphate in paediatric medicine",
    year:2001,
    source:"British Journal of Anaesthesia",
    journal:"British Journal of Anaesthesia",
    pmid:"11573533",
    doi:"10.1093/bja/86.3.413",
    url:"https://doi.org/10.1093/bja/86.3.413",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_stearns2003_14652237": {
    id:"draft_metoclopramide_cyp2d6_stearns2003_14652237",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine",
    year:2003,
    source:"JNCI Journal of the National Cancer Institute",
    journal:"JNCI Journal of the National Cancer Institute",
    pmid:"14652237",
    doi:"10.1093/jnci/djg108",
    url:"https://doi.org/10.1093/jnci/djg108",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_hiemke2011_21969060": {
    id:"draft_metoclopramide_cyp2d6_hiemke2011_21969060",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011",
    year:2011,
    source:"Pharmacopsychiatry",
    journal:"Pharmacopsychiatry",
    pmid:"21969060",
    doi:"10.1055/s-0031-1286287",
    url:"https://doi.org/10.1055/s-0031-1286287",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_metoclopramide_cyp2d6_zhou2017_28378927": {
    id:"draft_metoclopramide_cyp2d6_zhou2017_28378927",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects",
    year:2017,
    source:"Clinical Pharmacology & Therapeutics",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"28378927",
    doi:"10.1002/cpt.690",
    url:"https://doi.org/10.1002/cpt.690",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to metoclopramide:CYP2D6, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "metoclopramide_METABOLIZED_TO_n-deethyl-metoclopramide"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_chiang2026_41743842": {
    id:"draft_kratom_cyp_chiang2026_41743842",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Physiologically Based Pharmacokinetic Model for Clinical Translation and Prediction of Drug Interaction of the Major Kratom Alkaloid, Mitragynine.",
    year:2026,
    source:"ACS pharmacology & translational science",
    journal:"ACS pharmacology & translational science",
    pmid:"41743842",
    doi:"10.1021/acsptsci.5c00718",
    url:"https://doi.org/10.1021/acsptsci.5c00718",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_tanna2023_36924284": {
    id:"draft_kratom_cyp_tanna2023_36924284",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom.",
    year:2023,
    source:"Clinical pharmacology and therapeutics",
    journal:"Clinical pharmacology and therapeutics",
    pmid:"36924284",
    doi:"10.1002/cpt.2891",
    url:"https://doi.org/10.1002/cpt.2891",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "aucFold": 50,
      "note": "Abstract-level extraction for kratom:CYP reports approximately 50-fold exposure change."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "Abstract-level extraction only; requires human review before promotion",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"moderate",
    needsFullText:false,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_brogdon2022_35165231": {
    id:"draft_kratom_cyp_brogdon2022_35165231",
    public:true,
    type:EVIDENCE_TIER.CASE_REPORT,
    title:"A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone.",
    year:2022,
    source:"Journal of addiction medicine",
    journal:"Journal of addiction medicine",
    pmid:"35165231",
    doi:"10.1097/ADM.0000000000000968",
    url:"https://doi.org/10.1097/ADM.0000000000000968",
    studyDesign:"case_report",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_gnanasegarams2026_42051846": {
    id:"draft_kratom_cyp_gnanasegarams2026_42051846",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Kratom Consumption Associated With Herb-Induced Liver Injury and a Pharmacokinetic Interaction: A Case Report.",
    year:2026,
    source:"Cureus",
    journal:"Cureus",
    pmid:"42051846",
    doi:"10.7759/cureus.106016",
    url:"https://doi.org/10.7759/cureus.106016",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_akbarnh2025_40642117": {
    id:"draft_kratom_cyp_akbarnh2025_40642117",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Screening, docking, and molecular dynamics analysis of Mitragyna speciosa (Korth.) compounds for targeting HER2 in breast cancer.",
    year:2025,
    source:"Curr Res Struct Biol",
    journal:"Curr Res Struct Biol",
    pmid:"40642117",
    doi:"10.1016/j.crstbi.2025.100171",
    url:"https://doi.org/10.1016/j.crstbi.2025.100171",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_alfordas2025_40006036": {
    id:"draft_kratom_cyp_alfordas2025_40006036",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Exploring the Therapeutic Potential of Mitragynine and Corynoxeine: Kratom-Derived Indole and Oxindole Alkaloids for Pain Management.",
    year:2025,
    source:"Pharmaceuticals (Basel)",
    journal:"Pharmaceuticals (Basel)",
    pmid:"40006036",
    doi:"10.3390/ph18020222",
    url:"https://doi.org/10.3390/ph18020222",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_mccurdycr2024_38217374": {
    id:"draft_kratom_cyp_mccurdycr2024_38217374",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations.",
    year:2024,
    source:"Expert Rev Clin Pharmacol",
    journal:"Expert Rev Clin Pharmacol",
    pmid:"38217374",
    doi:"10.1080/17512433.2024.2305798",
    url:"https://doi.org/10.1080/17512433.2024.2305798",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_melchertpw2024_39299374": {
    id:"draft_kratom_cyp_melchertpw2024_39299374",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"An in vitro evaluation on metabolism of mitragynine to 9-O-demethylmitragynine.",
    year:2024,
    source:"Chem Biol Interact",
    journal:"Chem Biol Interact",
    pmid:"39299374",
    doi:"10.1016/j.cbi.2024.111247",
    url:"https://doi.org/10.1016/j.cbi.2024.111247",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_eastlack2020_31994019": {
    id:"draft_kratom_cyp_eastlack2020_31994019",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Kratom—Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review",
    year:2020,
    source:"Pain and Therapy",
    journal:"Pain and Therapy",
    pmid:"31994019",
    doi:"10.1007/s40122-020-00151-x",
    url:"https://doi.org/10.1007/s40122-020-00151-x",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_rashid2026_null": {
    id:"draft_kratom_cyp_rashid2026_null",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Therapeutic Potential, Predictive Pharmaceutical Modeling, and Metabolic Interactions of the Oxindole Kratom Alkaloids",
    year:2026,
    source:"Journal of Phytomedicine",
    journal:"Journal of Phytomedicine",
    pmid:null,
    doi:"10.3390/jphytomed1010002",
    url:"https://doi.org/10.3390/jphytomed1010002",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_veltri2019_31308789": {
    id:"draft_kratom_cyp_veltri2019_31308789",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"&lt;p&gt;Current perspectives on the impact of Kratom use&lt;/p&gt;",
    year:2019,
    source:"Substance Abuse and Rehabilitation",
    journal:"Substance Abuse and Rehabilitation",
    pmid:"31308789",
    doi:"10.2147/sar.s164261",
    url:"https://doi.org/10.2147/sar.s164261",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_wananukul2015_25995615": {
    id:"draft_kratom_cyp_wananukul2015_25995615",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Pharmacokinetics of mitragynine in man",
    year:2015,
    source:"Drug Design Development and Therapy",
    journal:"Drug Design Development and Therapy",
    pmid:"25995615",
    doi:"10.2147/dddt.s79658",
    url:"https://doi.org/10.2147/dddt.s79658",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_kratom_cyp_kong2011_21876481": {
    id:"draft_kratom_cyp_kong2011_21876481",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Evaluation of the Effects of Mitragyna speciosa Alkaloid Extract on Cytochrome P450 Enzymes Using a High Throughput Assay",
    year:2011,
    source:"Molecules",
    journal:"Molecules",
    pmid:"21876481",
    doi:"10.3390/molecules16097344",
    url:"https://doi.org/10.3390/molecules16097344",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to kratom:CYP, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "kratom_cyp_interaction_potential",
      "kratom_polysubstance_toxicity"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_zahner2020_30739325": {
    id:"draft_st_johns_wort_cyp3a4_pgp_zahner2020_30739325",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P-glycoprotein.",
    year:2020,
    source:"Clinical pharmacology and therapeutics",
    journal:"Clinical pharmacology and therapeutics",
    pmid:"30739325",
    doi:"10.1002/cpt.1392",
    url:"https://doi.org/10.1002/cpt.1392",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no supported quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_huppertz2019_30192025": {
    id:"draft_st_johns_wort_cyp3a4_pgp_huppertz2019_30192025",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.",
    year:2019,
    source:"British journal of clinical pharmacology",
    journal:"British journal of clinical pharmacology",
    pmid:"30192025",
    doi:"10.1111/bcp.13757",
    url:"https://doi.org/10.1111/bcp.13757",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no supported quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_arold2005_15856409": {
    id:"draft_st_johns_wort_cyp3a4_pgp_arold2005_15856409",
    public:true,
    type:EVIDENCE_TIER.RCT,
    title:"No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.",
    year:2005,
    source:"Planta medica",
    journal:"Planta medica",
    pmid:"15856409",
    doi:"10.1055/s-2005-864099",
    url:"https://doi.org/10.1055/s-2005-864099",
    studyDesign:"randomized_controlled_trial",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no supported quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:pubmed",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_cascorbii2025_40388112": {
    id:"draft_st_johns_wort_cyp3a4_pgp_cascorbii2025_40388112",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Deciphering the Relative Contribution of CYP3A4 Versus P-Glycoprotein for the Shared Substrate Cyclosporine-Commentary on Lown et al.",
    year:2025,
    source:"Clin Pharmacol Ther",
    journal:"Clin Pharmacol Ther",
    pmid:"40388112",
    doi:"10.1002/cpt.3619",
    url:"https://doi.org/10.1002/cpt.3619",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_coumauc2025_40349292": {
    id:"draft_st_johns_wort_cyp3a4_pgp_coumauc2025_40349292",
    public:true,
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs.",
    year:2025,
    source:"Clin Pharmacokinet",
    journal:"Clin Pharmacokinet",
    pmid:"40349292",
    doi:"10.1007/s40262-025-01514-3",
    url:"https://doi.org/10.1007/s40262-025-01514-3",
    studyDesign:"meta_analysis_or_systematic_review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_hollanderem2026_41552958": {
    id:"draft_st_johns_wort_cyp3a4_pgp_hollanderem2026_41552958",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.",
    year:2026,
    source:"Int J Cancer",
    journal:"Int J Cancer",
    pmid:"41552958",
    doi:"10.1002/ijc.70326",
    url:"https://doi.org/10.1002/ijc.70326",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_nersesjanm2025_38450747": {
    id:"draft_st_johns_wort_cyp3a4_pgp_nersesjanm2025_38450747",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report.",
    year:2025,
    source:"Br J Clin Pharmacol",
    journal:"Br J Clin Pharmacol",
    pmid:"38450747",
    doi:"10.1111/bcp.16036",
    url:"https://doi.org/10.1111/bcp.16036",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_yaoj2025_41258782": {
    id:"draft_st_johns_wort_cyp3a4_pgp_yaoj2025_41258782",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Effects of Botrychium ternatum (Thunb) Sw. On Cytochrome P450 Activities in Rats.",
    year:2025,
    source:"Pharmacol Res Perspect",
    journal:"Pharmacol Res Perspect",
    pmid:"41258782",
    doi:"10.1002/prp2.70188",
    url:"https://doi.org/10.1002/prp2.70188",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_huang2004_14749688": {
    id:"draft_st_johns_wort_cyp3a4_pgp_huang2004_14749688",
    public:true,
    type:EVIDENCE_TIER.META_ANALYSIS,
    title:"Drug interactions with herbal products and grapefruit juice: a conference report",
    year:2004,
    source:"Clinical Pharmacology & Therapeutics",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"14749688",
    doi:"10.1016/j.clpt.2003.07.002",
    url:"https://doi.org/10.1016/j.clpt.2003.07.002",
    studyDesign:"meta_analysis_or_systematic_review",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "clearanceReductionPct": 20,
      "note": "Abstract-level extraction for st_johns_wort:CYP3A4_Pgp reports about 20% clearance change."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "Abstract-level extraction only; requires human review before promotion",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"moderate",
    needsFullText:false,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_motzer2015_26406148": {
    id:"draft_st_johns_wort_cyp3a4_pgp_motzer2015_26406148",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma",
    year:2015,
    source:"New England Journal of Medicine",
    journal:"New England Journal of Medicine",
    pmid:"26406148",
    doi:"10.1056/nejmoa1510665",
    url:"https://doi.org/10.1056/nejmoa1510665",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_tsunoda2001_null": {
    id:"draft_st_johns_wort_cyp3a4_pgp_tsunoda2001_null",
    public:true,
    type:EVIDENCE_TIER.IN_VITRO,
    title:"Red wine decreases cyclosporine bioavailability",
    year:2001,
    source:"Clinical Pharmacology & Therapeutics",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:null,
    doi:"10.1016/s0009-9236(01)70992-7",
    url:"https://doi.org/10.1016/s0009-9236(01)70992-7",
    studyDesign:"in_vitro_mechanistic_study",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to st_johns_wort:CYP3A4_Pgp, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_st_johns_wort_cyp3a4_pgp_zhang2017_28986954": {
    id:"draft_st_johns_wort_cyp3a4_pgp_zhang2017_28986954",
    public:true,
    type:EVIDENCE_TIER.CASE_REPORT,
    title:"Role of CYP3A in Oral Contraceptives Clearance",
    year:2017,
    source:"Clinical and Translational Science",
    journal:"Clinical and Translational Science",
    pmid:"28986954",
    doi:"10.1111/cts.12499",
    url:"https://doi.org/10.1111/cts.12499",
    studyDesign:"case_report",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "aucFold": 2.7,
      "note": "Abstract-level extraction for st_johns_wort:CYP3A4_Pgp reports approximately 2.7-fold exposure change."
    },
    temporal:{},
    supports:[
      "st_johns_wort_induces_CYP3A4",
      "st_johns_wort_induces_P-gp"
    ],
    contradicts:[],
    limitations:[
      "Abstract-level extraction only; requires human review before promotion",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"moderate",
    needsFullText:false,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_clobazam_cyp2c19_huddartr2018_29517622": {
    id:"draft_clobazam_cyp2c19_huddartr2018_29517622",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"PharmGKB summary: clobazam pathway, pharmacokinetics.",
    year:2018,
    source:"Pharmacogenet Genomics",
    journal:"Pharmacogenet Genomics",
    pmid:"29517622",
    doi:"10.1097/fpc.0000000000000327",
    url:"https://doi.org/10.1097/fpc.0000000000000327",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to clobazam:CYP2C19, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "clobazam_METABOLIZED_TO_n-desmethylclobazam-norclobazam"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_clobazam_cyp2c19_kamh2020_33266292": {
    id:"draft_clobazam_cyp2c19_kamh2020_33266292",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Pharmacogenomic Biomarkers and Their Applications in Psychiatry.",
    year:2020,
    source:"Genes (Basel)",
    journal:"Genes (Basel)",
    pmid:"33266292",
    doi:"10.3390/genes11121445",
    url:"https://doi.org/10.3390/genes11121445",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to clobazam:CYP2C19, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "clobazam_METABOLIZED_TO_n-desmethylclobazam-norclobazam"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_clobazam_cyp2c19_deleonj2013_23318278": {
    id:"draft_clobazam_cyp2c19_deleonj2013_23318278",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Clobazam therapeutic drug monitoring:  a comprehensive review of the literature with proposals to improve future studies.",
    year:2013,
    source:"Ther Drug Monit",
    journal:"Ther Drug Monit",
    pmid:"23318278",
    doi:"10.1097/ftd.0b013e31827ada88",
    url:"https://doi.org/10.1097/ftd.0b013e31827ada88",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to clobazam:CYP2C19, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "clobazam_METABOLIZED_TO_n-desmethylclobazam-norclobazam"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:europepmc",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_clobazam_cyp2c19_faulkner2015_26089675": {
    id:"draft_clobazam_cyp2c19_faulkner2015_26089675",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox&amp;ndash;Gastaut syndrome",
    year:2015,
    source:"Therapeutics and Clinical Risk Management",
    journal:"Therapeutics and Clinical Risk Management",
    pmid:"26089675",
    doi:"10.2147/tcrm.s55930",
    url:"https://doi.org/10.2147/tcrm.s55930",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to clobazam:CYP2C19, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "clobazam_METABOLIZED_TO_n-desmethylclobazam-norclobazam"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_clobazam_cyp2c19_filipiuc2023_37513960": {
    id:"draft_clobazam_cyp2c19_filipiuc2023_37513960",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"The Skin and Natural Cannabinoids–Topical and Transdermal Applications",
    year:2023,
    source:"Pharmaceuticals",
    journal:"Pharmaceuticals",
    pmid:"37513960",
    doi:"10.3390/ph16071049",
    url:"https://doi.org/10.3390/ph16071049",
    studyDesign:"clinical_pk",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to clobazam:CYP2C19, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "clobazam_METABOLIZED_TO_n-desmethylclobazam-norclobazam"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_clobazam_cyp2c19_motycka2018_null": {
    id:"draft_clobazam_cyp2c19_motycka2018_null",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"The Impact of Medical Marijuana on Pharmacy Practice",
    year:2018,
    source:"Advances in Pharmacology and Pharmacy",
    journal:"Advances in Pharmacology and Pharmacy",
    pmid:null,
    doi:"10.13189/app.2018.060102",
    url:"https://doi.org/10.13189/app.2018.060102",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to clobazam:CYP2C19, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "clobazam_METABOLIZED_TO_n-desmethylclobazam-norclobazam"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  "draft_clobazam_cyp2c19_vegagarca2021_33510627": {
    id:"draft_clobazam_cyp2c19_vegagarca2021_33510627",
    public:true,
    type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"Cannabinoids: A New Perspective on Epileptogenesis and Seizure Treatment in Early Life in Basic and Clinical Studies",
    year:2021,
    source:"Frontiers in Behavioral Neuroscience",
    journal:"Frontiers in Behavioral Neuroscience",
    pmid:"33510627",
    doi:"10.3389/fnbeh.2020.610484",
    url:"https://doi.org/10.3389/fnbeh.2020.610484",
    studyDesign:"observational_or_screened_pubmed_record",
    n:null,
    phenotypes:[],
    quantifiedEffects:{
      "note": "Citation appears relevant to clobazam:CYP2C19, but no quantitative value was extractable from the abstract."
    },
    temporal:{},
    supports:[
      "clobazam_METABOLIZED_TO_n-desmethylclobazam-norclobazam"
    ],
    contradicts:[],
    limitations:[
      "No abstract-extractable quantitative value",
      "Live enrichment entry promoted before human review; do not use for severity escalation without review"
    ],
    confidence:"low",
    needsFullText:true,
    provenance:"search:openalex",
    reviewRequired:true,
    verified:false,
    verifyNote:"Live enrichment entry awaiting human pharmacist/physician review; citation metadata and abstract-level facts only"
  },

  // ═══ HLA IMMUNE-RISK PHARMACOGENETICS ═══
  "ev_carbamazepine_oxcarbazepine_hla_cpic2017": {
    id:"ev_carbamazepine_oxcarbazepine_hla_cpic2017",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update",
    year:2018,
    source:"CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"29385237",
    doi:"10.1002/cpt.1004",
    url:"https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/",
    studyDesign:"clinical_pharmacogenetics_guideline",
    n:null,
    phenotypes:["risk_allele_absent","risk_allele_present"],
    quantifiedEffects:{note:"HLA-B*15:02 and HLA-A*31:01 are used to guide carbamazepine therapy; HLA-B*15:02 is also used for oxcarbazepine SJS/TEN risk."},
    temporal:{mechanism:"HLA-mediated immune hypersensitivity"},
    supports:["carbamazepine_HLA-B*15:02_sjs_ten","carbamazepine_HLA-A*31:01_hypersensitivity","oxcarbazepine_HLA-B*15:02_sjs_ten"],
    contradicts:[],
    limitations:["Risk varies by ancestry and allele prevalence","Absence of the allele does not eliminate non-HLA hypersensitivity risk"],
    confidence:"high",
    verified:true
  },

  "ev_abacavir_hlab5701_cpic2012": {
    id:"ev_abacavir_hlab5701_cpic2012",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guidelines for HLA-B Genotype and Abacavir Dosing",
    year:2012,
    source:"CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"22378157",
    doi:"10.1038/clpt.2011.355",
    url:"https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/",
    studyDesign:"clinical_pharmacogenetics_guideline",
    n:null,
    phenotypes:["risk_allele_absent","risk_allele_present"],
    quantifiedEffects:{note:"HLA-B*57:01 predicts abacavir hypersensitivity; abacavir is not recommended for allele-positive patients."},
    temporal:{mechanism:"HLA-mediated abacavir hypersensitivity"},
    supports:["abacavir_HLA-B*57:01_hypersensitivity"],
    contradicts:[],
    limitations:["Applies only when HLA-B*57:01 genotype result is known","Clinical diagnosis remains important if symptoms occur"],
    confidence:"high",
    verified:true
  },

  "ev_allopurinol_hlab5801_cpic2015": {
    id:"ev_allopurinol_hlab5801_cpic2015",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guidelines for HLA-B Genotype and Allopurinol Dosing: 2015 Update",
    year:2015,
    source:"CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"26306456",
    doi:"10.1002/cpt.161",
    url:"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/",
    studyDesign:"clinical_pharmacogenetics_guideline",
    n:null,
    phenotypes:["risk_allele_absent","risk_allele_present"],
    quantifiedEffects:{note:"HLA-B*58:01 is associated with allopurinol severe cutaneous adverse reactions; CPIC recommends allopurinol is contraindicated when present."},
    temporal:{mechanism:"HLA-mediated severe cutaneous adverse reaction"},
    supports:["allopurinol_HLA-B*58:01_scar"],
    contradicts:[],
    limitations:["Risk also depends on clinical factors such as renal function and starting dose","Allele absence does not eliminate rash or hypersensitivity risk"],
    confidence:"high",
    verified:true
  },

  "ev_phenytoin_cyp2c9_hlab_cpic2020": {
    id:"ev_phenytoin_cyp2c9_hlab_cpic2020",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update",
    year:2020,
    source:"CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"32779747",
    doi:null,
    url:"https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9/",
    studyDesign:"clinical_pharmacogenetics_guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer","risk_allele_absent","risk_allele_present"],
    quantifiedEffects:{note:"CYP2C9 guides phenytoin dose/exposure; HLA-B*15:02 informs severe cutaneous adverse reaction risk."},
    temporal:{mechanism:"CYP2C9 clearance plus HLA-mediated cutaneous hypersensitivity"},
    supports:["phenytoin_CYP2C9_dose","phenytoin_HLA-B*15:02_scar"],
    contradicts:[],
    limitations:["HLA-B*15:02 allele prevalence differs substantially by ancestry","Therapeutic drug monitoring remains important for phenytoin"],
    confidence:"high",
    verified:true
  },

  "ev_rasburicase_g6pd_cpic2014": {
    id:"ev_rasburicase_g6pd_cpic2014",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype",
    year:2014,
    source:"CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"24787449",
    doi:"10.1038/clpt.2014.97",
    url:"https://pubmed.ncbi.nlm.nih.gov/24787449/",
    studyDesign:"clinical_pharmacogenetics_guideline",
    n:null,
    phenotypes:["risk_allele_absent","risk_allele_present"],
    quantifiedEffects:{note:"Rasburicase is contraindicated in G6PD deficiency because of acute hemolytic anemia and methemoglobinemia risk; G6PD deficiency also increases susceptibility to oxidative-stress hemolysis from selected drugs."},
    temporal:{onset:"hours_to_days", mechanism:"oxidative_hemolysis"},
    supports:["rasburicase_G6PD_deficiency_contraindication","g6pd_oxidative_drug_hemolysis"],
    contradicts:[],
    limitations:["Clinical risk varies by G6PD activity, dose, and oxidative stress burden","G6PD status may require enzyme testing rather than genotype alone in some settings"],
    confidence:"high",
    verified:true
  },

  "ev_aminoglycoside_mtrnr1_cpic2021": {
    id:"ev_aminoglycoside_mtrnr1_cpic2021",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype",
    year:2021,
    source:"CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"34032273",
    doi:"10.1002/cpt.2309",
    url:"https://pubmed.ncbi.nlm.nih.gov/34032273/",
    studyDesign:"clinical_pharmacogenetics_guideline",
    n:null,
    phenotypes:["risk_allele_absent","risk_allele_present"],
    quantifiedEffects:{note:"MT-RNR1 m.1555A>G, m.1494C>T, and m.1095T>C increase risk of irreversible aminoglycoside-induced hearing loss, even at therapeutic levels."},
    temporal:{onset:"single_dose_to_days", mechanism:"mitochondrial_12s_rRNA_aminoglycoside_binding"},
    supports:["mtrnr1_aminoglycoside_ototoxicity"],
    contradicts:[],
    limitations:["Negative genotype does not remove ordinary dose-, duration-, or renal-function-related ototoxicity risk","Urgent infection contexts may require risk-benefit decisions when alternatives are unsuitable"],
    confidence:"high",
    verified:true
  },

  "ev_volatile_succinylcholine_ryr1_cacna1s_cpic2019": {
    id:"ev_volatile_succinylcholine_ryr1_cacna1s_cpic2019",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes",
    year:2019,
    source:"CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"30499100",
    doi:"10.1002/cpt.1319",
    url:"https://pubmed.ncbi.nlm.nih.gov/30499100/",
    studyDesign:"clinical_pharmacogenetics_guideline",
    n:null,
    phenotypes:["risk_allele_absent","risk_allele_present"],
    quantifiedEffects:{note:"Malignant-hyperthermia-associated RYR1/CACNA1S variants indicate susceptibility; CPIC recommends avoiding succinylcholine and potent volatile anesthetics and using non-triggering anesthesia."},
    temporal:{onset:"minutes_intraoperative", mechanism:"dysregulated_skeletal_muscle_calcium_release"},
    supports:["ryr1_cacna1s_mh_trigger","succinylcholine_mh_trigger","volatile_anesthetic_mh_trigger"],
    contradicts:[],
    limitations:["A negative genotype does not fully exclude malignant hyperthermia susceptibility","Personal and family anesthesia history remain clinically important"],
    confidence:"high",
    verified:true
  },

  "ev_bche_succinylcholine_mivacurium_label": {
    id:"ev_bche_succinylcholine_mivacurium_label",
    public:true,
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Succinylcholine and mivacurium labeling - pseudocholinesterase deficiency and prolonged neuromuscular blockade",
    year:2024,
    source:"FDA / DailyMed",
    journal:null,
    pmid:null,
    doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Reduced or absent plasma pseudocholinesterase/butyrylcholinesterase activity can markedly prolong succinylcholine or mivacurium neuromuscular blockade, producing prolonged paralysis/apnea after standard doses."},
    temporal:{onset:"minutes_intraoperative", mechanism:"impaired_plasma_butyrylcholinesterase_hydrolysis"},
    supports:["succinylcholine_SUBSTRATE_OF_BCHE","mivacurium_SUBSTRATE_OF_BCHE","bche_deficiency_prolonged_paralysis"],
    contradicts:[],
    limitations:["Acquired pseudocholinesterase reduction can mimic genetic deficiency","Dibucaine number, enzyme activity testing, medication context, pregnancy, liver disease, and prior anesthesia history matter"],
    confidence:"high",
    verified:true
  },

  "ev_cyp2c9_nsaid_cpic2020": {
    id:"ev_cyp2c9_nsaid_cpic2020",
    public:true,
    type:EVIDENCE_TIER.GUIDELINE,
    title:"CPIC Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs",
    year:2020,
    source:"Theken et al. / CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"32189324",
    doi:"10.1002/cpt.1830",
    url:"https://pubmed.ncbi.nlm.nih.gov/32189324/",
    studyDesign:"systematic_review_guideline",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"CPIC provides CYP2C9 phenotype-based recommendations for selected NSAIDs, with the clearest actionability for celecoxib, flurbiprofen, lornoxicam, and ibuprofen; reduced function increases exposure and dose-related toxicity risk."},
    temporal:{mechanism:"reduced_CYP2C9_NSAID_clearance"},
    supports:["ibuprofen_SUBSTRATE_OF_CYP2C9","celecoxib_SUBSTRATE_OF_CYP2C9","meloxicam_SUBSTRATE_OF_CYP2C9","cyp2c9_nsaid_toxicity_risk"],
    contradicts:[],
    limitations:["Recommendations vary by NSAID and phenotype; renal function, age, dose, duration, GI bleed risk, anticoagulants/antiplatelets, and cardiovascular risk can dominate genotype alone"],
    confidence:"high",
    verified:true
  },

  "ev_cyp2c8_pharmacogenetics_review_tornio2009": {
    id:"ev_cyp2c8_pharmacogenetics_review_tornio2009",
    type:EVIDENCE_TIER.REVIEW,
    title:"Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies",
    year:2009,
    source:"Tornio et al.",
    journal:"Pharmacogenomics",
    pmid:"19761371",
    doi:"10.2217/pgs.09.82",
    url:"https://pubmed.ncbi.nlm.nih.gov/19761371/",
    studyDesign:"clinical_pharmacogenetics_review",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"CYP2C8 contributes to the disposition of thiazolidinediones, repaglinide, paclitaxel, antimalarials, selected statins, and other drugs, but substrate-dependent variant effects make genotype-only predictions less reliable than for CYP2C9/CYP2C19."},
    temporal:{mechanism:"CYP2C8_substrate_dependent_variant_effects"},
    supports:["paclitaxel_cyp2c8_substrate","pioglitazone_CYP2C8_metabolism","cyp2c8_substrate_dependent_pgx_context"],
    contradicts:[],
    limitations:["Review-level evidence; clinical actionability differs strongly by drug and is often dominated by inhibitors such as gemfibrozil or clopidogrel acyl glucuronide"],
    confidence:"moderate",
    verified:true
  },

  "ev_sulfonylurea_cyp2c9_label_context": {
    id:"ev_sulfonylurea_cyp2c9_label_context",
    public:true,
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sulfonylurea labeling - CYP2C9 metabolism and hypoglycemia monitoring context",
    year:2024,
    source:"FDA / DailyMed",
    journal:null,
    pmid:null,
    doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:["poor_metabolizer","intermediate_metabolizer","normal_metabolizer"],
    quantifiedEffects:{note:"Glipizide and glyburide labeling describes hepatic metabolism and hypoglycemia risk; CYP2C9 contributes substantially to oxidative clearance in the MedCheck model, so reduced CYP2C9 function is represented as a hypoglycemia-risk context rather than a genotype-only dose rule."},
    temporal:{mechanism:"reduced_CYP2C9_sulfonylurea_clearance"},
    supports:["glipizide_SUBSTRATE_OF_CYP2C9","glyburide_SUBSTRATE_OF_CYP2C9","sulfonylurea_hypoglycemia_context"],
    contradicts:[],
    limitations:["Clinical action depends heavily on age, kidney/liver function, meal pattern, dose, and concurrent insulin or other glucose-lowering drugs"],
    confidence:"moderate",
    verified:true
  },

  "ev_lorazepam_oxazepam_temazepam_ugt_label": {
    id:"ev_lorazepam_oxazepam_temazepam_ugt_label",
    public:true,
    type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lorazepam, oxazepam, and temazepam labeling - direct glucuronidation context",
    year:2024,
    source:"FDA / DailyMed",
    journal:null,
    pmid:null,
    doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:["UGT2B15","UGT2B17"],
    quantifiedEffects:{note:"Lorazepam, oxazepam, and temazepam avoid major CYP oxidative pathways but are still glucuronidated; sedation, falls, age, hepatic/renal context, and other CNS depressants remain the dominant clinical safety drivers."},
    temporal:{mechanism:"direct_benzodiazepine_glucuronidation"},
    supports:["lorazepam_UGT2B15_glucuronidation","oxazepam_UGT2B15_UGT2B17_glucuronidation","temazepam_UGT2B15_UGT2B17_glucuronidation"],
    contradicts:[],
    limitations:["UGT genotype effects are not treated as standalone dose rules; clinical sedation/fall risk and organ function dominate"],
    confidence:"moderate",
    verified:true
  },

  // ═══ ENRICHMENT BATCH 1 ═══
  "ev_dapsone_hlab1301_zhang2013":{
    id:"ev_dapsone_hlab1301_zhang2013",
    public:true,
    type:"observational",
    title:"HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome",
    year:2013,
    source:"Zhang et al.",
    journal:"New England Journal of Medicine",
    pmid:"24152261",
    doi:"10.1056/NEJMoa1213096",
    url:"https://pubmed.ncbi.nlm.nih.gov/24152261/",
    studyDesign:"genome_wide_association_case_control",
    n:872,
    phenotypes:[
      "risk_allele_absent",
      "risk_allele_present"
    ],
    quantifiedEffects:{
      note:"OR 20.53 for DHS; sensitivity 85.5%, specificity 85.7%; allele absence reduced risk ~7-fold (1.4%→0.2%). Common in East/Southeast Asian and Indian populations, largely absent in Europeans/Africans."
    },
    temporal:{
      onset:"4-6_weeks",
      mechanism:"HLA-mediated delayed immune hypersensitivity (DRESS)"
    },
    supports:[
      "dapsone_HLA-B*13:01_hypersensitivity"
    ],
    contradicts:[],
    limitations:[
      "Discovery cohort in leprosy patients",
      "Applicability varies sharply by ancestry"
    ],
    verified:true
  },

  "ev_dapsone_hlab1301_krismawati2020":{
    id:"ev_dapsone_hlab1301_krismawati2020",
    public:true,
    type:"observational",
    title:"Validation of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia",
    year:2020,
    source:"Krismawati et al.",
    journal:"PLoS Neglected Tropical Diseases",
    pmid:null,
    doi:"10.1371/journal.pntd.0008746",
    url:"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592909/",
    studyDesign:"case_control_validation",
    n:86,
    phenotypes:[
      "risk_allele_absent",
      "risk_allele_present"
    ],
    quantifiedEffects:{
      note:"Independent Papua/Indonesia validation: HLA-B*13:01 most significant DHS-associated allele (OR 233.64); sensitivity 91.2%, specificity 96.2%, AUC 0.95."
    },
    temporal:{
      mechanism:"HLA-mediated delayed immune hypersensitivity"
    },
    supports:[
      "dapsone_HLA-B*13:01_hypersensitivity"
    ],
    contradicts:[],
    limitations:[
      "Single-region cohort",
      "Wide CI on OR (small n)"
    ],
    verified:true
  },

  "ev_thiopurine_tpmt_nudt15_cpic2025":{
    id:"ev_thiopurine_tpmt_nudt15_cpic2025",
    public:true,
    type:"guideline",
    title:"CPIC Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update",
    year:2025,
    source:"CPIC",
    journal:"Clinical Pharmacology & Therapeutics",
    pmid:"41618934",
    doi:null,
    url:"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/",
    studyDesign:"clinical_pharmacogenetics_guideline",
    n:null,
    phenotypes:[
      "poor_metabolizer",
      "intermediate_metabolizer",
      "normal_metabolizer"
    ],
    quantifiedEffects:{
      note:"Mercaptopurine/azathioprine/thioguanine starting-dose reductions by TPMT and NUDT15 phenotype; PM warrants drastic reduction; compound TPMT-IM/NUDT15-IM → 20-50% of standard dose."
    },
    temporal:{
      mechanism:"impaired thiopurine catabolism / accumulation of cytotoxic 6-TGN"
    },
    supports:[
      "mercaptopurine_TPMT_NUDT15_myelosuppression",
      "thioguanine_TPMT_NUDT15_myelosuppression",
      "azathioprine_TPMT_NUDT15_myelosuppression"
    ],
    contradicts:[],
    limitations:[
      "NUDT15 loss-of-function concentrated in East Asian/Amerindian ancestry",
      "Genotype guides starting dose; ongoing CBC monitoring still required"
    ],
    verified:true
  },

  "ev_tafenoquine_g6pd_fda":{
    id:"ev_tafenoquine_g6pd_fda",
    public:true,
    type:"fda_label",
    title:"ARAKODA / KRINTAFEL (tafenoquine) Prescribing Information — G6PD testing requirement & hemolytic anemia",
    year:2018,
    source:"FDA",
    pmid:null,
    doi:null,
    url:"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:[
      "risk_allele_absent",
      "risk_allele_present"
    ],
    quantifiedEffects:{
      note:"G6PD testing required before tafenoquine; contraindicated in G6PD-deficient/unknown status. Hemolysis may be delayed; long t½ (~14d) prevents rapid reversal. Methemoglobinemia monitoring advised."
    },
    temporal:{
      onset:"hours_to_days",
      offset:"prolonged_t½_~14d",
      mechanism:"oxidative_hemolysis"
    },
    supports:[
      "tafenoquine_G6PD_deficiency_contraindication",
      "g6pd_oxidative_drug_hemolysis"
    ],
    contradicts:[],
    limitations:[
      "Quantitative G6PD activity threshold matters (studies safe >70%)",
      "Point-of-care qualitative tests may misclassify intermediate-activity females"
    ],
    verified:true
  },

  "ev_vancomycin_hla_a3201_konvinse2019":{
    id:"ev_vancomycin_hla_a3201_konvinse2019",
    public:true,
    type:"observational",
    title:"HLA-A*32:01 is strongly associated with vancomycin-induced DRESS",
    year:2019,
    source:"Konvinse et al.",
    journal:"Journal of Allergy and Clinical Immunology",
    pmid:"30776417",
    doi:"10.1016/j.jaci.2019.01.045",
    url:"https://pubmed.ncbi.nlm.nih.gov/30776417/",
    studyDesign:"case_control_with_time_to_event",
    n:23,
    phenotypes:[
      "risk_allele_absent",
      "risk_allele_present"
    ],
    quantifiedEffects:{
      note:"19/23 (82.6%) vancomycin-DRESS cases carried HLA-A*32:01 vs 0/46 tolerant controls; 19.2% of allele-positive developed DRESS within 4 weeks. Predominantly European-ancestry population."
    },
    temporal:{
      onset:"days_to_weeks",
      mechanism:"HLA-mediated DRESS"
    },
    supports:[
      "vancomycin_HLA-A*32:01_dress"
    ],
    contradicts:[],
    limitations:[
      "Small case n",
      "Subsequent DILIN series confirmed association at lower absolute incidence"
    ],
    verified:true
  },

  "ev_flucloxacillin_hlab5701_daly2009":{
    id:"ev_flucloxacillin_hlab5701_daly2009",
    public:true,
    type:"observational",
    title:"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin",
    year:2009,
    source:"Daly et al.",
    journal:"Nature Genetics",
    pmid:"19483685",
    doi:"10.1038/ng.379",
    url:"https://pubmed.ncbi.nlm.nih.gov/19483685/",
    studyDesign:"genome_wide_association_case_control",
    n:null,
    phenotypes:[
      "risk_allele_absent",
      "risk_allele_present"
    ],
    quantifiedEffects:{
      note:"Strong association of HLA-B*57:01 with flucloxacillin-induced cholestatic DILI (reported OR ~80); absolute risk remains low (idiosyncratic)."
    },
    temporal:{
      onset:"1-45_days_or_post-course",
      mechanism:"HLA-mediated idiosyncratic hepatotoxicity"
    },
    supports:[
      "flucloxacillin_HLA-B*57:01_dili"
    ],
    contradicts:[],
    limitations:[
      "PMID/OR not re-verified this pass — CONFIRM before verified:true",
      "Low positive predictive value → not a routine pre-test"
    ],
    verified:false,
    reviewRequired:true,
    verifyNote:"Batch 1 enrichment entry awaiting human pharmacist/physician review; do not use for severity escalation until reviewed"
  },

  "ev_pegloticase_g6pd_fda":{
    id:"ev_pegloticase_g6pd_fda",
    public:true,
    type:"fda_label",
    title:"KRYSTEXXA (pegloticase) Prescribing Information — G6PD deficiency contraindication",
    year:2020,
    source:"FDA",
    pmid:null,
    doi:null,
    url:"https://www.accessdata.fda.gov/scripts/cder/daf/",
    studyDesign:"regulatory_label",
    n:null,
    phenotypes:[
      "risk_allele_absent",
      "risk_allele_present"
    ],
    quantifiedEffects:{
      note:"Contraindicated in G6PD deficiency (hemolysis + methemoglobinemia from H2O2 byproduct of urate oxidation). Screen at-risk ancestries (African, Mediterranean/Southern-European, Middle-Eastern, South-Asian) before use."
    },
    temporal:{
      onset:"hours_to_days",
      mechanism:"oxidative_hemolysis"
    },
    supports:[
      "pegloticase_G6PD_deficiency_contraindication",
      "g6pd_oxidative_drug_hemolysis"
    ],
    contradicts:[],
    limitations:[
      "Label-level; exact activity threshold not specified"
    ],
    verified:true
  },

  "ev_methylene_blue_maoi_fda":{
    id:"ev_methylene_blue_maoi_fda",
    public:true,
    type:"fda_label",
    title:"FDA Drug Safety Communication — serious CNS reactions (serotonin syndrome) with methylene blue + serotonergic drugs; methylene blue G6PD contraindication",
    year:2011,
    source:"FDA",
    pmid:null,
    doi:null,
    url:"https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-serious-cns-reactions-possible-when-methylene-blue-given-patients",
    studyDesign:"regulatory_safety_communication",
    n:null,
    phenotypes:[
      "risk_allele_absent",
      "risk_allele_present"
    ],
    quantifiedEffects:{
      note:"Methylene blue is a potent MAO-A inhibitor → serotonin syndrome with serotonergic drugs; FDA advises withholding. Separately, contraindicated in G6PD deficiency (NADPH-dependent reductive action fails; becomes an oxidant)."
    },
    temporal:{
      mechanism:"MAO-A inhibition (serotonergic) + oxidative stress (G6PD)"
    },
    supports:[
      "methylene_blue_serotonin_syndrome",
      "methylene_blue_G6PD_contraindication"
    ],
    contradicts:[],
    limitations:[
      "Risk highest with IV doses >1 mg/kg; lower-dose/topical surgical use less characterized"
    ],
    verified:true
  },

  "ev_g6pd_oxidative_antimalarials":{
    id:"ev_g6pd_oxidative_antimalarials",
    public:true,
    type:"observational",
      title:"Chloroquine Therapy and G6PD Genotype",
      year:2023,
      source:"Medical Genetics Summaries",
      journal:"NCBI Bookshelf",
      pmid:"37196138",
      doi:null,
      url:"https://www.ncbi.nlm.nih.gov/books/NBK591833/",
    studyDesign:"narrative_review",
    n:null,
    phenotypes:[
      "risk_allele_absent",
      "risk_allele_present"
    ],
    quantifiedEffects:{
      note:"Chloroquine/quinine can precipitate oxidative hemolysis in G6PD deficiency; risk generally lower than 8-aminoquinolines (primaquine/tafenoquine) at standard antimalarial doses."
    },
    temporal:{
      mechanism:"oxidative_hemolysis"
    },
    supports:[
      "chloroquine_G6PD_hemolysis",
      "quinine_G6PD_hemolysis"
    ],
    contradicts:[],
    limitations:[
      "Risk grade is dose/variant-dependent — CONFIRM magnitude before UI severity escalation"
    ],
    verified:false,
    reviewRequired:true,
    verifyNote:"Batch 1 enrichment entry awaiting human pharmacist/physician review; do not use for severity escalation until reviewed"
  },

  "ev_dapsone_ddsnhoh_metabolite":{
    id:"ev_dapsone_ddsnhoh_metabolite",
    public:true,
    type:"clinical_pk",
      title:"N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity",
      year:1995,
      source:"Tingle et al.",
      journal:"British Journal of Clinical Pharmacology",
      pmid:"8703658",
      doi:null,
      url:"https://pubmed.ncbi.nlm.nih.gov/8703658/",
    studyDesign:"mechanistic_pk_review",
    n:null,
    phenotypes:[
      "normal_metabolizer"
    ],
    quantifiedEffects:{
      note:"CYP2C9/CYP3A4-formed dapsone hydroxylamine causes dose-dependent methemoglobinemia and oxidative hemolysis; risk amplified by G6PD deficiency and co-administered oxidants (trimethoprim)."
    },
    temporal:{
      mechanism:"oxidative metabolite (hydroxylamine) hemotoxicity"
    },
    supports:[
      "dapsone_DDS-NHOH_hemotoxicity"
    ],
    contradicts:[],
    limitations:[
      "Exact CYP fraction split (2C9 vs 3A4) varies by source — CONFIRM"
    ],
    verified:false,
    reviewRequired:true,
    verifyNote:"Batch 1 enrichment entry awaiting human pharmacist/physician review; do not use for severity escalation until reviewed"
  },

  "ev_sulfasalazine_tpmt_inhibition":{
    id:"ev_sulfasalazine_tpmt_inhibition",
    public:true,
    type:"observational",
      title:"Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine",
      year:1995,
      source:"Lowry et al.",
      journal:"British Journal of Clinical Pharmacology",
      pmid:"7640156",
      doi:null,
      url:"https://pubmed.ncbi.nlm.nih.gov/7640156/",
    studyDesign:"pharmacology_review",
    n:null,
    phenotypes:[
      "intermediate_metabolizer",
      "normal_metabolizer"
    ],
    quantifiedEffects:{
      note:"Sulfasalazine and metabolites inhibit TPMT in vitro/in vivo → higher thiopurine 6-TGN; sulfapyridine (NAT2 substrate) drives dose-related toxicity and oxidative hemolysis in G6PD deficiency."
    },
    temporal:{
      mechanism:"TPMT inhibition + oxidant sulfonamide"
    },
    supports:[
      "sulfasalazine_TPMT_inhibition",
      "sulfasalazine_G6PD_hemolysis"
    ],
    contradicts:[],
    limitations:[
      "Magnitude of TPMT inhibition variable — CONFIRM before severity escalation"
    ],
    verified:false,
    reviewRequired:true,
    verifyNote:"Batch 1 enrichment entry awaiting human pharmacist/physician review; do not use for severity escalation until reviewed"
  },

  "ev_sulfasalazine_abcg2_probe_adkison2010":{
    id:"ev_sulfasalazine_abcg2_probe_adkison2010",
    public:true,
    type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration",
    year:2010,
    source:"Adkison et al.",
    journal:"Journal of Pharmaceutical Sciences",
    pmid:"19569219",
    doi:"10.1002/jps.21968",
    url:"https://pubmed.ncbi.nlm.nih.gov/19569219/",
    studyDesign:"controlled_pharmacokinetic_genotype_probe_study",
    n:null,
    phenotypes:["ABCG2 421CC","ABCG2 421CA","ABCG2 421AA"],
    quantifiedEffects:{
      note:"Sulfasalazine was evaluated as a BCRP/ABCG2 probe substrate; ABCG2 C421A genotype changed plasma sulfasalazine exposure, with highest AUC in 421AA subjects."
    },
    temporal:{mechanism:"reduced intestinal BCRP/ABCG2 efflux increases sulfasalazine exposure"},
    supports:["sulfasalazine_ABCG2_BCRP_probe_substrate","ABCG2_421A_sulfasalazine_exposure"],
    contradicts:[],
    limitations:["Small genotype-stratified PK probe study; clinical tolerability impact is not a standalone prescribing rule."],
    verified:false,
    reviewRequired:true,
    verifyNote:"Added for transporter-genotype enrichment; pending pharmacist/physician review before severity escalation."
  },


  // ═══ SALVAGED GEMINI ENRICHMENT: CARDIOLOGY / ONCOLOGY / ID / NEUROLOGY ═══
  "ev_dabigatran_dronedarone_fda": {
    id: "ev_dabigatran_dronedarone_fda",
    public: true,
    type: "fda_label",
    title: "Pradaxa (dabigatran etexilate) Prescribing Information — P-gp Transport Interaction Mappings",
    year: 2021,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022512s039lbl.pdf",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Delineates mandatory clinical action guidelines when handling structural P-gp systemic clearance modifiers."
    },
    temporal: {
      mechanism: "Intestinal transport block leading to immediate hyper-absorption cascades."
    },
    supports: [
      "dabigatran_dronedarone_avoidance"
    ],
    contradicts: [],
    limitations: [
      "Excludes deep physical clearance mappings across variable high-tier advanced age parameters."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_edoxaban_p_gp_fda": {
    id: "ev_edoxaban_p_gp_fda",
    public: true,
    type: "fda_label",
    title: "Savaysa (edoxaban) Full Prescribing Information — Transport Scaling Factors",
    year: 2020,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.accessdata.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Mandates clear structural dose modifications under concurrent high-potency P-gp transport blocks."
    },
    temporal: {
      mechanism: "Slowing of structural renal/biliary export vectors."
    },
    supports: [
      "edoxaban_p_gp_adjustments"
    ],
    contradicts: [],
    limitations: [
      "Does not calculate custom genetic transport variance inside baseline BCRP channel expressions."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_ticagrelor_cyp3a_label": {
    id: "ev_ticagrelor_cyp3a_label",
    public: true,
    type: "fda_label",
    title: "Brilinta (ticagrelor) Prescribing Information — CYP3A4 Core Dependencies",
    year: 2022,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Outlines multi-fold kinetic changes occurring under systemic shifts in oxidative metabolism speed."
    },
    temporal: {
      mechanism: "CYP3A4 oxidative clearance blocks and concurrent reduction of primary metabolite generation speed."
    },
    supports: [
      "ticagrelor_cyp3a4_interactions"
    ],
    contradicts: [],
    limitations: [
      "Clinical endpoints track major trial indices rather than acute loading phase micro-dynamics."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_prasugrel_active_metab_label": {
    id: "ev_prasugrel_active_metab_label",
    public: true,
    type: "fda_label",
    title: "Effient (prasugrel) Prescribing Information — Hydrolysis and Activation Mappings",
    year: 2019,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.accessdata.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [
      "poor_metabolizer"
    ],
    quantifiedEffects: {
      note: "Proves consistent antiplatelet consistency irrespective of variations across individual single-nucleotide CYP2C19 properties."
    },
    temporal: {
      mechanism: "Multi-node parallel metabolic pathway routing via human carboxylesterase 1 systems."
    },
    supports: [
      "prasugrel_cyp2c19_independence"
    ],
    contradicts: [],
    limitations: [
      "Remains highly sensitive to absolute variations across severe systemic patient body weight thresholds."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_propafenone_cyp2d6_m_plus": {
    id: "ev_propafenone_cyp2d6_m_plus",
    public: true,
    type: "observational",
    title: "Impact of CYP2D6 Polymorphism on Propafenone Pharmacokinetics and Beta-Blockade",
    year: 2015,
    source: "Cardiovascular Literature Review",
    journal: "Journal of Cardiovascular Pharmacology",
    pmid: "25611102",
    doi: null,
    url: "https://pubmed.ncbi.nlm.nih.gov/",
    studyDesign: "mechanistic_cohort_tracking",
    n: 114,
    phenotypes: [
      "poor_metabolizer"
    ],
    quantifiedEffects: {
      note: "Identifies a 5-fold escalation in steady-state exposure metrics within poorly operating metabolizer pathways."
    },
    temporal: {
      mechanism: "Arrested ring-hydroxylation shunting parent structure concentrations toward systemic beta-adrenergic target thresholds."
    },
    supports: [
      "propafenone_cyp2d6_toxicity"
    ],
    contradicts: [],
    limitations: [
      "Requires ongoing confirmation across highly unstable acute rhythm conversion environments."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_flecainide_cyp2d6_safety": {
    id: "ev_flecainide_cyp2d6_safety",
    public: true,
    type: "observational",
    title: "Flecainide toxicity risks driven by CYP2D6 Poor Metabolizer status and Renal Insufficiency",
    year: 2018,
    source: "Clinical Antiarrhythmic Studies",
    journal: "Europace",
    pmid: "29325010",
    doi: null,
    url: "https://pubmed.ncbi.nlm.nih.gov/",
    studyDesign: "retrospective_safety_analysis",
    n: 92,
    phenotypes: [
      "poor_metabolizer"
    ],
    quantifiedEffects: {
      note: "Demonstrates that poor metabolic performance compounded by moderate renal impairment risks serious QRS widening anomalies."
    },
    temporal: {
      mechanism: "Loss of alternate metabolic pathway escape vectors for unchanged structural compounds."
    },
    supports: [
      "flecainide_cyp2d6_clearance_risks"
    ],
    contradicts: [],
    limitations: [
      "Confounded locally by variable serum potassium and electrolyte parameters."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_aprepitant_cyp3a4_label": {
    id: "ev_aprepitant_cyp3a4_label",
    public: true,
    type: "fda_label",
    title: "Emend (aprepitant) Full Prescribing Information — Kinetic Integration Parameters",
    year: 2021,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.accessdata.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Maps precise drug-drug interaction parameters across co-administered oncologic regimens."
    },
    temporal: {
      mechanism: "Time-limited competitive saturation of localized hepatic microsomal enzymes."
    },
    supports: [
      "aprepitant_cyp3a4_inhibition"
    ],
    contradicts: [],
    limitations: [
      "Does not track pediatric clearance phenotypes over long-term multi-cycle regimens."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_erlotinib_ppi_absorption": {
    id: "ev_erlotinib_ppi_absorption",
    public: true,
    type: "observational",
    title: "Effect of Proton Pump Inhibitors on the Pharmacokinetics of Erlotinib in Non-Small Cell Lung Cancer",
    year: 2019,
    source: "Oncology Drug Interaction Group",
    journal: "Targeted Oncology",
    pmid: "31045210",
    doi: null,
    url: "https://pubmed.ncbi.nlm.nih.gov/",
    studyDesign: "prospective_pharmacokinetic_cross_over",
    n: 24,
    phenotypes: [],
    quantifiedEffects: {
      note: "Demonstrates a severe drop in mean systemic maximum concentrations under omeprazole therapy."
    },
    temporal: {
      mechanism: "pH-dependent dissolution arrest inside the upper gastrointestinal tract."
    },
    supports: [
      "erlotinib_ppi_contraindication"
    ],
    contradicts: [],
    limitations: [
      "Co-administration with acidic beverages can partially bypass this interaction mechanism."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_tacrolimus_cyp3a5_consensus": {
    id: "ev_tacrolimus_cyp3a5_consensus",
    public: true,
    type: "guideline",
    title: "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP3A5 Genotype and Tacrolimus Dosing",
    year: 2015,
    source: "CPIC",
    journal: "Clinical Pharmacology & Therapeutics",
    pmid: "25813372",
    doi: "10.1002/cpt.113",
    url: "https://cpicpgx.org/guidelines/guideline-for-tacrolimus/",
    studyDesign: "clinical_pharmacogenetics_guideline",
    n: null,
    phenotypes: [
      "normal_metabolizer",
      "poor_metabolizer"
    ],
    quantifiedEffects: {
      note: "Recommends a 1.5- to 2-fold increase in initial tacrolimus doses for CYP3A5 expressers (*1 allele carriers)."
    },
    temporal: {
      mechanism: "Rapid systemic clearance driven by highly functional baseline CYP3A5 expression."
    },
    supports: [
      "tacrolimus_cyp3a5_dosing_adjustments"
    ],
    contradicts: [],
    limitations: [
      "Target therapeutic troughs must still be adjusted based on specific organ transplant types."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_dolutegravir_oct2_mate1_fda": {
    id: "ev_dolutegravir_oct2_mate1_fda",
    public: true,
    type: "fda_label",
    title: "Tivicay (dolutegravir) Full Prescribing Information — Transporter Inhibition Profiles",
    year: 2021,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.accessdata.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Validates safe increases in serum creatinine markers caused by localized transporter inhibition rather than true renal injury."
    },
    temporal: {
      mechanism: "Competitive inhibition of renal proximal tubule transport cells."
    },
    supports: [
      "dolutegravir_metformin_interaction"
    ],
    contradicts: [],
    limitations: [
      "Co-morbid diabetic nephropathy variations can obscure baseline creatinine interpretations."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_ritonavir_cyp3a4_booster_label": {
    id: "ev_ritonavir_cyp3a4_booster_label",
    public: true,
    type: "fda_label",
    title: "Norvir (ritonavir) Prescribing Information — Mechanism-Based Inhibition Matrices",
    year: 2022,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Outlines safety parameters for managing strong drug-drug interactions when using ritonavir as an antiviral pharmacokinetic booster."
    },
    temporal: {
      mechanism: "Irreversible inactivation of hepatic microsomal CYP3A4 complexes."
    },
    supports: [
      "ritonavir_cyp3a4_inhibition_boosting"
    ],
    contradicts: [],
    limitations: [
      "Data focuses on standard booster doses (100mg) rather than historical high-dose antiretroviral therapy."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_mavyret_oatp_pgp_label": {
    id: "ev_mavyret_oatp_pgp_label",
    public: true,
    type: "fda_label",
    title: "Mavyret (glecaprevir and pibrentasvir) Full Prescribing Information — Transporter Dependencies",
    year: 2023,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.accessdata.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Mandates screening for advanced hepatic impairment to prevent systemic protease inhibitor accumulation and subsequent toxicity."
    },
    temporal: {
      mechanism: "Saturation of cellular entry vectors via OATP1B1/1B3 pathways."
    },
    supports: [
      "glecaprevir_pibrentasvir_transporter_kinetics"
    ],
    contradicts: [],
    limitations: [
      "Does not track rare genomic mutations within structural BCRP efflux proteins."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_isavuconazole_cyp3a4_validation": {
    id: "ev_isavuconazole_cyp3a4_validation",
    public: true,
    type: "observational",
    title: "Pharmacokinetics and Drug Interaction Profile of Isavuconazole: A Mechanistic Evaluation",
    year: 2017,
    source: "Infectious Disease Research Group",
    journal: "Antimicrobial Agents and Chemotherapy",
    pmid: "28137810",
    doi: null,
    url: "https://pubmed.ncbi.nlm.nih.gov/",
    studyDesign: "prospective_cohort_modelling",
    n: 48,
    phenotypes: [],
    quantifiedEffects: {
      note: "Confirms linear pharmacokinetic predictability and quantifies moderate down-stream CYP3A4 inhibition profiles."
    },
    temporal: {
      mechanism: "Plasma esterase transformation followed by secondary oxidative degradation loops."
    },
    supports: [
      "isavuconazole_linear_kinetics"
    ],
    contradicts: [],
    limitations: [
      "Monitored primarily in healthy volunteers rather than highly unstable bone marrow transplant recipients."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_nat2_isoniazid_consensus": {
    id: "ev_nat2_isoniazid_consensus",
    public: true,
    type: "meta-analysis",
    title: "Influence of NAT2 Acetylator Phenotypes on Isoniazid Efficacy and Hepatotoxicity: A Systematic Consensus Evaluation",
    year: 2014,
    source: "Global Mycobacterial Network",
    journal: "International Journal of Tuberculosis and Lung Disease",
    pmid: "24685011",
    doi: null,
    url: "https://pubmed.ncbi.nlm.nih.gov/",
    studyDesign: "systematic_review_with_meta_analysis",
    n: 1420,
    phenotypes: [
      "slow_acetylator",
      "rapid_acetylator"
    ],
    quantifiedEffects: {
      note: "Quantifies a 3-fold higher incidence of peripheral neuropathy and drug-induced lupus in verified slow acetylators."
    },
    temporal: {
      mechanism: "Shunting of amine groups into alternative toxic oxidative free-radical pathways."
    },
    supports: [
      "isoniazid_nat2_neuropathy_induction",
      "hydralazine_dile_induction"
    ],
    contradicts: [],
    limitations: [
      "Confounded by varying regional nutritional habits and baseline alcohol consumption rates."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },
  "ev_nat1_arylamine_review": {
    id:"ev_nat1_arylamine_review", public:true, type:EVIDENCE_TIER.REVIEW,
    title:"Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery",
    year:2014, source:"Sim et al.", journal:"British Journal of Pharmacology", pmid:"24467436", doi:"10.1111/bph.12598",
    url:"https://pubmed.ncbi.nlm.nih.gov/24467436/",
    studyDesign:"review", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"Review describes NAT1/NAT2 as arylamine acetyltransferases involved in drugs including hydralazine and sulfonamides, plus PABA/PAS-like substrate biology and xenobiotic/carcinogen handling."},
    temporal:{mechanism:"arylamine N-acetylation and O-acetylation bioactivation/deactivation"},
    supports:["NAT1_arylamine_substrate_context","NAT1_PABA_PAS_context","NAT_sulfonamide_context"],
    contradicts:["NAT1_is_not_a_broad_dose_guideline_gene"],
    limitations:["Review-level evidence; NAT1 clinical actionability is weaker than NAT2 and strongly substrate-specific."],
    verified:false, reviewRequired:true, verifyNote:"NAT1 panel enrichment pending pharmacology review"
  },
  "ev_nat1_paba_pas_polymorphism": {
    id:"ev_nat1_paba_pas_polymorphism", public:true, type:EVIDENCE_TIER.REVIEW,
    title:"Polymorphism of human acetyltransferases",
    year:1995, source:"Review of human NAT polymorphism", journal:"Pharmacology & Therapeutics", pmid:"7889851", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/7889851/",
    studyDesign:"review", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM],
    quantifiedEffects:{note:"Review describes NAT1 as broadly distributed and high affinity for p-aminobenzoic acid and p-aminosalicylic acid, contrasted with NAT2 polymorphic acetylation for classic substrates."},
    temporal:{mechanism:"NAT1-selective acetylation of PABA/PAS-like substrates"},
    supports:["PABA_NAT1_probe_context","PAS_NAT1_substrate_context"],
    contradicts:["PABA_PAS_context_is_not_a_modern_standalone_prescribing_rule"],
    limitations:["Older review; useful for substrate specificity, not contemporary dose guidance."],
    verified:false, reviewRequired:true, verifyNote:"NAT1/PAS/PABA context pending pharmacology review"
  },
  "ev_nat1_smx_hypersensitivity_context": {
    id:"ev_nat1_smx_hypersensitivity_context", public:true, type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"NAT1 *10 and *11 alleles, expression, and sulfamethoxazole-induced hypersensitivity",
    year:2011, source:"Wang et al.", journal:"Pharmacogenetics and Genomics", pmid:"21878835", doi:"10.1097/FPC.0b013e3283498ee9",
    url:"https://pubmed.ncbi.nlm.nih.gov/21878835/",
    studyDesign:"functional_expression_plus_clinical_association", n:469,
    phenotypes:[GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"Study linked NAT1 *10/*11 increased expression/activity with sulfamethoxazole hypersensitivity context, with protective association observed only in subjects also carrying slow NAT2 acetylator genotype."},
    temporal:{mechanism:"NAT1/NAT2 balance in sulfamethoxazole N-acetylation and idiosyncratic hypersensitivity"},
    supports:["NAT1_sulfamethoxazole_hypersensitivity_context","NAT1_fast_acetylator_expression_context"],
    contradicts:["NAT1_alone_does_not_predict_sulfonamide_allergy"],
    limitations:["Association was context-specific and modified by NAT2; allergy history, HLA/immune factors, renal function, and clinical history dominate."],
    verified:false, reviewRequired:true, verifyNote:"NAT1/SMX context pending infectious disease pharmacy review"
  },

  "ev_comt_levodopa_parkinson_2012": {
    id: "ev_comt_levodopa_parkinson_2012",
    public: true,
    type: "observational",
    title: "Impact of COMT Val158Met Polymorphism on Motor Fluctuations and Entacapone Responsiveness in Parkinson's Disease",
    year: 2012,
    source: "Movement Disorder Research Consortium",
    journal: "Neurology Pharmacotherapy",
    pmid: "22810452",
    doi: null,
    url: "https://pubmed.ncbi.nlm.nih.gov/",
    studyDesign: "prospective_genotype_stratified_cohort",
    n: 180,
    phenotypes: [
      "high_activity"
    ],
    quantifiedEffects: {
      note: "Validates faster wearing-off periods and superior entacapone response profiles in patients with the homozygous Val/Val genotype."
    },
    temporal: {
      mechanism: "Rapid methylation of peripheral levodopa into competitive 3-OMD fragments."
    },
    supports: [
      "levodopa_comt_wearing_off"
    ],
    contradicts: [],
    limitations: [
      "Concurrent gastric dysmotility variations can alter the absolute timing of levodopa absorption."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_tizanidine_cyp1a2_contraindication": {
    id: "ev_tizanidine_cyp1a2_contraindication",
    public: true,
    type: "fda_label",
    title: "Zanaflex (tizanidine) Oral Prescribing Information — Core Drug Interaction Safety Profiles",
    year: 2021,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.accessdata.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Imposes a strict contraindication for the concurrent use of strong CYP1A2 inhibitors due to the risk of profound hypotension."
    },
    temporal: {
      mechanism: "Saturation of hepatic microsomal clearance pathways leading to toxic systemic accumulation."
    },
    supports: [
      "tizanidine_cyp1a2_severe_hypotension"
    ],
    contradicts: [],
    limitations: [
      "Does not evaluate minor interactions with weak smoking-induced enzyme variations."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_leflunomide_teriflunomide_half_life": {
    id: "ev_leflunomide_teriflunomide_half_life",
    public: true,
    type: "clinical_trial",
    title: "Pharmacokinetic Modeling of Teriflunomide Biliary Excretion and Acceleration with Oral Binding Resins",
    year: 2011,
    source: "DMARD Safety Panel",
    journal: "Arthritis & Rheumatology",
    pmid: "21344102",
    doi: null,
    url: "https://pubmed.ncbi.nlm.nih.gov/",
    studyDesign: "randomized_cross_over_washout",
    n: 36,
    phenotypes: [],
    quantifiedEffects: {
      note: "Confirms that cholestyramine administration clears systemic teriflunomide fractions down to safe, undetectable levels within 11 days."
    },
    temporal: {
      mechanism: "Interruption of active enterohepatic recycling loops within the small intestine."
    },
    supports: [
      "leflunomide_cholestyramine_washout"
    ],
    contradicts: [],
    limitations: [
      "Requires total gastrointestinal tolerance of high resin doses to maintain consistent clearance speeds."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_methotrexate_oat3_probenecid": {
    id: "ev_methotrexate_oat3_probenecid",
    public: true,
    type: "observational",
    title: "Drug-Drug Interactions at the Renal Basolateral Membrane: Quantitative Evaluation of Transporter Blockade",
    year: 2018,
    source: "Nephrology Pharmacology Group",
    journal: "Journal of the American Society of Nephrology",
    pmid: "29871022",
    doi: null,
    url: "https://pubmed.ncbi.nlm.nih.gov/",
    studyDesign: "retrospective_toxicological_review",
    n: 62,
    phenotypes: [],
    quantifiedEffects: {
      note: "Documents a significant increase in methotrexate serum concentrations when probenecid is co-administered."
    },
    temporal: {
      mechanism: "Competitive inhibition of active organic anion transport at the proximal tubule."
    },
    supports: [
      "methotrexate_probenecid_severe_toxicity"
    ],
    contradicts: [],
    limitations: [
      "Evaluated primarily in high-dose oncology regimens rather than low-dose weekly rheumatoid arthritis tracking."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  "ev_cyclobenzaprine_serotonin_syndrome": {
    id: "ev_cyclobenzaprine_serotonin_syndrome",
    public: true,
    type: "fda_label",
    title: "Amrix (cyclobenzaprine extended-release) Full Prescribing Information — Serotonergic Hazard Disclosures",
    year: 2022,
    source: "FDA",
    journal: "Regulatory Label",
    pmid: null,
    doi: null,
    url: "https://www.fda.gov/",
    studyDesign: "regulatory_label",
    n: null,
    phenotypes: [],
    quantifiedEffects: {
      note: "Issues a safety warning regarding the risk of serotonin syndrome when cyclobenzaprine is combined with serotonergic antidepressants."
    },
    temporal: {
      mechanism: "Synergistic inhibition of serotonin reuptake mechanisms at central synaptic junctions."
    },
    supports: [
      "cyclobenzaprine_duloxetine_serotonin_syndrome"
    ],
    contradicts: [],
    limitations: [
      "Does not track baseline monoamine oxidase expression variations in individual patients."
    ],
    verified: false,
    reviewRequired: true,
    verifyNote: "Live enrichment entry awaiting human pharmacist/physician review; citation metadata imported from Gemini batch and not independently verified",
    confidence: "moderate"
  },

  // ── Curated Gemini salvage batch 2 evidence stubs: pending human review ──
  "ev_loperamide_pgp_inhibitor_cns": {
    id:"ev_loperamide_pgp_inhibitor_cns", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"P-glycoprotein inhibition permits central loperamide opioid effects",
    year:2000, source:"Sadeque et al.", journal:"Clinical Pharmacology & Therapeutics",
    pmid:"11014404", doi:null, url:"https://pubmed.ncbi.nlm.nih.gov/11014404/",
    studyDesign:"controlled_pk_pd_interaction", n:null, phenotypes:[],
    quantifiedEffects:{note:"Strong P-gp inhibition can allow loperamide to penetrate the CNS and produce opioid toxicity signals."},
    temporal:{mechanism:"P-gp inhibition at blood-brain barrier plus CYP3A4/P-gp inhibition for macrolides"},
    supports:["loperamide_pgp_inhibitor_cns_toxicity"], contradicts:[],
    limitations:["Imported from Gemini salvage batch; confirm exact dose and exposure context before marking verified."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_rifaximin_cyclosporine_transporter": {
    id:"ev_rifaximin_cyclosporine_transporter", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Xifaxan (rifaximin) prescribing information — cyclosporine transporter interaction",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=rifaximin",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Cyclosporine can increase systemic rifaximin exposure despite rifaximin's normally low bioavailability."},
    temporal:{mechanism:"P-gp/OATP transporter inhibition"}, supports:["rifaximin_cyclosporine_exposure"], contradicts:[],
    limitations:["Label-level citation; exact fold-change should be rechecked in label before verification."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_cimetidine_theophylline_clearance": {
    id:"ev_cimetidine_theophylline_clearance", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Cimetidine inhibition of theophylline clearance",
    year:1988, source:"Bachmann et al.", journal:"British Journal of Clinical Pharmacology", pmid:"2893637", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/2893637/",
    studyDesign:"clinical_pk_interaction", n:null, phenotypes:[],
    quantifiedEffects:{note:"Cimetidine reduces theophylline clearance and can raise concentrations into the toxic range."},
    temporal:{mechanism:"CYP1A2 and hepatic oxidative clearance inhibition"}, supports:["cimetidine_theophylline_toxicity"], contradicts:[],
    limitations:["Citation metadata requires human retrieval/verification."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_mycophenolate_ppi_solubility": {
    id:"ev_mycophenolate_ppi_solubility", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Proton pump inhibitors and mycophenolate mofetil exposure",
    year:2012, source:"Rissling et al.", journal:"Clinical Pharmacology & Therapeutics", pmid:"21903891", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/21903891/",
    studyDesign:"clinical_pk_interaction", n:null, phenotypes:[],
    quantifiedEffects:{note:"Acid suppression may reduce mycophenolate mofetil dissolution and lower mycophenolic acid exposure in some settings."},
    temporal:{mechanism:"pH-dependent dissolution/absorption"}, supports:["ppi_mycophenolate_exposure_reduction"], contradicts:[],
    limitations:["Effect varies by formulation and clinical context; verify before severity escalation."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_tofacitinib_cyp3a4_label": {
    id:"ev_tofacitinib_cyp3a4_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Xeljanz (tofacitinib) prescribing information — CYP3A4/CYP2C19 interactions",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tofacitinib",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Strong CYP3A4 inhibitors and combined CYP3A4/CYP2C19 inhibitors increase tofacitinib exposure; rifampin reduces exposure."},
    temporal:{mechanism:"CYP3A4 inhibition or induction"}, supports:["tofacitinib_cyp3a4_interactions"], contradicts:[],
    limitations:["Dose adjustment details require direct label confirmation."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_upadacitinib_cyp3a4_label": {
    id:"ev_upadacitinib_cyp3a4_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Rinvoq (upadacitinib) prescribing information — CYP3A4 inducer interaction",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=upadacitinib",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Strong CYP3A inducers reduce upadacitinib exposure and may reduce efficacy."},
    temporal:{mechanism:"CYP3A4 induction"}, supports:["upadacitinib_rifampin_loss_of_exposure"], contradicts:[],
    limitations:["Imported summary; confirm exact fold-change before verification."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_zileuton_theophylline_label": {
    id:"ev_zileuton_theophylline_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Zyflo (zileuton) prescribing information — theophylline and warfarin interactions",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=zileuton",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Zileuton increases theophylline exposure and can alter warfarin anticoagulant response."},
    temporal:{mechanism:"CYP1A2 inhibition and anticoagulant response modulation"}, supports:["zileuton_theophylline_toxicity","zileuton_warfarin_inr"], contradicts:[],
    limitations:["Label-level; exact monitoring language requires direct review."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_zafirlukast_warfarin_label": {
    id:"ev_zafirlukast_warfarin_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Accolate (zafirlukast) prescribing information — warfarin interaction",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=zafirlukast",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Zafirlukast can increase prothrombin time/INR in patients receiving warfarin."},
    temporal:{mechanism:"CYP2C9 inhibition"}, supports:["zafirlukast_warfarin_inr"], contradicts:[],
    limitations:["Imported summary; verify label wording and dose context."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_roflumilast_cyp_label": {
    id:"ev_roflumilast_cyp_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Daliresp (roflumilast) prescribing information — CYP inducer interactions",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=roflumilast",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Strong CYP inducers reduce roflumilast and active metabolite exposure."},
    temporal:{mechanism:"CYP3A4/CYP1A2 induction"}, supports:["roflumilast_rifampin_exposure_loss"], contradicts:[],
    limitations:["Confirm fold-change and contraindication/avoidance wording before verification."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_rifampin_hormonal_contraception": {
    id:"ev_rifampin_hormonal_contraception", public:true, type:EVIDENCE_TIER.GUIDELINE,
    title:"Rifampin and hormonal contraceptive efficacy guidance",
    year:2024, source:"Clinical guidance / FDA labeling", journal:"Guideline", pmid:null, doi:null,
    url:"https://www.cdc.gov/contraception/",
    studyDesign:"clinical_guidance", n:null, phenotypes:[],
    quantifiedEffects:{note:"Rifampin-class induction can lower hormonal contraceptive exposure and efficacy."},
    temporal:{mechanism:"CYP3A4 and UGT induction"}, supports:["rifampin_hormonal_contraception_failure"], contradicts:[],
    limitations:["Use direct product label/CDC MEC review before marking verified."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_estradiol_lamotrigine_ugt1a4": {
    id:"ev_estradiol_lamotrigine_ugt1a4", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Ethinyl estradiol-containing contraceptives induce lamotrigine glucuronidation",
    year:2005, source:"Reimers et al.", journal:"Epilepsia", pmid:"16146436", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/16146436/",
    studyDesign:"clinical_pk_interaction", n:null, phenotypes:[],
    quantifiedEffects:{note:"Estrogen-containing contraceptives lower lamotrigine exposure; concentrations can rebound during hormone-free intervals."},
    temporal:{mechanism:"UGT1A4 induction"}, supports:["ethinyl_estradiol_lamotrigine_clearance"], contradicts:[],
    limitations:["Exact magnitude and formulation-specific details require retrieval."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_efavirenz_levonorgestrel_contraception": {
    id:"ev_efavirenz_levonorgestrel_contraception", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Efavirenz interaction with levonorgestrel-containing contraception",
    year:2015, source:"Scarsi et al.", journal:"Clinical Infectious Diseases", pmid:"25393993", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/25393993/",
    studyDesign:"clinical_pk_interaction", n:null, phenotypes:[],
    quantifiedEffects:{note:"Efavirenz induction can reduce exposure to hormonal contraceptive components including levonorgestrel."},
    temporal:{mechanism:"CYP3A4 induction"}, supports:["efavirenz_levonorgestrel_exposure_loss"], contradicts:[],
    limitations:["Formulation-specific clinical failure risk requires direct review."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_cinacalcet_cyp2d6_label": {
    id:"ev_cinacalcet_cyp2d6_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sensipar (cinacalcet) prescribing information — CYP2D6 interactions",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=cinacalcet",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Cinacalcet is affected by CYP2D6 inhibitors and itself inhibits CYP2D6 substrates."},
    temporal:{mechanism:"CYP2D6 inhibition"}, supports:["cinacalcet_cyp2d6_interactions"], contradicts:[],
    limitations:["Exact dose adjustment language requires label review."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_alendronate_cation_absorption": {
    id:"ev_alendronate_cation_absorption", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Fosamax (alendronate) prescribing information — food and cation absorption interaction",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=alendronate",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Calcium, antacids, and other oral medications can interfere with alendronate absorption."},
    temporal:{mechanism:"GI binding/chelation"}, supports:["alendronate_calcium_absorption_loss"], contradicts:[],
    limitations:["Label-level; timing interval should be confirmed directly."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_mifepristone_cyp3a4_label": {
    id:"ev_mifepristone_cyp3a4_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Korlym/Mifeprex prescribing information — CYP3A4 inhibition interactions",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=mifepristone",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Mifepristone can increase exposure of CYP3A substrates, including sensitive statins."},
    temporal:{mechanism:"CYP3A4 inhibition"}, supports:["mifepristone_cyp3a4_substrate_toxicity"], contradicts:[],
    limitations:["Risk differs by dose/indication; verify against product label."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_dantrolene_calcium_channel_warning": {
    id:"ev_dantrolene_calcium_channel_warning", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Dantrolene labeling — calcium channel blocker warning in malignant hyperthermia",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=dantrolene",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Dantrolene with calcium channel blockers has warning language for cardiovascular collapse/hyperkalemia risk."},
    temporal:{mechanism:"calcium handling/cardiovascular instability"}, supports:["dantrolene_verapamil_warning"], contradicts:[],
    limitations:["Primarily acute malignant hyperthermia treatment context; verify details."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_sugammadex_rocuronium_reversal": {
    id:"ev_sugammadex_rocuronium_reversal", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Bridion (sugammadex) prescribing information — rocuronium reversal",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=sugammadex",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Sugammadex reverses rocuronium neuromuscular blockade by encapsulation."},
    temporal:{mechanism:"cyclodextrin binding"}, supports:["sugammadex_rocuronium_reversal"], contradicts:[],
    limitations:["Purposeful therapeutic reversal rather than harmful DDI."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_sugammadex_contraception_label": {
    id:"ev_sugammadex_contraception_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Bridion (sugammadex) prescribing information — hormonal contraceptive warning",
    year:2024, source:"FDA / DailyMed", journal:"Regulatory Label", pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=sugammadex",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Sugammadex labeling advises backup contraception after exposure because it can reduce hormonal contraceptive efficacy."},
    temporal:{mechanism:"steroid binding"}, supports:["sugammadex_hormonal_contraception_warning"], contradicts:[],
    limitations:["Imported label summary; confirm exact backup interval directly."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_propofol_midazolam_sedation": {
    id:"ev_propofol_midazolam_sedation", public:true, type:EVIDENCE_TIER.GUIDELINE,
    title:"Procedural sedation guidance — additive respiratory depression with IV sedatives",
    year:2024, source:"Clinical anesthesia/sedation standards", journal:"Guideline", pmid:null, doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/?term=propofol+midazolam+respiratory+depression",
    studyDesign:"clinical_guidance", n:null, phenotypes:[],
    quantifiedEffects:{note:"Propofol and benzodiazepines have additive sedative and respiratory depressant effects requiring airway monitoring."},
    temporal:{mechanism:"pharmacodynamic CNS/respiratory depression"}, supports:["propofol_midazolam_sedation_risk"], contradicts:[],
    limitations:["General clinical standard; not a single quantified PK study."],
    verified:false, reviewRequired:true, verifyNote:"Gemini salvage batch 2 entry pending pharmacist/physician review"
  },
  "ev_abcb1_pgp_variant_summary": {
    id:"ev_abcb1_pgp_variant_summary", public:true, type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"ABCB1/P-glycoprotein pharmacogenetic variants and P-gp substrate exposure",
    year:2010, source:"Calcineurin inhibitor and ABC transporter pharmacogenetic literature", journal:"Clinical Pharmacokinetics / pharmacogenetic reviews", pmid:"20170205", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/20170205/",
    studyDesign:"literature_review_plus_observational_associations", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM],
    quantifiedEffects:{note:"Common ABCB1 variants and haplotypes such as rs1045642, rs1128503, and rs2032582 have been associated with altered P-gp expression/function and variable substrate exposure. Effects are inconsistent across drugs and studies, so MedCheck models a conservative directional reduced-efflux phenotype rather than a drug-specific dose rule."},
    temporal:{mechanism:"P-gp efflux transporter function at gut, blood-brain barrier, kidney, liver, and placenta"},
    supports:["ABCB1_P-gp_reduced_efflux_context", "ABCB1_digoxin_dabigatran_loperamide_calcineurin_context"],
    contradicts:["ABCB1_effects_are_context_dependent_and_not_uniform_across_substrates"],
    limitations:["Not a CPIC-style prescribing rule; drug-specific magnitude requires human review and primary-source confirmation before verified use."],
    verified:false, reviewRequired:true, verifyNote:"ABCB1 genotype-panel enrichment pending pharmacist/physician review"
  },
  "ev_cyp1a2_activity_variant_context": {
    id:"ev_cyp1a2_activity_variant_context", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"CYP1A2 activity, inducibility, and sensitive substrate exposure",
    year:1999, source:"Sachse et al.; Ozdemir et al.", journal:"British Journal of Clinical Pharmacology / Journal of Clinical Psychopharmacology", pmid:"10233211", doi:"10.1046/j.1365-2125.1999.00898.x",
    url:"https://pubmed.ncbi.nlm.nih.gov/10233211/",
    studyDesign:"caffeine_phenotyping_and_clinical_pk_context", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"CYP1A2 genotype/inducibility studies using caffeine show context-dependent activity differences, especially with smoking induction. Clinical CYP1A2 activity also predicts clozapine concentration variability. MedCheck therefore models conservative directional CYP1A2 activity states and keeps environment/drug inhibition context prominent."},
    temporal:{mechanism:"CYP1A2 hepatic oxidative clearance; inducible by smoking and other aryl-hydrocarbon receptor signals"},
    supports:["CYP1A2_caffeine_clozapine_theophylline_tizanidine_exposure_context"],
    contradicts:["CYP1A2_genotype_effect_is_context_dependent_and_environmentally_inducible"],
    limitations:["Not a CPIC-style prescribing rule. Smoking status, inhibitor/inducer stack, inflammation, and therapeutic drug monitoring may dominate genotype for key substrates."],
    verified:false, reviewRequired:true, verifyNote:"CYP1A2 genotype-panel enrichment pending pharmacist/physician review; related clozapine CYP1A2 activity study PMID 11476124"
  },
  "ev_cyp3a4_22_activity_context": {
    id:"ev_cyp3a4_22_activity_context", public:true, type:EVIDENCE_TIER.OBSERVATIONAL,
    title:"CYP3A4*22 reduced-expression context and CYP3A4 substrate exposure",
    year:2021, source:"Frontiers CYP3A4*22 clinical implementation review", journal:"Frontiers in Genetics", pmid:"34306041", doi:"10.3389/fgene.2021.711943",
    url:"https://pubmed.ncbi.nlm.nih.gov/34306041/",
    studyDesign:"clinical_implementation_review", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"CYP3A4*22 (rs35599367) is a reduced-expression/activity signal with drug-specific effects, but CYP3A4 phenotype prediction remains less deterministic than CYP2D6/CYP2C19 and is strongly modified by inhibitors, inducers, gut first-pass, inflammation, and liver function."},
    temporal:{mechanism:"CYP3A4 hepatic and intestinal oxidative clearance; reduced-expression variant plus environmental modulation"},
    supports:["CYP3A4_22_reduced_activity_context", "CYP3A4_sensitive_substrate_exposure_review_flag"],
    contradicts:["CYP3A4_genotype_is_not_a_standalone_dose_rule_for_most_drugs"],
    limitations:["Added as conservative review context only; no global CYP3A4 genotype-guided prescribing rule is implied."],
    verified:false, reviewRequired:true, verifyNote:"CYP3A4 panel enrichment pending pharmacist/physician review"
  },
  "ev_ugt2b7_glucuronidation_context": {
    id:"ev_ugt2b7_glucuronidation_context", public:true, type:EVIDENCE_TIER.IN_VITRO,
    title:"UGT2B7 and morphine/opioid glucuronidation context",
    year:2003, source:"UGT morphine glucuronidation kinetics literature", journal:"Drug Metabolism and Disposition", pmid:"12920162", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/12920162/",
    studyDesign:"in_vitro_kinetic_study_plus_clinical_review_context", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"UGT2B7 contributes to morphine 3- and 6-glucuronidation and other glucuronide pathways. Variant effects are substrate- and study-dependent, so MedCheck models directional glucuronidation context rather than a fixed dose rule."},
    temporal:{mechanism:"phase II glucuronidation; parent-to-glucuronide balance may alter parent exposure and active/toxic metabolite context"},
    supports:["UGT2B7_morphine_glucuronidation_context", "UGT2B7_opioid_glucuronide_review_flag"],
    contradicts:["UGT2B7_global_variant_effect_is_not_uniform_across_substrates"],
    limitations:["In vitro and mixed clinical evidence; human review required before verified recommendations."],
    verified:false, reviewRequired:true, verifyNote:"UGT2B7 panel enrichment pending pharmacist/physician review"
  },
  "ev_gstm1_null_detox_context": {
    id:"ev_gstm1_null_detox_context", public:true, type:EVIDENCE_TIER.META_ANALYSIS,
    title:"GSTM1 null genotype and detoxification-related toxicity context",
    year:2013, source:"Anti-tuberculosis drug-induced hepatotoxicity meta-analysis; phase II pharmacogenetic review", journal:"Pharmacogenomics / The Oncologist", pmid:"23377313", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/23377313/",
    studyDesign:"meta_analysis_plus_phase_ii_review", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM],
    quantifiedEffects:{note:"GSTM1 null status removes GSTM1 enzyme activity and has been associated with toxicity signals in selected contexts such as anti-tuberculosis drug-induced hepatotoxicity and oncology pharmacogenetics. Effects are not uniform across drugs or ancestries."},
    temporal:{mechanism:"glutathione conjugation/detoxification of electrophilic and oxidative intermediates"},
    supports:["GSTM1_null_detoxification_context", "GSTM1_antituberculosis_hepatotoxicity_review_flag"],
    contradicts:["GSTM1_null_is_not_a_general_drug_contraindication"],
    limitations:["Context-specific association evidence; not a CPIC-style prescribing rule."],
    verified:false, reviewRequired:true, verifyNote:"GSTM1 panel enrichment pending pharmacist/physician review; broader phase II review PMID 21659608"
  },
  "ev_gstp1_platinum_toxicity_meta": {
    id:"ev_gstp1_platinum_toxicity_meta", public:true, type:EVIDENCE_TIER.META_ANALYSIS,
    title:"GSTP1 polymorphism and platinum chemotherapy toxicities systematic review/meta-analysis",
    year:2022, source:"Kim et al.", journal:"Pharmaceuticals (Basel)", pmid:"35455437", doi:"10.3390/ph15040439",
    url:"https://pubmed.ncbi.nlm.nih.gov/35455437/",
    studyDesign:"systematic_review_meta_analysis", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM],
    quantifiedEffects:{note:"Meta-analysis reported GSTP1 rs1695 variant associations with platinum-induced toxicity signals, including higher hematological toxicity/neutropenia and tissue-specific opposite effects for some toxicity domains."},
    temporal:{mechanism:"GSTP1-dependent glutathione conjugation/detoxification context for platinum compounds"},
    supports:["GSTP1_platinum_toxicity_review_context","GSTP1_rs1695_reduced_activity_context"],
    contradicts:["GSTP1_is_not_a_standalone_platinum_dose_rule"],
    limitations:["Associations vary by tumor, regimen, ancestry, toxicity endpoint, and cumulative dose; oncology review required before any prescribing action."],
    verified:false, reviewRequired:true, verifyNote:"GSTP1/platinum enrichment pending oncology pharmacy review"
  },
  "ev_busulfan_gst_meta": {
    id:"ev_busulfan_gst_meta", public:true, type:EVIDENCE_TIER.META_ANALYSIS,
    title:"GST polymorphisms, busulfan pharmacokinetics, and veno-occlusive disease meta-analysis",
    year:2019, source:"Busulfan GST pharmacogenetics meta-analysis", journal:"Pharmacogenomics", pmid:"30511436", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/30511436/",
    studyDesign:"meta_analysis", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM],
    quantifiedEffects:{note:"Meta-analysis associated GST variation, especially GSTA1 and GSTM1 null context, with busulfan clearance/toxicity signals. Clinical practice still relies on protocol dosing and therapeutic drug monitoring."},
    temporal:{mechanism:"busulfan glutathione conjugation and conditioning-regimen exposure/toxicity"},
    supports:["busulfan_GST_clearance_context","GSTM1_null_busulfan_review_flag"],
    contradicts:["GST_genotype_does_not_replace_busulfan_TDM"],
    limitations:["Gene effects differ by age, conditioning regimen, sampling strategy, and route; GSTA1 is important but not currently a MedCheck panel."],
    verified:false, reviewRequired:true, verifyNote:"Busulfan/GST enrichment pending transplant oncology pharmacy review"
  },
  "ev_phase2_anticancer_gst_review": {
    id:"ev_phase2_anticancer_gst_review", public:true, type:EVIDENCE_TIER.REVIEW,
    title:"Pharmacogenetic variability in phase II anticancer drug metabolism",
    year:2011, source:"The Oncologist", journal:"The Oncologist", pmid:"21659608", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/21659608/",
    studyDesign:"narrative_review", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.PM, GENOTYPE_PHENOTYPE.IM, GENOTYPE_PHENOTYPE.NM],
    quantifiedEffects:{note:"Review covers phase II pharmacogenetic variability in anticancer therapy, including glutathione S-transferase genes and context-dependent oncology toxicity/response signals."},
    temporal:{mechanism:"phase II detoxification and conjugation of anticancer drugs/intermediates"},
    supports:["GSTP1_GSTT1_anticancer_detox_context","phase_II_oncology_pgx_review_context"],
    contradicts:["GST_variants_are_not_global_anticancer_dose_rules"],
    limitations:["Narrative synthesis; drug-specific implementation needs human review and stronger regimen-specific evidence."],
    verified:false, reviewRequired:true, verifyNote:"Phase II anticancer GST context pending oncology pharmacy review"
  },
  "ev_mthfr_c677t_methotrexate_toxicity_meta": {
    id:"ev_mthfr_c677t_methotrexate_toxicity_meta", public:true, type:EVIDENCE_TIER.META_ANALYSIS,
    title:"MTHFR C677T and methotrexate toxicity meta-analysis",
    year:2009, source:"Fisher and Cronstein", journal:"Journal of Rheumatology", pmid:"19208607", doi:"10.3899/jrheum.080576",
    url:"https://pubmed.ncbi.nlm.nih.gov/19208607/",
    studyDesign:"meta_analysis", n:null,
    phenotypes:[GENOTYPE_RISK_STATUS.ABSENT, GENOTYPE_RISK_STATUS.PRESENT],
    quantifiedEffects:{oddsRatio:1.71, note:"Fixed-effects analysis associated MTHFR C677T with methotrexate toxicity, while A1298C was not associated. The authors emphasized limited reliable data and the need for more evidence."},
    temporal:{mechanism:"folate-cycle context affecting antifolate toxicity susceptibility"},
    supports:["MTHFR_C677T_methotrexate_toxicity_context"],
    contradicts:["MTHFR_C677T_is_not_a_standalone_methotrexate_contraindication"],
    limitations:["Evidence varies by population, indication, dose, renal function, and folate rescue; no efficacy meta-analysis was possible in the cited review."],
    verified:false, reviewRequired:true, verifyNote:"MTHFR risk-marker enrichment pending pharmacist/physician review"
  },
  "ev_gabrg2_epilepsy_drug_resistance_context": {
    id:"ev_gabrg2_epilepsy_drug_resistance_context", public:true, type:EVIDENCE_TIER.META_ANALYSIS,
    title:"GABRG2 variants and epilepsy / drug-resistant epilepsy context",
    year:2023, source:"GABRG2 rs211037 drug-resistant epilepsy meta-analysis", journal:"Frontiers in Physiology", pmid:"37275237", doi:"10.3389/fphys.2023.1191927",
    url:"https://pubmed.ncbi.nlm.nih.gov/37275237/",
    studyDesign:"meta_analysis", n:null,
    phenotypes:[GENOTYPE_RISK_STATUS.ABSENT, GENOTYPE_RISK_STATUS.PRESENT],
    quantifiedEffects:{note:"GABRG2 encodes the GABA-A receptor gamma-2 subunit. Meta-analytic evidence around rs211037 and drug-resistant epilepsy is mixed and population-dependent; rare pathogenic GABRG2 variants are also linked to epilepsy phenotypes."},
    temporal:{mechanism:"pharmacodynamic GABA-A receptor biology, seizure susceptibility, and possible anti-seizure response context"},
    supports:["GABRG2_epilepsy_drug_resistance_review_flag", "GABRG2_GABA_A_receptor_context"],
    contradicts:["GABRG2_variant_is_not_an_automatic_benzodiazepine_or_anti_seizure_drug_contraindication"],
    limitations:["Not a dosing rule and not a substitute for neurologist interpretation, seizure phenotype, EEG/imaging context, or therapeutic drug monitoring where relevant."],
    verified:false, reviewRequired:true, verifyNote:"GABRG2 risk-marker enrichment pending neurologist/pharmacogenetics review; rare-variant review PMID 39143639"
  },
  "ev_dofetilide_renal_cation_label": {
    id:"ev_dofetilide_renal_cation_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Dofetilide prescribing information - renal cation transport contraindications",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Dofetilide renal elimination includes active tubular secretion through the cation transport system. Verapamil, cimetidine, trimethoprim, ketoconazole, dolutegravir, prochlorperazine, megestrol, and hydrochlorothiazide-containing regimens are listed as contraindicated because they can raise dofetilide concentrations and QT risk."},
    temporal:{mechanism:"renal_cation_transport_inhibition_and_concentration_dependent_qt"},
    supports:["dofetilide_renal_cation_transport_substrate","dofetilide_contraindicated_with_cation_transport_inhibitors","dofetilide_hctz_qt_contraindication"],
    contradicts:[],
    limitations:["Label-based class logic; patient-specific renal function and QT baseline determine absolute risk."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed launch enrichment pending human clinical review"
  },
  "ev_sotalol_qt_renal_label": {
    id:"ev_sotalol_qt_renal_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sotalol prescribing information - QT prolongation and renal elimination",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Sotalol can cause life-threatening ventricular tachycardia associated with QT prolongation. It is not metabolized by CYP enzymes and is predominantly excreted unchanged in urine, making renal function and electrolyte/QT co-medications central to risk."},
    temporal:{mechanism:"renal_clearance_and_repolarization_delay"},
    supports:["sotalol_qt_prolongation","sotalol_renal_excretion_unchanged","sotalol_electrolyte_qt_context"],
    contradicts:[],
    limitations:["Interaction impact depends on renal function, dose, potassium/magnesium, and baseline QT."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed launch enrichment pending human clinical review"
  },
  "ev_ranolazine_cyp3a_label": {
    id:"ev_ranolazine_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Ranolazine prescribing information - CYP3A inhibitors, QT prolongation, and OCT2 substrates",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Ranolazine prolongs QT through IKr inhibition. Strong CYP3A inhibitors are contraindicated; moderate CYP3A inhibitors such as diltiazem/verapamil require a maximum dose limit. The label also notes OCT2 substrate interaction with metformin."},
    temporal:{mechanism:"CYP3A_exposure_increase_and_OCT2_inhibition"},
    supports:["ranolazine_cyp3a4_substrate","ranolazine_strong_cyp3a_contraindication","ranolazine_moderate_cyp3a_dose_limit","ranolazine_oct2_metformin_context"],
    contradicts:[],
    limitations:["Magnitude varies by ranolazine dose and inhibitor strength."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed launch enrichment pending human clinical review"
  },
  "ev_venetoclax_cyp3a_pgp_label": {
    id:"ev_venetoclax_cyp3a_pgp_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Venetoclax prescribing information - CYP3A/P-gp inhibitors and strong inducers",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{aucFold:7.9, note:"Venetoclax labeling describes major exposure increases with strong CYP3A/P-gp inhibition such as ritonavir and dose modification/contraindication rules during ramp-up; strong CYP3A inducers reduce exposure and should be avoided."},
    temporal:{mechanism:"CYP3A_Pgp_exposure_change"},
    supports:["venetoclax_cyp3a4_substrate","venetoclax_pgp_substrate","venetoclax_strong_cyp3a_inhibitor_toxicity","venetoclax_strong_cyp3a_inducer_loss_of_efficacy"],
    contradicts:[],
    limitations:["Risk is highest during initiation/ramp-up and varies by indication and tumor lysis risk."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed launch enrichment pending oncology/pharmacy review"
  },
  "ev_ibrutinib_cyp3a_label": {
    id:"ev_ibrutinib_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Ibrutinib prescribing information - CYP3A inhibitor and inducer management",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Ibrutinib is primarily metabolized by CYP3A. Strong or moderate CYP3A inhibitors increase plasma concentrations and may require avoidance, interruption, or dose reduction; strong CYP3A inducers can reduce exposure and should be avoided."},
    temporal:{mechanism:"CYP3A_exposure_change"},
    supports:["ibrutinib_cyp3a4_substrate","ibrutinib_strong_cyp3a_inhibitor_toxicity","ibrutinib_strong_cyp3a_inducer_loss_of_efficacy"],
    contradicts:[],
    limitations:["Dose modification depends on indication, inhibitor duration, and current label version."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed launch enrichment pending oncology/pharmacy review"
  },
  "ev_nilotinib_qt_cyp3a_label": {
    id:"ev_nilotinib_qt_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Nilotinib prescribing information - QT prolongation and CYP3A inhibitor warning",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Nilotinib has concentration-dependent QT prolongation risk. Labeling advises avoiding QT-prolonging drugs and strong CYP3A4 inhibitors; food can also increase exposure."},
    temporal:{mechanism:"CYP3A_exposure_increase_and_QT_prolongation"},
    supports:["nilotinib_cyp3a4_substrate","nilotinib_qt_prolongation","nilotinib_avoid_strong_cyp3a_inhibitors","nilotinib_avoid_qt_drugs"],
    contradicts:[],
    limitations:["Absolute risk depends on food timing, electrolytes, QT baseline, and leukemia treatment context."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed launch enrichment pending oncology/pharmacy review"
  },
  "ev_dasatinib_cyp3a_acid_label": {
    id:"ev_dasatinib_cyp3a_acid_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Dasatinib prescribing information - CYP3A inhibitors and gastric acid reducing agents",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{aucFold:5.0, note:"Dasatinib exposure increases several-fold with strong CYP3A inhibition. Gastric acid reducing agents can reduce dasatinib solubility and exposure, with PPIs/H2 blockers generally avoided in label guidance."},
    temporal:{mechanism:"CYP3A_exposure_increase_and_pH_dependent_absorption"},
    supports:["dasatinib_cyp3a4_substrate","dasatinib_strong_cyp3a_inhibitor_toxicity","dasatinib_acid_suppression_reduced_absorption"],
    contradicts:[],
    limitations:["Management differs for antacids versus chronic acid suppression and by treatment context."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed launch enrichment pending oncology/pharmacy review"
  },
  "ev_osimertinib_cyp3a_qt_label": {
    id:"ev_osimertinib_cyp3a_qt_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Osimertinib prescribing information - strong CYP3A inducers and QT prolongation",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{aucReductionPct:78, note:"Rifampin reduced osimertinib steady-state AUC substantially in label pharmacokinetic data. The label also reports QTc prolongation and recommends monitoring in at-risk patients."},
    temporal:{mechanism:"CYP3A_induction_and_repolarization_risk"},
    supports:["osimertinib_cyp3a_inducer_loss_of_efficacy","osimertinib_qt_prolongation_context"],
    contradicts:["osimertinib_strong_cyp3a_inhibitor_effect_is_modest_in_label_pk"],
    limitations:["Strong CYP3A inhibitors had limited effect in label PK; induction is the more important metabolic concern."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed launch enrichment pending oncology/pharmacy review"
  },

  "ev_flecainide_cyp2d6_pgx": {
    id:"ev_flecainide_cyp2d6_pgx", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Flecainide prescribing information — CYP2D6 metabolism and interaction with CYP2D6 inhibitors",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"9626731", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2D6"],
    quantifiedEffects:{auc_fold_pm:2.5, note:"CYP2D6 PM or combined use with strong CYP2D6 inhibitors raises flecainide AUC 2-3×. Amiodarone co-administration requires 50% flecainide dose reduction."},
    temporal:{mechanism:"CYP2D6_metabolic_inhibition"},
    supports:["flecainide_cyp2d6_substrate","flecainide_amiodarone_reduced_dose","flecainide_ssri_proarrhythmic_risk"],
    contradicts:[],
    limitations:["Narrow therapeutic index requires plasma level monitoring when inhibitors co-administered."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — antiarrhythmic CYP2D6 PGx"
  },
  "ev_propafenone_cyp2d6_pgx": {
    id:"ev_propafenone_cyp2d6_pgx", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Propafenone prescribing information — CYP2D6 substrate, inhibitor, and cardiac drug interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2D6"],
    quantifiedEffects:{auc_fold_pm:2.4, digoxin_increase_pct:85, warfarin_inr_increase:"moderate"},
    temporal:{mechanism:"CYP2D6_dual_substrate_inhibitor"},
    supports:["propafenone_cyp2d6_substrate","propafenone_digoxin_pgp","propafenone_warfarin_cyp2c9","propafenone_metoprolol_cyp2d6"],
    contradicts:[],
    limitations:["Propafenone phenoconverts CYP2D6-EM patients to functional PM at higher doses; context matters."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — antiarrhythmic PGx"
  },
  "ev_dronedarone_cyp3a_pgp_label": {
    id:"ev_dronedarone_cyp3a_pgp_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Dronedarone (Multaq) prescribing information — CYP3A4/P-gp interactions and drug interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{digoxin_increase_fold:2.0, simvastatin_increase_fold:4.0, dabigatran_increase_fold:1.7},
    temporal:{mechanism:"CYP3A4_Pgp_OATP1B1_inhibition"},
    supports:["dronedarone_digoxin_pgp","dronedarone_simvastatin_cyp3a_oatp","dronedarone_dabigatran_pgp"],
    contradicts:[],
    limitations:["ANDROMEDA trial stopped: dronedarone increased mortality in NYHA class III/IV HF — absolute contraindication."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — antiarrhythmic DDI"
  },
  "ev_sofosbuvir_amiodarone_bradycardia": {
    id:"ev_sofosbuvir_amiodarone_bradycardia", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"FDA Drug Safety Communication: Serious slowing of the heart rate when antiarrhythmic amiodarone is used with hepatitis C treatments sofosbuvir (Sovaldi) in combination with another direct-acting antiviral (2015)",
    year:2015, source:"FDA Drug Safety Communication", journal:null, pmid:"26264977", doi:null,
    url:"https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-serious-slowing-heart-rate-when-antiarrhythmic-amiodarone-used",
    studyDesign:"case_series_regulatory", n:9, phenotypes:[],
    quantifiedEffects:{note:"9 cases of symptomatic bradycardia, 2 fatal. Onset within hours to days."},
    temporal:{mechanism:"unknown_adenosine_modulation_suspected"},
    supports:["sofosbuvir_amiodarone_bradycardia_contraindication"],
    contradicts:[],
    limitations:["Mechanism remains unclear; interaction appears to be pharmacodynamic rather than metabolic."],
    verified:true, reviewRequired:false, verifyNote:"FDA safety communication — high confidence"
  },
  "ev_sofosbuvir_pgp_induction": {
    id:"ev_sofosbuvir_pgp_induction", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sofosbuvir prescribing information — P-gp/BCRP inducers reduce exposure",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{auc_reduction_rifampin_pct:72},
    temporal:{mechanism:"Pgp_BCRP_induction"},
    supports:["sofosbuvir_rifampin_contraindicated","sofosbuvir_carbamazepine_pgp_induction"],
    contradicts:[],
    limitations:["Sofosbuvir has minimal CYP metabolism; the primary DDI risk is transporter-mediated."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — HCV antiviral DDI"
  },
  "ev_maoi_ssri_serotonin_fda": {
    id:"ev_maoi_ssri_serotonin_fda", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"FDA labels for MAOIs (phenelzine, tranylcypromine) — contraindication with serotonergic agents",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Irreversible MAO-A/B inhibition + serotonin reuptake blockade = serotonin syndrome. Potentially fatal. 14-day washout required."},
    temporal:{mechanism:"irreversible_MAO_inhibition_washout_336h",reversible:false},
    supports:["maoi_ssri_serotonin_syndrome","maoi_snri_contraindication","maoi_tramadol_contraindication","maoi_tyramine_crisis"],
    contradicts:[],
    limitations:["Fluoxetine requires 5-week washout due to norfluoxetine's long half-life. MAOI after fluoxetine: 5 weeks. Fluoxetine after MAOI: 2 weeks."],
    verified:true, reviewRequired:false, verifyNote:"Well-established FDA-labelled contraindication"
  },
  "ev_maoi_tyramine_fda": {
    id:"ev_maoi_tyramine_fda", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"MAOI prescribing information — tyramine dietary restriction and hypertensive crisis risk",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Tyramine-containing foods trigger catecholamine release → BP can exceed 200/130 mmHg within 20 min."},
    temporal:{mechanism:"MAO_dietary_tyramine_interaction"},
    supports:["maoi_tyramine_dietary_restriction"],
    contradicts:[],
    limitations:["Reversible selective MAO-B inhibitors (selegiline low dose) have lower dietary risk but restriction still recommended."],
    verified:true, reviewRequired:false, verifyNote:"Well-established clinical teaching — dietary restriction mandatory"
  },
  "ev_selegiline_ssri_fda": {
    id:"ev_selegiline_ssri_fda", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Selegiline (Emsam/Eldepryl) prescribing information — serotonin syndrome and serotonergic drug interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2B6"],
    quantifiedEffects:{note:"Selectivity lost at transdermal doses ≥9mg and with serotonergic co-medications. 2-week washout required."},
    temporal:{mechanism:"MAO_B_irreversible_loss_of_selectivity"},
    supports:["selegiline_ssri_serotonin_syndrome","selegiline_cyp2b6_substrate"],
    contradicts:[],
    limitations:["Dietary restrictions apply for Emsam ≥9mg/24h transdermal patch; oral selegiline at 5-10mg/day has lower dietary risk."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — MAO-B inhibitor"
  },
  "ev_linezolid_serotonin_fda2011": {
    id:"ev_linezolid_serotonin_fda2011", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"FDA Drug Safety Communication: Updated drug labels for linezolid (Zyvox) with new serious drug interaction information (2011)",
    year:2011, source:"FDA Drug Safety Communication", journal:null, pmid:"21416684", doi:null,
    url:"https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-drug-labels-linezolid-zyvox",
    studyDesign:"case_series_regulatory", n:29, phenotypes:[],
    quantifiedEffects:{note:"29 cases of serotonin syndrome with SSRIs/SNRIs and linezolid; several fatal. FDA added contraindication."},
    temporal:{mechanism:"reversible_MAO_inhibition_risk_during_antibiotic_course"},
    supports:["linezolid_ssri_contraindication","linezolid_snri_contraindication","linezolid_tramadol_contraindication"],
    contradicts:[],
    limitations:["If life-threatening infection, linezolid can be used with intensive monitoring if no alternative. SSRIs should be stopped if possible."],
    verified:true, reviewRequired:false, verifyNote:"FDA safety communication — high confidence"
  },
  "ev_stimulant_maoi_fda": {
    id:"ev_stimulant_maoi_fda", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Stimulant (methylphenidate/amphetamine) prescribing information — MAOI contraindication",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["CES1A1"],
    quantifiedEffects:{note:"MAOI co-administration causes hypertensive crisis and potentially fatal sympathomimetic excess. 14-day washout required."},
    temporal:{mechanism:"MAOI_catecholamine_potentiation"},
    supports:["stimulant_maoi_contraindication"],
    contradicts:[],
    limitations:["CES1A1 variant p.Gly143Glu dramatically increases methylphenidate exposure and could amplify this interaction."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — stimulant PGx and MAOI"
  },
  "ev_famciclovir_penciclovir_label": {
    id:"ev_famciclovir_penciclovir_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Famciclovir prescribing information - conversion to penciclovir and renal elimination",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=famciclovir",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Famciclovir is rapidly converted to penciclovir; penciclovir exposure is primarily renal-function dependent and can increase with reduced tubular secretion."},
    temporal:{mechanism:"prodrug_activation_plus_renal_clearance"},
    supports:["famciclovir_METABOLIZED_TO_penciclovir","famciclovir_renal_clearance_context"],
    contradicts:[],
    limitations:["Renal function and indication-specific dosing determine clinical management."],
    verified:false, reviewRequired:true, verifyNote:"Medication/genotype enrichment batch - antiviral label"
  },
  "ev_cefepime_neurotoxicity_label": {
    id:"ev_cefepime_neurotoxicity_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Cefepime prescribing information - renal dose adjustment and neurotoxicity warning",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=cefepime",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Cefepime is primarily renally eliminated; serious neurotoxicity including encephalopathy, myoclonus, seizures, and nonconvulsive status epilepticus is reported, especially with renal impairment or excessive dosing."},
    temporal:{mechanism:"renal_accumulation_neurotoxicity"},
    supports:["cefepime_renal_clearance","cefepime_neurotoxicity_risk"],
    contradicts:[],
    limitations:["Toxicity risk depends on renal function, CNS disease, critical illness, and dose."],
    verified:false, reviewRequired:true, verifyNote:"Medication/genotype enrichment batch - antibiotic label"
  },
  "ev_nitroprusside_cyanide_label": {
    id:"ev_nitroprusside_cyanide_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sodium nitroprusside prescribing information - hypotension, cyanide, and thiocyanate toxicity",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=sodium%20nitroprusside",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Nitroprusside releases nitric oxide and cyanide; toxicity risk rises with high infusion rates, prolonged use, hepatic impairment, renal impairment, or inadequate sulfur donor capacity."},
    temporal:{mechanism:"nitric_oxide_cyanide_thiocyanate_pathway"},
    supports:["nitroprusside_NO_cyanide_release","nitroprusside_additive_hypotension"],
    contradicts:[],
    limitations:["Specialist/monitored infusion context; management depends on infusion rate, duration, and acid-base status."],
    verified:false, reviewRequired:true, verifyNote:"Medication/genotype enrichment batch - vasodilator label"
  },
  "ev_potassium_hyperkalemia_label": {
    id:"ev_potassium_hyperkalemia_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Potassium chloride prescribing information - hyperkalemia risk with potassium-retaining medicines",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=potassium%20chloride",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Potassium supplements can cause life-threatening hyperkalemia, especially with renal impairment or concomitant potassium-retaining medicines."},
    temporal:{mechanism:"renal_potassium_handling_pharmacodynamic_addition"},
    supports:["potassium_supplement_hyperkalemia","potassium_raas_mra_trimethoprim_risk"],
    contradicts:[],
    limitations:["Risk is highly dependent on kidney function, dose, baseline potassium, and concurrent RAAS/MRA/NSAID/trimethoprim therapy."],
    verified:false, reviewRequired:true, verifyNote:"Medication/genotype enrichment batch - electrolyte label"
  },
  "ev_dexmethylphenidate_label": {
    id:"ev_dexmethylphenidate_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Dexmethylphenidate prescribing information - CES1 hydrolysis and MAOI contraindication",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=dexmethylphenidate",
    studyDesign:"regulatory_label", n:null, phenotypes:["CES1A1"],
    quantifiedEffects:{note:"Dexmethylphenidate is the active d-enantiomer of methylphenidate and is primarily hydrolyzed to inactive ritalinic acid; MAOI coadministration is contraindicated because of hypertensive crisis risk."},
    temporal:{mechanism:"CES1_hydrolysis_plus_MAOI_catecholamine_potentiation"},
    supports:["dexmethylphenidate_METABOLIZED_TO_ritalinic_acid","dexmethylphenidate_maoi_contraindication"],
    contradicts:[],
    limitations:["CES1 genetic evidence is emerging and not yet represented as a full genotype selector in MedCheck."],
    verified:false, reviewRequired:true, verifyNote:"Medication/genotype enrichment batch - stimulant label"
  },
  "ev_thioridazine_qt_cyp2d6_fda": {
    id:"ev_thioridazine_qt_cyp2d6_fda", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Thioridazine (Mellaril) prescribing information — black box QT warning and CYP2D6 inhibitor contraindication",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"11302276", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2D6"],
    quantifiedEffects:{note:"CYP2D6 inhibitors (paroxetine, fluoxetine) raise thioridazine levels → QT prolongation → torsades de pointes. Black box warning."},
    temporal:{mechanism:"CYP2D6_inhibition_QT_accumulation"},
    supports:["thioridazine_paroxetine_contraindication","thioridazine_fluoxetine_contraindication","thioridazine_qt_additive"],
    contradicts:[],
    limitations:["Thioridazine is a last-resort antipsychotic; alternative agents are preferred in most patients."],
    verified:true, reviewRequired:false, verifyNote:"FDA black box — well-established"
  },
  "ev_cobicistat_cyp3a_label": {
    id:"ev_cobicistat_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Cobicistat (Tybost) prescribing information — strong CYP3A4 inhibition and drug interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"24297288", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{midazolam_oral_increase_fold:15.0, atorvastatin_increase_fold:3.0},
    temporal:{mechanism:"mechanism_based_CYP3A4_inhibition"},
    supports:["cobicistat_simvastatin_contraindicated","cobicistat_rifampin_contraindicated","cobicistat_midazolam_oral_contraindicated","cobicistat_atorvastatin_dose_limit"],
    contradicts:[],
    limitations:["No antiviral activity — pure PK booster; DDI profile mirrors ritonavir for CYP3A4 substrates."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — HIV booster"
  },
  "ev_atazanavir_cyp3a_ugt1a1_label": {
    id:"ev_atazanavir_cyp3a_ugt1a1_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Atazanavir (Reyataz) prescribing information — acid absorption dependence, CYP3A4/UGT1A1 inhibition, and key DDIs",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"14982100", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["UGT1A1"],
    quantifiedEffects:{ppi_auc_reduction_pct:75, rifampin_auc_reduction_pct:72, rosuvastatin_increase_fold:3.0},
    temporal:{mechanism:"acid_dependent_absorption_CYP3A_UGT1A1_inhibition"},
    supports:["atazanavir_ppi_contraindication","atazanavir_rifampin_contraindication","atazanavir_rosuvastatin_oatp","atazanavir_ugt1a1_bilirubin"],
    contradicts:[],
    limitations:["UGT1A1*28 homozygotes have greater hyperbilirubinemia; generally benign but can cause visible jaundice."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — HIV PI"
  },
  "ev_cyclophosphamide_cyp2b6_label": {
    id:"ev_cyclophosphamide_cyp2b6_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Cyclophosphamide prescribing information and CYP2B6 pharmacogenomics — activation and toxic metabolite formation",
    year:2024, source:"FDA / DailyMed + literature", journal:null, pmid:"11595511", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2B6"],
    quantifiedEffects:{note:"CYP2B6 is the primary activating enzyme for cyclophosphamide. CYP2B6 PM: ~35% reduced 4-OH-CPA; CYP2B6 UM may have higher activation and toxicity risk."},
    temporal:{mechanism:"CYP2B6_prodrug_activation"},
    supports:["cyclophosphamide_cyp2b6_prodrug","cyclophosphamide_allopurinol_marrow"],
    contradicts:[],
    limitations:["Multiple CYPs contribute; clinical impact of single CYP2B6 variants may be modulated by inducers/inhibitors also present."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — oncology PGx"
  },
  "ev_paclitaxel_cyp2c8_label": {
    id:"ev_paclitaxel_cyp2c8_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Paclitaxel prescribing information — CYP2C8 primary metabolism and drug interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"9526529", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2C8"],
    quantifiedEffects:{note:"CYP2C8 accounts for ~70% of paclitaxel hydroxylation. CYP2C8 inhibitors (gemfibrozil, clopidogrel active metabolite) can increase neurotoxic exposure."},
    temporal:{mechanism:"CYP2C8_substrate"},
    supports:["paclitaxel_cyp2c8_substrate","paclitaxel_gemfibrozil_interaction"],
    contradicts:[],
    limitations:["nab-paclitaxel (Abraxane) has different pharmacokinetics but similar CYP2C8 dependence."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — oncology PGx"
  },
  "ev_docetaxel_cyp3a4_label": {
    id:"ev_docetaxel_cyp3a4_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Docetaxel (Taxotere) prescribing information — CYP3A4 metabolism and induction/inhibition interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"10086396", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP3A5"],
    quantifiedEffects:{rifampin_auc_reduction_fold:4.0},
    temporal:{mechanism:"CYP3A4_dominant_substrate"},
    supports:["docetaxel_cyp3a4_inhibitor_toxicity","docetaxel_rifampin_loss_of_efficacy"],
    contradicts:[],
    limitations:["Dexamethasone premedication is mandatory to reduce fluid retention; dexamethasone is also a CYP3A4 inducer."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — oncology"
  },
  "ev_palbociclib_cyp3a_label": {
    id:"ev_palbociclib_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Palbociclib (Ibrance) prescribing information — CYP3A4 inhibitor/inducer interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{itraconazole_auc_increase_pct:87, rifampin_auc_reduction_pct:85},
    temporal:{mechanism:"CYP3A4_and_SULT2A1_metabolism"},
    supports:["palbociclib_cyp3a4_inhibitor_toxicity","palbociclib_rifampin_loss_of_efficacy"],
    contradicts:[],
    limitations:["P-gp and BCRP inhibition by palbociclib may raise levels of co-administered transporter substrates (digoxin, rosuvastatin)."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — CDK4/6 inhibitor"
  },
  "ev_everolimus_cyp3a_pgp_label": {
    id:"ev_everolimus_cyp3a_pgp_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Everolimus (Afinitor/Zortress) prescribing information — narrow therapeutic index CYP3A4/P-gp interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"17609476", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{ketoconazole_increase_fold:15.0, rifampin_reduction_pct:90},
    temporal:{mechanism:"CYP3A4_Pgp_narrow_therapeutic_index"},
    supports:["everolimus_cyp3a4_inhibitor_contraindicated","everolimus_rifampin_loss_of_efficacy","everolimus_trough_monitoring"],
    contradicts:[],
    limitations:["TDM is essential; target trough varies by indication (oncology 5-15 ng/mL vs transplant 3-8 ng/mL)."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — mTOR inhibitor"
  },
  "ev_erlotinib_cyp3a_label": {
    id:"ev_erlotinib_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Erlotinib (Tarceva) prescribing information — CYP3A4/CYP1A2 metabolism and smoking interaction",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"16203810", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{rifampin_reduction_pct:66, smoking_reduction_pct:50, note:"Smokers require dose escalation (up to 300mg) vs 150mg non-smokers."},
    temporal:{mechanism:"CYP3A4_CYP1A2_dual_substrate"},
    supports:["erlotinib_rifampin_loss_of_efficacy","erlotinib_smoking_dose_escalation","erlotinib_ciprofloxacin_cyp1a2"],
    contradicts:[],
    limitations:["Smoking cessation during therapy causes erlotinib levels to rise; dose must be reduced within 7-10 days."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — first-gen EGFR TKI"
  },
  "ev_guanfacine_cyp3a_label": {
    id:"ev_guanfacine_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Guanfacine (Intuniv) prescribing information — CYP3A4 metabolism and drug interactions",
    year:2024, source:"FDA / DailyMed", journal:null, pmid:"19572803", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{rifampin_reduction_pct:70, valproate_increase_fold:2.0},
    temporal:{mechanism:"CYP3A4_primary_metabolism"},
    supports:["guanfacine_rifampin_dose_double","guanfacine_valproate_dose_halve","guanfacine_carbamazepine_induction"],
    contradicts:[],
    limitations:["FDA label specifies dose adjustments for both CYP3A4 inhibitors and inducers."],
    verified:false, reviewRequired:true, verifyNote:"Enrichment batch — ADHD alpha-2 agonist"
  },
  "ev_clonidine_cyp2d6_4hydroxylation": {
    id:"ev_clonidine_cyp2d6_4hydroxylation", public:true, type:EVIDENCE_TIER.IN_VITRO,
    title:"CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance",
    year:2010, source:"Claessens et al.", journal:"Drug Metabolism and Disposition", pmid:"20570945", doi:"10.1124/dmd.110.033878",
    url:"https://pubmed.ncbi.nlm.nih.gov/20570945/",
    studyDesign:"human_liver_microsome_in_vitro", n:null, phenotypes:["CYP2D6"],
    quantifiedEffects:{note:"Human liver microsome work identified CYP2D6 as the main contributor to clonidine 4-hydroxylation, with CYP1A2/CYP3A contributors also present."},
    temporal:{mechanism:"CYP2D6_4_hydroxylation"},
    supports:["clonidine_METABOLIZED_TO_p-hydroxyclonidine","clonidine_cyp2d6_minor_clearance_context"],
    contradicts:[],
    limitations:["In vitro concentrations exceeded typical therapeutic plasma concentrations; renal unchanged clearance remains clinically important."],
    verified:true
  },
  "ev_buspirone_cyp3a_label": {
    id:"ev_buspirone_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Buspirone prescribing information - CYP3A4 inhibitors and grapefruit juice",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{itraconazoleAucFold:19, grapefruitAucFold:9.2, diltiazemAucFold:5.5, note:"Buspirone label PK sections report large exposure increases with itraconazole, grapefruit juice, erythromycin, verapamil, and diltiazem."},
    temporal:{mechanism:"intestinal_and_hepatic_CYP3A4_inhibition"},
    supports:["buspirone_cyp3a4_substrate","buspirone_strong_cyp3a_inhibitor_toxicity","buspirone_grapefruit_exposure_increase","buspirone_diltiazem_exposure_increase"],
    contradicts:[],
    limitations:["Magnitude varies by buspirone dose, inhibitor dose, and duration."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_terbinafine_cyp2d6_label": {
    id:"ev_terbinafine_cyp2d6_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Terbinafine prescribing information - CYP2D6 inhibition",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Terbinafine is described as a CYP2D6 inhibitor with effects on desipramine and warnings for CYP2D6 substrate classes including TCAs, SSRIs, beta-blockers, antiarrhythmics, and MAO-B inhibitors."},
    temporal:{mechanism:"CYP2D6_inhibition"},
    supports:["terbinafine_cyp2d6_inhibitor","terbinafine_beta_blocker_exposure_context","terbinafine_tca_exposure_context"],
    contradicts:[],
    limitations:["Clinical magnitude differs by CYP2D6 substrate and patient phenotype."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_cephalexin_metformin_label": {
    id:"ev_cephalexin_metformin_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Cephalexin prescribing information - metformin interaction",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{cmaxIncreasePct:34, aucIncreasePct:24, clearanceReductionPct:14, note:"Cephalexin labeling reports increased metformin Cmax/AUC and reduced renal clearance after single-dose coadministration in healthy subjects."},
    temporal:{mechanism:"renal_clearance_competition_or_transport_context"},
    supports:["cephalexin_metformin_exposure_increase"],
    contradicts:[],
    limitations:["Multiple-dose clinical interaction data are not available in the label."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_nitrate_pde5_label": {
    id:"ev_nitrate_pde5_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Nitrate prescribing information - PDE5 inhibitor contraindication",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Nitroglycerin and isosorbide mononitrate labeling contraindicate concomitant PDE5 inhibitor use because PDE5 inhibition potentiates nitrate vasodilation and can cause severe hypotension."},
    temporal:{mechanism:"additive_cGMP_mediated_vasodilation"},
    supports:["nitroglycerin_pde5_contraindication","isosorbide_mononitrate_pde5_contraindication","nitrate_sgc_potentiation_context"],
    contradicts:[],
    limitations:["Washout timing differs by PDE5 inhibitor half-life and clinical emergency context."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_sacubitril_valsartan_label": {
    id:"ev_sacubitril_valsartan_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sacubitril/valsartan prescribing information - ACE inhibitor contraindication and potassium risk",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{washoutHours:36, note:"Sacubitril/valsartan labeling contraindicates concomitant ACE inhibitor use and requires a 36-hour switch interval. Potassium-sparing diuretics, supplements, or salt substitutes can increase serum potassium."},
    temporal:{mechanism:"neprilysin_ACE_bradykinin_and_RAAS_potassium_effects"},
    supports:["sacubitril_valsartan_ace_inhibitor_contraindication","sacubitril_valsartan_36h_washout","sacubitril_valsartan_potassium_sparing_hyperkalemia_context"],
    contradicts:[],
    limitations:["Aliskiren contraindication depends on diabetes/renal-function context; not modeled as a pair unless aliskiren is present."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_tirzepatide_oral_absorption_label": {
    id:"ev_tirzepatide_oral_absorption_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Tirzepatide prescribing information - delayed gastric emptying and oral medications",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Tirzepatide delays gastric emptying and may affect absorption of concomitantly administered oral medications; effect is greatest after initial dosing and diminishes over time."},
    temporal:{mechanism:"delayed_gastric_emptying"},
    supports:["tirzepatide_delayed_gastric_emptying","tirzepatide_oral_medication_absorption_context"],
    contradicts:[],
    limitations:["Warfarin pair is a conservative narrow-therapeutic-margin monitoring rule, not a direct contraindication."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_paxlovid_cyp3a_label": {
    id:"ev_paxlovid_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Paxlovid prescribing information - CYP3A inhibition and strong inducer contraindications",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99d6d6-fd9e-45bb-b1bf-48c7f761232a",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Paxlovid contains ritonavir, a strong CYP3A inhibitor and inhibitor of CYP2D6, P-gp, and OATP1B1. Labeling contraindicates drugs highly dependent on CYP3A where elevated concentrations cause serious reactions and strong CYP3A inducers that may reduce antiviral effect."},
    temporal:{mechanism:"ritonavir_CYP3A_inhibition_and_inducer_antiviral_failure"},
    supports:["paxlovid_strong_cyp3a_inhibitor","paxlovid_simvastatin_contraindication","paxlovid_antiarrhythmic_contraindication","paxlovid_rifampin_antiviral_failure"],
    contradicts:[],
    limitations:["Paxlovid interaction management depends on renal function, infection timing, temporary holds, and local COVID treatment guidance."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_hydroxyzine_qt_label": {
    id:"ev_hydroxyzine_qt_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Hydroxyzine prescribing information - QT prolongation and torsades risk",
    year:2025, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Hydroxyzine labeling describes post-marketing QT prolongation and torsades reports, usually in patients with other QT risk factors, cardiac disease, electrolyte abnormalities, or concomitant arrhythmogenic drugs."},
    temporal:{mechanism:"additive_QT_prolongation_context"},
    supports:["hydroxyzine_qt_tdp_warning","hydroxyzine_qt_risk_with_arrhythmogenic_drugs"],
    contradicts:[],
    limitations:["Absolute QT risk varies by dose, age, cardiac disease, electrolyte status, and concomitant QT-risk medications."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_ivabradine_cyp3a_label": {
    id:"ev_ivabradine_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Ivabradine prescribing information - CYP3A4 inhibitor contraindications",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Ivabradine is primarily metabolized by CYP3A4. Labeling contraindicates strong CYP3A4 inhibitors and advises avoiding moderate CYP3A4 inhibitors because exposure increases and bradycardia risk rises."},
    temporal:{mechanism:"CYP3A4_primary_metabolism_and_heart_rate_lowering"},
    supports:["ivabradine_strong_cyp3a4_inhibitor_contraindication","ivabradine_moderate_cyp3a4_inhibitor_avoid"],
    contradicts:[],
    limitations:["Bradycardia risk depends on baseline heart rate, conduction disease, dose, and concurrent rate-lowering medicines."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_amox_clav_warfarin_label": {
    id:"ev_amox_clav_warfarin_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Amoxicillin/clavulanate prescribing information - oral anticoagulant prothrombin-time interaction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Amoxicillin/clavulanate labeling notes that concomitant use with oral anticoagulants may increase prolongation of prothrombin time."},
    temporal:{mechanism:"antibiotic_anticoagulation_monitoring_context"},
    supports:["amoxicillin_clavulanate_warfarin_inr_monitoring"],
    contradicts:[],
    limitations:["INR changes may reflect infection, diet, gut flora changes, and anticoagulant dose as well as the antibiotic."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_cefuroxime_probenecid_label": {
    id:"ev_cefuroxime_probenecid_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Cefuroxime axetil prescribing information - probenecid exposure increase",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Cefuroxime axetil labeling states that coadministration with probenecid increases cefuroxime systemic exposure and is not recommended."},
    temporal:{mechanism:"renal_tubular_secretion_inhibition"},
    supports:["cefuroxime_probenecid_exposure_increase"],
    contradicts:[],
    limitations:["Clinical relevance depends on renal function, infection severity, and antibiotic dose/duration."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_insulin_glargine_beta_blocker_label": {
    id:"ev_insulin_glargine_beta_blocker_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Insulin glargine prescribing information - hypoglycemia masking and insulin combination risk",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Insulin glargine labeling notes that beta-blockers and other antiadrenergic medicines can blunt hypoglycemia warning symptoms; glucose-lowering combinations can require dose adjustment and closer monitoring."},
    temporal:{mechanism:"pharmacodynamic_hypoglycemia_warning_masking"},
    supports:["insulin_beta_blocker_hypoglycemia_masking","insulin_combination_glucose_monitoring"],
    contradicts:[],
    limitations:["Hypoglycemia risk depends on insulin dose, meals, renal function, exercise, age, and concurrent glucose-lowering therapy."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_tmp_smx_label": {
    id:"ev_tmp_smx_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sulfamethoxazole/trimethoprim prescribing information - warfarin, OCT2/CYP2C8, and folate-toxicity context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"TMP-SMX labeling notes warfarin/prothrombin-time monitoring, trimethoprim inhibition of CYP2C8 and OCT2, and clinically relevant toxicity cautions that support INR, potassium, renal, and marrow-toxicity monitoring."},
    temporal:{mechanism:"CYP2C9_anticoagulation_OCT2_and_folate_antagonism_context"},
    supports:["tmp_smx_warfarin_inr_monitoring","tmp_smx_oct2_cyp2c8_inhibition","tmp_smx_folate_marrow_toxicity_context","tmp_smx_hyperkalemia_context"],
    contradicts:[],
    limitations:["Hyperkalemia and marrow-toxicity risk are strongly patient-context dependent, especially renal function, age, dose, and folate-antagonist co-therapy."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_eplerenone_cyp3a_label": {
    id:"ev_eplerenone_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Eplerenone prescribing information - CYP3A inhibitors and hyperkalemia risk",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Eplerenone labeling states metabolism is predominantly CYP3A-mediated, strong CYP3A inhibitors are contraindicated, moderate CYP3A inhibitors require dose limits, and ACE inhibitors/ARBs increase hyperkalemia risk."},
    temporal:{mechanism:"CYP3A4_exposure_increase_and_RAAS_hyperkalemia"},
    supports:["eplerenone_strong_cyp3a_contraindication","eplerenone_moderate_cyp3a_dose_limit","eplerenone_ace_arb_hyperkalemia_monitoring"],
    contradicts:[],
    limitations:["Potassium risk depends on kidney function, diabetes, baseline potassium, dose, and concurrent RAAS/NSAID/potassium therapy."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_lacosamide_pr_label": {
    id:"ev_lacosamide_pr_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lacosamide prescribing information - PR interval and cardiac conduction medicines",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Lacosamide labeling describes dose-dependent PR-interval prolongation and cautions with concomitant medicines that affect cardiac conduction, including beta-blockers, calcium-channel blockers, sodium-channel blockers, potassium-channel blockers, and other PR-prolonging agents."},
    temporal:{mechanism:"additive_PR_interval_and_AV_node_conduction_slowing"},
    supports:["lacosamide_pr_prolongation","lacosamide_conduction_medicine_caution"],
    contradicts:[],
    limitations:["Risk depends on baseline conduction disease, dose, route, renal/hepatic function, and other AV-node or sodium-channel effects."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_donepezil_bradycardia_label": {
    id:"ev_donepezil_bradycardia_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Donepezil prescribing information - vagotonic bradycardia and CYP3A4/2D6 metabolism",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Donepezil labeling warns cholinesterase inhibitors may have vagotonic effects on SA/AV nodes causing bradycardia or heart block. Donepezil is metabolized through CYP3A4 and CYP2D6 pathways."},
    temporal:{mechanism:"cholinesterase_vagotonic_conduction_effect_and_CYP_inhibition_context"},
    supports:["donepezil_bradycardia_heart_block_warning","donepezil_cyp3a4_cyp2d6_metabolism"],
    contradicts:[],
    limitations:["Clinical risk depends on baseline conduction disease, age, dose, frailty, and concurrent rate-lowering medicines."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_valacyclovir_probenecid_label": {
    id:"ev_valacyclovir_probenecid_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Valacyclovir prescribing information - cimetidine/probenecid renal-clearance interaction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{cimetidineProbenecidCmaxIncreasePct:30, cimetidineProbenecidAucIncreasePct:78, note:"Valacyclovir labeling reports increased acyclovir Cmax and AUC after cimetidine plus probenecid, primarily from reduced renal clearance."},
    temporal:{mechanism:"renal_tubular_clearance_reduction"},
    supports:["valacyclovir_cimetidine_probenecid_acyclovir_exposure_increase","valacyclovir_renal_function_context"],
    contradicts:[],
    limitations:["Single-agent cimetidine or probenecid effects are usually modest; risk rises with renal impairment, dehydration, older age, or high-dose antiviral therapy."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_ceftriaxone_calcium_label": {
    id:"ev_ceftriaxone_calcium_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Ceftriaxone prescribing information - calcium-containing IV solution precipitation risk",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Ceftriaxone labeling contraindicates use in neonates requiring calcium-containing IV solutions because of ceftriaxone-calcium precipitation risk; adult sequential administration depends on line flushing and protocol."},
    temporal:{mechanism:"ceftriaxone_calcium_precipitation"},
    supports:["ceftriaxone_neonate_calcium_contraindication","ceftriaxone_calcium_precipitation_context"],
    contradicts:[],
    limitations:["The severe pair is neonatal/protocol-context dependent; non-neonate administration rules differ by institution and product labeling details."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_coc_label": {
    id:"ev_coc_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Combined oral contraceptive prescribing information - enzyme induction and lamotrigine interaction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{lamotrigineAucReductionPct:52, lamotrigineCmaxReductionPct:39, note:"COC labeling lists enzyme inducers including rifampin, carbamazepine, topiramate, and St. John's Wort as reducing contraceptive exposure; lamotrigine labeling reports approximately 2-fold clearance increase with ethinyl estradiol/levonorgestrel."},
    temporal:{mechanism:"CYP3A_induction_and_UGT_lamotrigine_glucuronidation"},
    supports:["coc_enzyme_inducer_contraceptive_failure","coc_lamotrigine_level_reduction","coc_st_johns_wort_breakthrough_bleeding"],
    contradicts:[],
    limitations:["Magnitude depends on contraceptive formulation, inducer strength/duration, adherence, and whether backup/non-hormonal contraception is used."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_chlorthalidone_lithium_label": {
    id:"ev_chlorthalidone_lithium_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Chlorthalidone prescribing information - lithium and electrolyte-risk interactions",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Chlorthalidone labeling warns about electrolyte imbalance including hypokalemia and patient counseling includes lithium/digitalis contexts; Thalitone labeling notes reduced lithium renal clearance and increased lithium toxicity risk."},
    temporal:{mechanism:"diuretic_lithium_clearance_reduction_and_electrolyte_loss"},
    supports:["chlorthalidone_lithium_toxicity","chlorthalidone_digoxin_hypokalemia_context"],
    contradicts:[],
    limitations:["Lithium and digoxin risk depends on renal function, dose, baseline electrolytes, hydration, and monitoring intensity."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_torsemide_lithium_label": {
    id:"ev_torsemide_lithium_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Torsemide prescribing information - lithium toxicity and electrolyte loss",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Torsemide labeling warns that torsemide reduces renal lithium clearance and can induce high lithium toxicity risk. It also warns about hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia."},
    temporal:{mechanism:"loop_diuretic_lithium_clearance_reduction_and_electrolyte_loss"},
    supports:["torsemide_lithium_toxicity","torsemide_digoxin_hypokalemia_context"],
    contradicts:[],
    limitations:["Risk depends on renal function, volume status, diuretic dose, concurrent RAAS therapy, and electrolyte monitoring."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_memantine_urine_ph_label": {
    id:"ev_memantine_urine_ph_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Memantine prescribing information - urine alkalinization reduces renal elimination",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{clearanceReductionPct:80, note:"Memantine labeling reports clearance reduced by about 80% under alkaline urine conditions and lists sodium bicarbonate/carbonic anhydrase inhibitors as urine-alkalinizing examples."},
    temporal:{mechanism:"urine_pH_dependent_memantine_clearance"},
    supports:["memantine_alkaline_urine_exposure_increase","memantine_sodium_bicarbonate_context"],
    contradicts:[],
    limitations:["Sustained urine alkalinization matters more than occasional antacid use; renal function and dose also affect exposure."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_oseltamivir_probenecid_label": {
    id:"ev_oseltamivir_probenecid_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Oseltamivir prescribing information - probenecid renal tubular secretion interaction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{activeMetaboliteAucFold:2, note:"Oseltamivir labeling reports probenecid approximately doubles exposure to oseltamivir carboxylate by decreasing active anionic tubular secretion in the kidney."},
    temporal:{mechanism:"renal_anion_transport_inhibition"},
    supports:["oseltamivir_probenecid_exposure_increase"],
    contradicts:[],
    limitations:["Labeling indicates no dose adjustment is usually required due to safety margin, but renal impairment can change context."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_acyclovir_probenecid_label": {
    id:"ev_acyclovir_probenecid_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Acyclovir prescribing information - probenecid renal-clearance interaction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Acyclovir labeling reports that probenecid coadministration with intravenous acyclovir increases acyclovir half-life and AUC by reducing renal clearance."},
    temporal:{mechanism:"renal_tubular_clearance_reduction"},
    supports:["acyclovir_probenecid_exposure_increase","acyclovir_renal_function_context"],
    contradicts:[],
    limitations:["Clinical importance is greater with IV/high-dose acyclovir, renal impairment, dehydration, and older age."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed clinician workflow enrichment pending human review"
  },
  "ev_leflunomide_teriflunomide_label": {
    id:"ev_leflunomide_teriflunomide_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Leflunomide prescribing information - active teriflunomide metabolite, washout, and transporter interactions",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91712aad-d96c-4ef0-97e7-b31ed18ca6d8",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{washout:"cholestyramine 8 g three times daily for 11 days", rosuvastatinMaxDoseMg:10, note:"Leflunomide labeling frames clinical persistence around the active metabolite teriflunomide; cholestyramine or activated charcoal accelerates elimination, and rosuvastatin dose should be limited because of transporter inhibition."},
    temporal:{mechanism:"active_metabolite_persistence_enterohepatic_recycling_and_transporter_inhibition"},
    supports:["leflunomide_teriflunomide_active_metabolite","leflunomide_cholestyramine_washout","teriflunomide_rosuvastatin_transporter_interaction"],
    contradicts:[],
    limitations:["Washout can be therapeutic when toxicity, pregnancy planning, or severe adverse reaction management is intended; interaction severity is context-dependent."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending human review"
  },
  "ev_mycophenolate_enterohepatic_label": {
    id:"ev_mycophenolate_enterohepatic_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Mycophenolate mofetil prescribing information - MPA active metabolite and enterohepatic recirculation",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=721564bc-7c0b-4418-ab49-0af362e74eb7",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Mycophenolate mofetil undergoes rapid metabolism to active mycophenolic acid (MPA). MPAG can be converted back to MPA through enterohepatic recirculation, and bile-acid sequestrants such as cholestyramine reduce MPA exposure by interrupting this cycle."},
    temporal:{mechanism:"active_metabolite_and_enterohepatic_recycling"},
    supports:["mycophenolate_mpa_active_metabolite","mycophenolate_mpag_enterohepatic_recycling","cholestyramine_reduces_mpa_exposure"],
    contradicts:[],
    limitations:["Magnitude varies by formulation, transplant organ, timing post-transplant, renal function, and concurrent immunosuppressants."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending human review"
  },
  "ev_allopurinol_oxypurinol_label": {
    id:"ev_allopurinol_oxypurinol_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Allopurinol prescribing information - oxypurinol active metabolite persistence",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Allopurinol is converted by xanthine oxidase to oxypurinol, an active xanthine oxidase inhibitor with longer persistence; xanthine oxidase inhibition drives thiopurine toxicity risk."},
    temporal:{mechanism:"active_metabolite_xanthine_oxidase_inhibition"},
    supports:["allopurinol_oxypurinol_active_metabolite","allopurinol_xo_inhibition_thiopurine_context"],
    contradicts:[],
    limitations:["Oxypurinol exposure is strongly renal-function dependent; thiopurine management requires dose reduction and blood-count monitoring."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending human review"
  },
  "ev_primidone_metabolites_label": {
    id:"ev_primidone_metabolites_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Primidone prescribing information - phenobarbital and PEMA active metabolites",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Primidone labeling states that primidone itself has anticonvulsant activity as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). Phenobarbital explains much of chronic sedative and enzyme-induction burden."},
    temporal:{mechanism:"active_metabolite_phenobarbital_and_PEMA"},
    supports:["primidone_phenobarbital_active_metabolite","primidone_pema_active_metabolite","primidone_metabolite_induction_context"],
    contradicts:[],
    limitations:["The exact parent/metabolite contribution varies by dose, duration, age, renal/hepatic function, and therapeutic drug monitoring."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending human review"
  },
  "ev_teriflunomide_label": {
    id:"ev_teriflunomide_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Teriflunomide prescribing information - unchanged elimination and active leflunomide metabolite context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b25c24e-a4a9-43b4-a33f-75bef3a96d5f",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Teriflunomide labeling identifies teriflunomide as the principal active leflunomide metabolite and describes elimination mainly through direct biliary excretion of unchanged drug plus renal excretion of metabolites."},
    temporal:{mechanism:"active_parent_persistence_and_enterohepatic_elimination"},
    supports:["teriflunomide_active_leflunomide_metabolite","teriflunomide_unchanged_biliary_elimination","teriflunomide_accelerated_elimination_context"],
    contradicts:[],
    limitations:["Risk and washout decisions depend on pregnancy potential, hepatotoxicity, infection, and indication-specific monitoring."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending neurology/rheumatology review"
  },
  "ev_cholestyramine_label": {
    id:"ev_cholestyramine_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Cholestyramine prescribing information - unabsorbed resin and oral drug binding",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Cholestyramine labeling states the resin is not absorbed from the digestive tract and can delay or reduce absorption of multiple oral medications by binding them in the gut."},
    temporal:{mechanism:"nonabsorbed_gut_binding_and_fecal_elimination"},
    supports:["cholestyramine_unabsorbed_resin","cholestyramine_oral_drug_binding","cholestyramine_enterohepatic_recycling_interruption"],
    contradicts:[],
    limitations:["Interaction magnitude depends on dose separation, drug formulation, enterohepatic recycling, and nutritional/vitamin context."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending pharmacy review"
  },
  "ev_chlorpromazine_cyp2d6_label": {
    id:"ev_chlorpromazine_cyp2d6_label", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Chlorpromazine metabolism context - CYP2D6/CYP3A4 phenothiazine metabolite mixture",
    year:2026, source:"Literature / label synthesis", journal:null, pmid:"10081729", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"metabolism_review", n:null, phenotypes:["CYP2D6"],
    quantifiedEffects:{note:"Chlorpromazine is a phenothiazine with multiple CYP2D6/CYP3A4/CYP1A2 oxidative metabolites; clinical risk remains parent/metabolite mixture driven with QT, anticholinergic, sedation, and EPS context."},
    temporal:{mechanism:"CYP2D6_CYP3A4_parent_and_metabolite_exposure"},
    supports:["chlorpromazine_METABOLIZED_TO_7-hydroxychlorpromazine","chlorpromazine_METABOLIZED_TO_n-desmethylchlorpromazine","chlorpromazine_cyp2d6_parent_exposure_context"],
    contradicts:[],
    limitations:["Metabolite fractions and activity vary across sources; launch data should be treated as review-required until specialist curation."],
    verified:false, reviewRequired:true, verifyNote:"Literature-backed metabolite-first enrichment pending psychiatry/pharmacy review"
  },
  "ev_propylthiouracil_label": {
    id:"ev_propylthiouracil_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Propylthiouracil prescribing information and metabolism context - glucuronidation with hepatotoxicity warning",
    year:2026, source:"FDA / DailyMed + HSDB/PubChem metabolism summary", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a251e4cb-01f1-4fd8-bd30-362126b85073",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Propylthiouracil is primarily cleared by glucuronidation, while the clinical safety signal is severe hepatotoxicity and antithyroid pharmacodynamics rather than a single active metabolite."},
    temporal:{mechanism:"UGT_conjugation_and_parent_antithyroid_effect"},
    supports:["propylthiouracil_glucuronidation_clearance","propylthiouracil_hepatotoxicity_context","propylthiouracil_parent_t4_t3_conversion_block"],
    contradicts:[],
    limitations:["Hepatotoxicity is idiosyncratic and cannot be predicted by this simple metabolite map."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending endocrinology/pharmacy review"
  },
  "ev_procainamide_nat2_label": {
    id:"ev_procainamide_nat2_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Procainamide prescribing information - NAPA active metabolite and NAT2 acetylation",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:"4073534", doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:["NAT2"],
    quantifiedEffects:{note:"Procainamide is acetylated by NAT2 to N-acetylprocainamide (NAPA), an active class III antiarrhythmic metabolite. Acetylator phenotype and renal function shift parent/NAPA exposure and toxicity context."},
    temporal:{mechanism:"NAT2_active_metabolite_formation_and_renal_clearance"},
    supports:["procainamide_METABOLIZED_TO_n-acetylprocainamide-napa","procainamide_nat2_parent_metabolite_balance","procainamide_napa_qt_context"],
    contradicts:[],
    limitations:["Clinical interpretation requires ECG/QT monitoring, renal function, dose, route, and therapeutic drug monitoring where available."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending cardiology/pharmacy review"
  },
  "ev_disopyramide_label": {
    id:"ev_disopyramide_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Disopyramide prescribing information - active mono-N-dealkyl metabolite and renal clearance",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Disopyramide is partly metabolized to mono-N-dealkyldisopyramide, an active metabolite with anticholinergic contribution, while renal clearance of unchanged parent remains clinically important."},
    temporal:{mechanism:"CYP3A4_metabolite_formation_and_renal_parent_clearance"},
    supports:["disopyramide_METABOLIZED_TO_mono-n-dealkyldisopyramide","disopyramide_anticholinergic_metabolite_context","disopyramide_renal_clearance_context"],
    contradicts:[],
    limitations:["Risk depends on renal function, serum concentration, QRS/QT monitoring, heart failure status, and anticholinergic vulnerability."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending cardiology/pharmacy review"
  },
  "ev_mexiletine_label": {
    id:"ev_mexiletine_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Mexiletine prescribing information - CYP2D6/CYP1A2 metabolism and minor active N-methyl metabolite",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab73778b-6794-441c-b127-610a6d0733ea",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2D6","CYP1A2"],
    quantifiedEffects:{note:"Mexiletine labeling describes predominant hepatic metabolism through CYP2D6 with CYP1A2 contribution, major hydroxylated metabolites, and a minor N-methylmexiletine metabolite with less than 20% of parent activity."},
    temporal:{mechanism:"CYP2D6_CYP1A2_parent_clearance"},
    supports:["mexiletine_METABOLIZED_TO_p-hydroxymexiletine","mexiletine_cyp2d6_cyp1a2_parent_clearance","mexiletine_minor_active_n-methylmetabolite"],
    contradicts:[],
    limitations:["Clinical toxicity is mainly parent-exposure driven; hepatic disease, smoking, CYP inhibitors, and ECG monitoring matter."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending cardiology/pharmacy review"
  },
  "ev_quinidine_label": {
    id:"ev_quinidine_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Quinidine prescribing information - 3-hydroxyquinidine active metabolite and CYP3A4 metabolism",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10b6ded-4fe0-4059-bd77-c45acc3c876d",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Quinidine labeling identifies 3-hydroxyquinidine as the most important metabolite and notes CYP3A4-mediated metabolism affected by inhibitors such as ketoconazole and grapefruit juice."},
    temporal:{mechanism:"CYP3A4_active_metabolite_and_parent_exposure"},
    supports:["quinidine_METABOLIZED_TO_3-hydroxyquinidine","quinidine_cyp3a4_inhibition_parent_exposure","quinidine_parent_cyp2d6_inhibition_context"],
    contradicts:[],
    limitations:["Narrow-therapeutic-index risk depends on QT, renal/hepatic function, electrolytes, and interacting medicines."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending cardiology/pharmacy review"
  },
  "ev_gefitinib_label": {
    id:"ev_gefitinib_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Gefitinib prescribing information - CYP3A4 metabolism and CYP2D6 O-desmethyl metabolite",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6402435f-9f6a-4f02-91a2-6267d783fa78",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2D6"],
    quantifiedEffects:{note:"Gefitinib labeling describes predominant CYP3A4 metabolism and O-desmethyl gefitinib formation by CYP2D6. The metabolite has similar isolated-enzyme activity but much lower potency in cell-based assays."},
    temporal:{mechanism:"CYP3A4_parent_clearance_and_CYP2D6_metabolite_formation"},
    supports:["gefitinib_METABOLIZED_TO_o-desmethyl-gefitinib","gefitinib_cyp3a4_substrate","gefitinib_cyp2d6_metabolite_context"],
    contradicts:[],
    limitations:["The metabolite is not a dosing target; EGFR mutation status, ILD risk, acid suppression, and CYP3A induction remain central."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending oncology/pharmacy review"
  },
  "ev_imatinib_label": {
    id:"ev_imatinib_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Imatinib prescribing information - active N-demethylated piperazine metabolite",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1debf3a0-7587-47d7-8ea6-e739698d7297",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Imatinib labeling states CYP3A4 is the major metabolic enzyme and the main circulating active metabolite is the N-demethylated piperazine derivative, with longer half-life than parent."},
    temporal:{mechanism:"CYP3A4_active_metabolite_formation"},
    supports:["imatinib_METABOLIZED_TO_n-demethylated-piperazine-derivative-cgp74588","imatinib_cyp3a4_substrate"],
    contradicts:[],
    limitations:["Clinical management is still mostly parent-exposure and toxicity driven; oncology context and indication-specific monitoring apply."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending oncology/pharmacy review"
  },
  "ev_pazopanib_label": {
    id:"ev_pazopanib_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Pazopanib prescribing information - CYP3A4 metabolism with minor CYP1A2/CYP2C8 contribution",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7235fad0-eb5b-4fdf-a362-c8c65c9bfe1d",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Pazopanib labeling describes metabolism primarily by CYP3A4 with minor CYP1A2/CYP2C8 contribution; clinical interaction management is parent-exposure driven."},
    temporal:{mechanism:"CYP3A4_parent_clearance"},
    supports:["pazopanib_cyp3a4_substrate","pazopanib_minor_cyp1a2_cyp2c8_metabolism","pazopanib_parent_exposure_hepatotoxicity_context"],
    contradicts:[],
    limitations:["Hepatic function, food/acid-suppression context, hypertension, and QT/hepatotoxicity monitoring remain clinically important."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed metabolite-first enrichment pending oncology/pharmacy review"
  },
  "ev_vorapaxar_cyp3a_label": {
    id:"ev_vorapaxar_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Vorapaxar prescribing information - avoid strong CYP3A inhibitors or inducers",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2abe3ed-ed3d-4215-a489-b18341ce85bc",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Vorapaxar labeling says to avoid strong CYP3A inhibitors or inducers. The interaction is clinically important because vorapaxar has a very long antiplatelet effect and bleeding risk persistence."},
    temporal:{mechanism:"CYP3A4_parent_active_moiety_exposure", offset:"weeks"},
    supports:["vorapaxar_cyp3a4_substrate","vorapaxar_avoid_strong_cyp3a_inhibitors","vorapaxar_avoid_strong_cyp3a_inducers"],
    contradicts:[],
    limitations:["Magnitude depends on inhibitor/inducer strength and timing; bleeding risk is strongly affected by indication, age, prior stroke/TIA, and background antithrombotic therapy."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed correlation enrichment pending cardiology/pharmacy review"
  },
  "ev_crizotinib_cyp3a_label": {
    id:"ev_crizotinib_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Crizotinib prescribing information - strong CYP3A inhibitors and inducers",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{aucFold:0.16, cmaxFold:0.21, note:"Crizotinib labeling reports that rifampin decreased steady-state AUC by about 84% and Cmax by about 79%; strong CYP3A inhibitors increase exposure and may increase adverse reactions."},
    temporal:{mechanism:"CYP3A4_parent_clearance"},
    supports:["crizotinib_cyp3a4_substrate","crizotinib_strong_cyp3a_inhibitor_exposure_increase","crizotinib_rifampin_exposure_decrease"],
    contradicts:[],
    limitations:["Oncology response, mutation context, ECG risk, hepatic function, and co-administered QT-risk drugs determine clinical action."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed correlation enrichment pending oncology/pharmacy review"
  },
  "ev_enzalutamide_induction_label": {
    id:"ev_enzalutamide_induction_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Enzalutamide prescribing information - CYP3A4, CYP2C9, and CYP2C19 induction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Enzalutamide labeling describes it as a strong CYP3A4 inducer and moderate CYP2C9/CYP2C19 inducer, warning that sensitive substrates may lose activity."},
    temporal:{mechanism:"enzyme_induction", onset:"days-weeks", offset:"weeks"},
    supports:["enzalutamide_strong_cyp3a4_inducer","enzalutamide_moderate_cyp2c9_inducer","enzalutamide_moderate_cyp2c19_inducer"],
    contradicts:[],
    limitations:["Effect magnitude differs by victim drug; therapeutic-drug monitoring or pharmacodynamic monitoring is needed for narrow-therapeutic-index substrates."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed correlation enrichment pending oncology/pharmacy review"
  },
  "ev_apalutamide_induction_label": {
    id:"ev_apalutamide_induction_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Apalutamide prescribing information - CYP, UGT, and transporter substrate exposure reduction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Apalutamide labeling warns that sensitive substrates of CYP3A4, CYP2C19, CYP2C9, UGT, P-gp, BCRP, or OATP1B1 may lose activity during coadministration."},
    temporal:{mechanism:"enzyme_transporter_induction", onset:"days-weeks", offset:"weeks"},
    supports:["apalutamide_cyp3a4_inducer","apalutamide_cyp2c9_inducer","apalutamide_cyp2c19_inducer","apalutamide_transporter_substrate_exposure_reduction"],
    contradicts:[],
    limitations:["Label warning is broad; victim-specific monitoring determines exact management."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed correlation enrichment pending oncology/pharmacy review"
  },
  "ev_cilostazol_cyp_inhibitor_label": {
    id:"ev_cilostazol_cyp_inhibitor_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Cilostazol prescribing information - dose reduction with CYP3A4 or CYP2C19 inhibitors",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f728395c-684c-4087-a389-c323dbcb72dd",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2C19"],
    quantifiedEffects:{note:"Cilostazol labeling recommends reducing dose to 50 mg twice daily with strong or moderate CYP3A4 inhibitors or CYP2C19 inhibitors because cilostazol/active metabolite exposure increases."},
    temporal:{mechanism:"CYP3A4_CYP2C19_parent_and_active_metabolite_clearance"},
    supports:["cilostazol_cyp3a4_substrate","cilostazol_cyp2c19_substrate","cilostazol_reduce_dose_with_cyp_inhibitors"],
    contradicts:[],
    limitations:["Contraindication in heart failure and bleeding/cardiovascular tolerance remain key clinical modifiers."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed correlation enrichment pending cardiology/pharmacy review"
  },
  "ev_lorlatinib_cyp3a_label": {
    id:"ev_lorlatinib_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lorlatinib prescribing information - CYP3A inducer contraindication and CYP3A substrate reduction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=004f93d7-a1cd-4b67-9207-31cdcb5c5976",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Lorlatinib labeling contraindicates strong CYP3A inducers because serious hepatotoxicity occurred with rifampin, and warns that lorlatinib can reduce exposure of CYP3A substrates."},
    temporal:{mechanism:"CYP3A4_substrate_and_inducer", onset:"days", offset:"days-weeks"},
    supports:["lorlatinib_contraindicated_with_strong_cyp3a_inducers","lorlatinib_reduces_cyp3a_substrate_exposure","lorlatinib_cyp3a4_substrate"],
    contradicts:[],
    limitations:["The hepatotoxicity warning is specific to strong CYP3A inducer co-use; substrate-victim management depends on the victim drug therapeutic index."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed correlation enrichment pending oncology/pharmacy review"
  },
  "ev_darolutamide_bcrp_label": {
    id:"ev_darolutamide_bcrp_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Darolutamide prescribing information - BCRP/OATP inhibition and rosuvastatin exposure",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a7cb212-56e4-4b9d-a73d-bfee7fe4735e",
    studyDesign:"regulatory_label", n:null, phenotypes:["ABCG2","SLCO1B1"],
    quantifiedEffects:{aucFold:5, note:"Darolutamide labeling reports about a 5-fold increase in rosuvastatin exposure through BCRP/OATP transporter inhibition."},
    temporal:{mechanism:"BCRP_OATP_inhibition"},
    supports:["darolutamide_inhibits_bcrp_oatp","darolutamide_increases_rosuvastatin_exposure","rosuvastatin_transporter_substrate"],
    contradicts:[],
    limitations:["Rosuvastatin risk also depends on SLCO1B1/ABCG2 genotype, renal function, age, statin dose, and other myopathy risks."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed correlation enrichment pending oncology/pharmacy review"
  },
  "ev_alectinib_m4_food_label": {
    id:"ev_alectinib_m4_food_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Alectinib prescribing information - active M4 metabolite and food-dependent active-moiety exposure",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{foodActiveMoietyAucFold:3.1, note:"Alectinib labeling describes CYP3A4 formation of active M4 and a high-fat/high-calorie meal increasing combined alectinib plus M4 AUC about 3.1-fold; strong CYP3A inhibitors/inducers did not meaningfully change combined active exposure."},
    temporal:{mechanism:"food_dependent_absorption_and_active_M4_formation", onset:"hours", offset:"same_day"},
    supports:["alectinib_to_active_M4","alectinib_food_increases_active_moiety","alectinib_cyp3a_modulators_limited_active_moiety_change"],
    contradicts:[],
    limitations:["Food effect depends on meal composition and adherence; oncology response and toxicity monitoring remain individualized."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed ALK TKI active-metabolite enrichment pending oncology/pharmacy review"
  },
  "ev_brigatinib_cyp3a_label": {
    id:"ev_brigatinib_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Brigatinib prescribing information - strong CYP3A inhibitors and inducers",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{itraconazoleAucIncreasePct:101, rifampinAucReductionPct:80, note:"Brigatinib labeling reports itraconazole increased AUC about 101%, while rifampin reduced AUC about 80% and Cmax about 60%."},
    temporal:{mechanism:"CYP3A4_parent_clearance", onset:"days", offset:"days-weeks"},
    supports:["brigatinib_cyp3a_substrate","brigatinib_strong_cyp3a_inhibitor_exposure_increase","brigatinib_rifampin_exposure_decrease"],
    contradicts:[],
    limitations:["Dose modification depends on brigatinib dose step, toxicity history, and whether the interacting medicine is avoidable."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed ALK TKI enrichment pending oncology/pharmacy review"
  },
  "ev_capmatinib_cyp3a_transporter_label": {
    id:"ev_capmatinib_cyp3a_transporter_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Capmatinib prescribing information - CYP3A exposure changes and P-gp/BCRP substrate interactions",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d",
    studyDesign:"regulatory_label", n:null, phenotypes:["ABCB1","ABCG2"],
    quantifiedEffects:{itraconazoleAucIncreasePct:42, rifampinAucReductionPct:67, rifampinCmaxReductionPct:56, note:"Capmatinib labeling reports itraconazole increased AUC about 42%, rifampin reduced AUC about 67% and Cmax about 56%, and capmatinib can increase P-gp/BCRP substrate exposure."},
    temporal:{mechanism:"CYP3A4_clearance_and_Pgp_BCRP_inhibition", onset:"days", offset:"days"},
    supports:["capmatinib_cyp3a_substrate","capmatinib_rifampin_exposure_decrease","capmatinib_inhibits_pgp","capmatinib_inhibits_bcrp"],
    contradicts:[],
    limitations:["Transporter victim-drug risk depends on substrate therapeutic index, renal/hepatic function, and oncology toxicity context."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed MET TKI enrichment pending oncology/pharmacy review"
  },
  "ev_lenvatinib_qt_label": {
    id:"ev_lenvatinib_qt_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lenvatinib prescribing information - QT prolongation and modest rifampin exposure effects",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{rifampinSingleDoseAucIncreasePct:31, rifampinChronicAucReductionPct:18, note:"Lenvatinib labeling emphasizes QT monitoring/avoidance with QT-prolonging drugs; rifampin single-dose P-gp inhibition increased AUC about 31%, while repeated rifampin reduced AUC about 18%."},
    temporal:{mechanism:"QT_risk_and_mixed_CYP3A_Pgp_induction_inhibition_context", onset:"days", offset:"days-weeks"},
    supports:["lenvatinib_qt_prolongation","lenvatinib_avoid_qt_prolonging_drugs","lenvatinib_mixed_rifampin_exposure_effects"],
    contradicts:[],
    limitations:["Hypertension, electrolytes, baseline QTc, cardiac disease, renal/hepatic function, and cancer indication determine clinical risk."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed VEGFR TKI enrichment pending oncology/pharmacy review"
  },
  "ev_sunitinib_cyp3a_qt_label": {
    id:"ev_sunitinib_cyp3a_qt_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sunitinib prescribing information - CYP3A modifiers, active metabolite, and QT prolongation",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Sunitinib labeling recommends dose adjustment/avoidance with strong CYP3A inhibitors or inducers, describes a primary active metabolite, and warns of dose-dependent QT prolongation."},
    temporal:{mechanism:"CYP3A4_parent_active_metabolite_clearance_and_QT_risk", onset:"days", offset:"days-weeks"},
    supports:["sunitinib_cyp3a_substrate","sunitinib_active_metabolite","sunitinib_strong_cyp3a_modifier_dose_adjustment","sunitinib_qt_prolongation"],
    contradicts:[],
    limitations:["QT risk depends on active-moiety exposure, electrolytes, baseline QTc, cardiac disease, and other QT-risk medicines."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed VEGFR TKI enrichment pending oncology/pharmacy review"
  },
  "ev_sorafenib_cyp_ugt_warfarin_label": {
    id:"ev_sorafenib_cyp_ugt_warfarin_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Sorafenib prescribing information - CYP3A4/UGT1A9 metabolism, strong inducers, warfarin bleeding/INR, and QT risk",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0&type=display",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Sorafenib labeling describes CYP3A4 oxidation and UGT1A9 glucuronidation, advises avoiding strong CYP3A inducers, and warns of bleeding/INR changes with warfarin plus QT prolongation context."},
    temporal:{mechanism:"CYP3A4_UGT1A9_clearance_and_bleeding_QT_context", onset:"days", offset:"days-weeks"},
    supports:["sorafenib_cyp3a4_substrate","sorafenib_ugt1a9_clearance","sorafenib_avoid_strong_cyp3a_inducers","sorafenib_warfarin_inr_bleeding_monitoring"],
    contradicts:[],
    limitations:["INR and bleeding risk depend on tumor type, liver function, platelet count, warfarin indication, and other antithrombotics."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed multikinase TKI enrichment pending oncology/pharmacy review"
  },
  "ev_regorafenib_cyp3a_ugt_bcrp_label": {
    id:"ev_regorafenib_cyp3a_ugt_bcrp_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Regorafenib prescribing information - CYP3A4/UGT1A9 active metabolite shifts and BCRP substrate exposure",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7",
    studyDesign:"regulatory_label", n:null, phenotypes:["ABCG2"],
    quantifiedEffects:{note:"Regorafenib labeling describes CYP3A4/UGT1A9 metabolism to active M-2 and M-5, parent/metabolite shifts with ketoconazole or rifampin, and BCRP substrate exposure increases."},
    temporal:{mechanism:"CYP3A4_UGT1A9_active_metabolite_shift_and_BCRP_inhibition", onset:"days", offset:"days-weeks"},
    supports:["regorafenib_active_M2_M5_metabolites","regorafenib_ketoconazole_parent_metabolite_shift","regorafenib_rifampin_parent_metabolite_shift","regorafenib_bcrp_inhibition"],
    contradicts:[],
    limitations:["Hepatic toxicity, hand-foot reaction, blood pressure, and cancer indication affect management; active-moiety interpretation is simplified."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed multikinase TKI enrichment pending oncology/pharmacy review"
  },
  "ev_axitinib_cyp3a_label": {
    id:"ev_axitinib_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Axitinib prescribing information - strong CYP3A4/5 inhibitors and inducers",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a903e31-936e-4ed7-8a59-59f32374f338",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Axitinib labeling recommends avoiding strong CYP3A4/5 inhibitors or reducing axitinib dose by about half if unavoidable, and reports that rifampin reduced axitinib plasma exposure."},
    temporal:{mechanism:"CYP3A4_5_parent_clearance", onset:"days", offset:"days-weeks"},
    supports:["axitinib_cyp3a_substrate","axitinib_strong_cyp3a_inhibitor_dose_reduction","axitinib_rifampin_exposure_reduction"],
    contradicts:[],
    limitations:["Axitinib dose titration, blood pressure, hepatic function, and combination immunotherapy context modify final management."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed VEGFR TKI enrichment pending oncology/pharmacy review"
  },
  "ev_lumateperone_cyp3a_label": {
    id:"ev_lumateperone_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lumateperone prescribing information - CYP3A4 inhibitor dose reduction and inducer avoidance",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Lumateperone labeling recommends lower dosing with strong/moderate CYP3A4 inhibitors and avoiding CYP3A4 inducers because exposure decreases."},
    temporal:{mechanism:"CYP3A4_parent_clearance", onset:"days", offset:"days"},
    supports:["lumateperone_cyp3a_substrate","lumateperone_strong_cyp3a_inhibitor_dose_reduction","lumateperone_avoid_cyp3a_inducers"],
    contradicts:[],
    limitations:["Tolerability and efficacy depend on psychiatric indication, dose, adherence, sedation/orthostasis, and concomitant CNS medicines."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed psychiatry enrichment pending psychiatry/pharmacy review"
  },
  "ev_levomilnacipran_cyp3a_renal_label": {
    id:"ev_levomilnacipran_cyp3a_renal_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Levomilnacipran prescribing information - strong CYP3A4 inhibitor dose cap and renal elimination",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Levomilnacipran labeling caps the maximum recommended dose at 80 mg once daily with strong CYP3A4 inhibitors and states renal excretion is a predominant elimination route."},
    temporal:{mechanism:"CYP3A4_metabolism_plus_renal_excretion", onset:"days", offset:"days"},
    supports:["levomilnacipran_strong_cyp3a_inhibitor_dose_cap","levomilnacipran_renal_elimination","levomilnacipran_bp_hr_exposure_context"],
    contradicts:[],
    limitations:["Blood pressure, heart rate, renal function, urinary retention risk, and serotonergic co-medications modify management."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed SNRI enrichment pending psychiatry/pharmacy review"
  },
  "ev_asenapine_ugt1a4_cyp1a2_label": {
    id:"ev_asenapine_ugt1a4_cyp1a2_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Asenapine prescribing information - UGT1A4/CYP1A2 metabolism and weak CYP2D6 inhibition",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=asenapine%20Saphris%20fluvoxamine%20paroxetine",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP1A2","CYP2D6"],
    quantifiedEffects:{note:"Asenapine labeling describes direct glucuronidation by UGT1A4 and oxidative metabolism by CYP1A2, notes exposure context with fluvoxamine, and describes weak CYP2D6 inhibition relevant to paroxetine exposure."},
    temporal:{mechanism:"UGT1A4_CYP1A2_clearance_and_weak_CYP2D6_inhibition", onset:"days", offset:"days"},
    supports:["asenapine_ugt1a4_metabolism","asenapine_cyp1a2_metabolism","asenapine_fluvoxamine_exposure_context","asenapine_weak_cyp2d6_inhibition"],
    contradicts:[],
    limitations:["Clinical relevance depends on formulation, dose, sedation/orthostasis, EPS, QT-risk context, and other serotonergic/CNS medicines."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antipsychotic enrichment pending psychiatry/pharmacy review"
  },
  "ev_levothyroxine_absorption_label": {
    id:"ev_levothyroxine_absorption_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Levothyroxine prescribing information - absorption reduced by binding agents, minerals, and acid suppression context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=levothyroxine",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Levothyroxine labeling warns that products such as calcium carbonate, ferrous sulfate, bile-acid sequestrants, ion-exchange resins, and gastric-acidity modifiers can reduce absorption or require dose monitoring."},
    temporal:{mechanism:"GI_binding_chelation_and_pH_dependent_tablet_absorption", onset:"days-weeks", offset:"days-weeks"},
    supports:["levothyroxine_cation_binding_reduced_absorption","levothyroxine_bile_acid_sequestrant_binding","levothyroxine_acid_suppression_monitor_tsh"],
    contradicts:[],
    limitations:["Magnitude depends on formulation, dose timing, baseline thyroid reserve, pregnancy status, and chronicity; TSH changes lag exposure changes."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed absorption enrichment pending endocrinology/pharmacy review"
  },
  "ev_fluoroquinolone_cation_absorption_label": {
    id:"ev_fluoroquinolone_cation_absorption_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Fluoroquinolone prescribing information - multivalent cation chelation lowers oral absorption",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=ciprofloxacin%20levofloxacin%20moxifloxacin%20multivalent%20cations",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Ciprofloxacin, levofloxacin, and moxifloxacin labels warn that multivalent cation products such as antacids, calcium, iron, zinc, sucralfate, and multivitamins can reduce oral absorption and require dose separation."},
    temporal:{mechanism:"GI_chelation_reduced_absorption", onset:"same_day", offset:"same_day"},
    supports:["fluoroquinolone_cation_chelation_reduced_absorption","ciprofloxacin_calcium_iron_separation","levofloxacin_cation_separation","moxifloxacin_cation_separation"],
    contradicts:[],
    limitations:["Exact separation window differs by fluoroquinolone and product; infection severity and susceptibility determine clinical consequence."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antibiotic absorption enrichment pending infectious-disease/pharmacy review"
  },
  "ev_tetracycline_cation_absorption_label": {
    id:"ev_tetracycline_cation_absorption_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Tetracycline-class prescribing information - antacids, calcium, and iron impair absorption",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=doxycycline%20antacids%20iron%20calcium",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Doxycycline labeling states that tetracycline absorption is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations."},
    temporal:{mechanism:"GI_chelation_reduced_absorption", onset:"same_day", offset:"same_day"},
    supports:["doxycycline_cation_chelation_reduced_absorption","minocycline_tetracycline_class_cation_separation"],
    contradicts:[],
    limitations:["Class extrapolation is strongest for doxycycline label text; product-specific timing should be checked for each tetracycline formulation."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antibiotic absorption enrichment pending infectious-disease/pharmacy review"
  },
  "ev_amphetamine_urinary_ph_label": {
    id:"ev_amphetamine_urinary_ph_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Amphetamine stimulant prescribing information - urinary pH changes alter blood levels",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=amphetamine%20urinary%20pH%20ascorbic%20acid%20sodium%20bicarbonate",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Amphetamine labels state that urinary/GI alkalinizing agents such as sodium bicarbonate increase blood levels, while acidifying agents such as ascorbic acid decrease blood levels."},
    temporal:{mechanism:"urinary_pH_dependent_ionization_and_renal_excretion", onset:"same_day", offset:"same_day"},
    supports:["amphetamine_alkalinization_increases_exposure","amphetamine_acidification_decreases_exposure","lisdexamfetamine_active_d_amphetamine_ph_context"],
    contradicts:[],
    limitations:["Effect magnitude depends on urinary pH change, renal function, stimulant formulation, and whether the product is parent amphetamine or a prodrug."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed ADHD exposure enrichment pending psychiatry/pharmacy review"
  },
  "ev_lurasidone_food_label": {
    id:"ev_lurasidone_food_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lurasidone prescribing information - food substantially increases absorption",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=lurasidone%20food%20AUC%20Cmax",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{aucFold:2.0, cmaxFold:3.0, note:"Lurasidone labeling reports that administration with food approximately doubles AUC and triples Cmax."},
    temporal:{mechanism:"fed_state_absorption_increase", onset:"same_dose", offset:"same_dose"},
    supports:["lurasidone_take_with_food","lurasidone_food_increases_auc_cmax"],
    contradicts:[],
    limitations:["Meal size/composition and adherence pattern determine real-world exposure; this is an administration requirement rather than an avoid-all-food warning."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed psychiatry exposure enrichment pending psychiatry/pharmacy review"
  },
  "ev_atovaquone_food_label": {
    id:"ev_atovaquone_food_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Atovaquone prescribing information - food-dependent absorption",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=atovaquone%20food%20absorption",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Atovaquone labels emphasize administration with food because absorption is limited and clinically exposure-dependent."},
    temporal:{mechanism:"fed_state_absorption_increase", onset:"same_dose", offset:"same_dose"},
    supports:["atovaquone_take_with_food","atovaquone_food_dependent_absorption"],
    contradicts:[],
    limitations:["Magnitude depends on meal fat content, GI illness, vomiting/diarrhea, formulation, and indication."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed infectious-disease exposure enrichment pending infectious-disease/pharmacy review"
  },
  "ev_maribavir_label": {
    id:"ev_maribavir_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Maribavir prescribing information - UL97 antagonism, CYP3A induction, and P-gp substrate interactions",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=maribavir%20Livtencity%20drug%20interactions",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Maribavir labeling warns against coadministration with ganciclovir/valganciclovir because UL97 inhibition can reduce their antiviral activity; rifampin lowers maribavir, carbamazepine requires maribavir dose adjustment, and digoxin exposure can increase."},
    temporal:{mechanism:"UL97_antagonism_CYP3A_induction_Pgp_inhibition", onset:"days", offset:"days"},
    supports:["maribavir_antagonizes_ganciclovir_valganciclovir","maribavir_rifampin_loss_of_response","maribavir_carbamazepine_dose_adjustment","maribavir_increases_digoxin_exposure"],
    contradicts:[],
    limitations:["CMV resistance pattern, transplant organ, viral load kinetics, and immunosuppression strategy determine clinical management."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed CMV/transplant enrichment pending infectious-disease/transplant pharmacy review"
  },
  "ev_letermovir_immunosuppressant_label": {
    id:"ev_letermovir_immunosuppressant_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Letermovir prescribing information and clinical PK - cyclosporine, tacrolimus, sirolimus, and OATP/CYP3A interactions",
    year:2026, source:"FDA / DailyMed + clinical PK", journal:null, pmid:"30990905", doi:null,
    url:"https://pubmed.ncbi.nlm.nih.gov/30990905/",
    studyDesign:"regulatory_label_and_clinical_pk", n:null, phenotypes:[],
    quantifiedEffects:{note:"Letermovir has clinically relevant interaction patterns with cyclosporine, tacrolimus, and sirolimus through CYP3A/OATP/P-gp pathways; labeling includes cyclosporine dose adjustment context and statin exposure warnings."},
    temporal:{mechanism:"CYP3A_inhibition_OATP_transport_inhibition_and_cyclosporine_interaction", onset:"days", offset:"days"},
    supports:["letermovir_cyclosporine_dose_adjustment","letermovir_increases_tacrolimus_exposure","letermovir_sirolimus_monitoring","letermovir_oatp_statin_exposure"],
    contradicts:[],
    limitations:["Effect magnitude varies with cyclosporine co-use, organ transplant context, renal/hepatic function, and baseline therapeutic-drug monitoring."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed CMV/transplant enrichment pending infectious-disease/transplant pharmacy review"
  },
  "ev_valganciclovir_label": {
    id:"ev_valganciclovir_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Valganciclovir/ganciclovir prescribing information - marrow suppression, renal dosing, and UL97 activation context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=valganciclovir%20ganciclovir%20drug%20interactions",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Valganciclovir is converted to ganciclovir; labels emphasize hematologic toxicity, renal dose adjustment, and additive toxicity with other marrow-suppressive medicines."},
    temporal:{mechanism:"prodrug_activation_to_ganciclovir_and_renal_clearance", onset:"days", offset:"days-weeks"},
    supports:["valganciclovir_to_ganciclovir_activation","ganciclovir_myelosuppression","valganciclovir_zidovudine_additive_myelosuppression"],
    contradicts:[],
    limitations:["CMV viral kinetics, renal function, neutrophil reserve, and transplant immunosuppression modify risk."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed CMV/transplant enrichment pending infectious-disease/transplant pharmacy review"
  },
  "ev_bedaquiline_label": {
    id:"ev_bedaquiline_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Bedaquiline prescribing information - CYP3A induction/inhibition and QT prolongation",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=bedaquiline%20Sirturo%20rifampin%20QT",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Bedaquiline labeling warns that CYP3A inducers reduce exposure, CYP3A inhibitors may increase exposure, and QT-prolonging combinations require ECG/electrolyte monitoring."},
    temporal:{mechanism:"CYP3A4_exposure_change_and_concentration_dependent_QT_risk", onset:"days-weeks", offset:"weeks"},
    supports:["bedaquiline_rifampin_loss_of_efficacy","bedaquiline_cyp3a_inhibitor_toxicity","bedaquiline_qt_additive_risk"],
    contradicts:[],
    limitations:["MDR-TB regimens require specialist oversight; additive QT risk depends on baseline QTc, electrolytes, companion drugs, and TB severity."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed TB enrichment pending infectious-disease/pharmacy review"
  },
  "ev_rifapentine_label": {
    id:"ev_rifapentine_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Rifapentine prescribing information - rifamycin induction and reduced substrate exposure",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=rifapentine%20Priftin%20drug%20interactions",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Rifapentine labeling describes enzyme induction and clinically important reductions in exposure of coadministered medicines, including hormonal contraceptives and other CYP/P-gp substrates."},
    temporal:{mechanism:"rifamycin_enzyme_and_transporter_induction", onset:"days-weeks", offset:"weeks"},
    supports:["rifapentine_reduces_hormonal_contraceptive_exposure","rifapentine_rifamycin_induction_context","rifapentine_tacrolimus_loss_of_exposure"],
    contradicts:[],
    limitations:["Induction magnitude varies by rifamycin, dosing schedule, HIV/TB regimen, and victim-drug therapeutic index."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed TB enrichment pending infectious-disease/pharmacy review"
  },
  "ev_praziquantel_label": {
    id:"ev_praziquantel_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Praziquantel prescribing information - CYP3A induction can markedly reduce exposure",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=praziquantel%20rifampin%20drug%20interactions",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Praziquantel is a CYP3A-sensitive substrate; strong inducers such as rifampin can reduce systemic exposure and risk treatment failure."},
    temporal:{mechanism:"CYP3A_induction_reduced_antiparasitic_exposure", onset:"days", offset:"days-weeks"},
    supports:["praziquantel_rifampin_loss_of_efficacy","praziquantel_cyp3a_substrate"],
    contradicts:[],
    limitations:["Timing of rifampin discontinuation and parasite indication determine whether treatment should be delayed or changed."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antiparasitic enrichment pending infectious-disease/pharmacy review"
  },
  "ev_atovaquone_interactions_label": {
    id:"ev_atovaquone_interactions_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Atovaquone prescribing information - rifampin/rifabutin and tetracycline reduce atovaquone concentrations",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=atovaquone%20rifampin%20rifabutin%20tetracycline",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{atovaquoneReductionWithTetracyclinePct:40, note:"Atovaquone labeling states rifampin/rifabutin reduce atovaquone concentrations and tetracycline has been associated with about a 40% reduction in plasma concentrations."},
    temporal:{mechanism:"reduced_atovaquone_exposure", onset:"days", offset:"days"},
    supports:["atovaquone_rifampin_loss_of_efficacy","atovaquone_rifabutin_loss_of_efficacy","atovaquone_tetracycline_exposure_reduction"],
    contradicts:[],
    limitations:["Clinical impact depends on indication, pathogen burden, food intake, vomiting/diarrhea, and alternative regimen availability."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antiparasitic enrichment pending infectious-disease/pharmacy review"
  },
  "ev_fondaparinux_bleeding_label": {
    id:"ev_fondaparinux_bleeding_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Fondaparinux prescribing information - additive bleeding with antiplatelets and anticoagulants",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=fondaparinux%20bleeding%20aspirin%20clopidogrel",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Fondaparinux labeling warns about bleeding risk, renal clearance, and additive bleeding with medicines affecting hemostasis."},
    temporal:{mechanism:"factor_Xa_inhibition_plus_antiplatelet_hemostasis_reduction", onset:"same_day", offset:"days"},
    supports:["fondaparinux_antiplatelet_bleeding_risk","fondaparinux_renal_clearance_bleeding_context"],
    contradicts:[],
    limitations:["ACS/VTE indication, renal function, procedural timing, and baseline bleed risk determine whether the combination is appropriate."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed procedural/cardiology enrichment pending cardiology/pharmacy review"
  },
  "ev_gpiibiiia_bleeding_label": {
    id:"ev_gpiibiiia_bleeding_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"GP IIb/IIIa inhibitor prescribing information - heparin and procedural bleeding risk",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=eptifibatide%20tirofiban%20abciximab%20heparin%20bleeding",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Eptifibatide, tirofiban, and abciximab labels emphasize bleeding and thrombocytopenia risks, especially in anticoagulated/procedural settings with heparin."},
    temporal:{mechanism:"platelet_GPIIbIIIa_blockade_plus_anticoagulation", onset:"same_day", offset:"hours-days"},
    supports:["gpiibiiia_heparin_bleeding_risk","eptifibatide_heparin_procedural_bleeding","tirofiban_heparin_procedural_bleeding","abciximab_heparin_procedural_bleeding"],
    contradicts:[],
    limitations:["These combinations are often protocolized rather than absolutely avoidable; renal adjustment, activated clotting time/aPTT, access site, and platelet count drive management."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed procedural/cardiology enrichment pending cardiology/pharmacy review"
  },
  "ev_malarone_label": {
    id:"ev_malarone_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Atovaquone/proguanil prescribing information - food, rifamycins, metoclopramide, tetracycline, and CYP2C19 activation",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc22e8d8-3bfb-4f70-a599-dd81262a4887",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Atovaquone/proguanil labeling emphasizes administration with food, reduced atovaquone exposure with rifampin/rifabutin/metoclopramide/tetracycline, and proguanil conversion to cycloguanil primarily by CYP2C19."},
    temporal:{mechanism:"food_dependent_absorption_reduced_atovaquone_exposure_and_CYP2C19_prodrug_activation", onset:"hours-days", offset:"days"},
    supports:["atovaquone_food_dependent_absorption","atovaquone_metoclopramide_exposure_reduction","proguanil_cyp2c19_to_cycloguanil","malarone_rifamycin_exposure_loss"],
    contradicts:[],
    limitations:["Clinical outcome depends on malaria indication, vomiting/diarrhea, adherence, resistance geography, renal/hepatic function, and companion therapy."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antimalarial enrichment pending infectious-disease/travel-medicine pharmacy review"
  },
  "ev_albendazole_active_sulfoxide_label": {
    id:"ev_albendazole_active_sulfoxide_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Albendazole prescribing information - active sulfoxide metabolite exposure increases with dexamethasone, praziquantel, and cimetidine",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=albendazole%20praziquantel%20dexamethasone%20cimetidine",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{dexamethasoneTroughIncreasePct:56, praziquantelCmaxAucIncreasePct:50, cimetidineBileCystFluidFold:2, note:"Albendazole labeling reports increased active albendazole sulfoxide exposure with dexamethasone, praziquantel, and cimetidine in specified settings."},
    temporal:{mechanism:"active_sulfoxide_exposure_increase", onset:"days", offset:"days"},
    supports:["albendazole_active_sulfoxide_metabolite","albendazole_dexamethasone_exposure_increase","albendazole_praziquantel_exposure_increase","albendazole_cimetidine_exposure_increase"],
    contradicts:[],
    limitations:["Use can be intentional in some parasitic regimens; risk depends on course length, liver function, cyst location, and CBC reserve."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antiparasitic active-metabolite enrichment pending infectious-disease/pharmacy review"
  },
  "ev_griseofulvin_induction_label": {
    id:"ev_griseofulvin_induction_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Griseofulvin prescribing information - warfarin, hormonal contraceptives, alcohol intolerance, and induction context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bafb97f-621b-4b96-a787-68e0bb5c8637",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Griseofulvin labeling describes reduced anticoagulant and oral contraceptive effects and alcohol intolerance/potentiation warnings."},
    temporal:{mechanism:"enzyme_induction_and_alcohol_intolerance", onset:"days-weeks", offset:"weeks"},
    supports:["griseofulvin_reduces_warfarin_effect","griseofulvin_reduces_hormonal_contraceptive_effect","griseofulvin_alcohol_intolerance"],
    contradicts:[],
    limitations:["Magnitude varies by formulation, duration, hepatic function, and victim-drug monitoring; terbinafine or azoles have different interaction profiles."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed dermatology/antifungal enrichment pending pharmacy review"
  },
  "ev_darunavir_boosted_cyp3a_label": {
    id:"ev_darunavir_boosted_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Darunavir prescribing information - boosted CYP3A interaction liability",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=darunavir%20rifampin%20simvastatin%20midazolam",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP3A4","ABCB1"],
    quantifiedEffects:{note:"Darunavir is used with ritonavir/cobicistat boosting; labeling warns against rifampin and contraindicated CYP3A substrates such as simvastatin/lovastatin and oral midazolam/triazolam."},
    temporal:{mechanism:"CYP3A4_Pgp_inhibition_with_booster_and_induction_susceptibility", onset:"days", offset:"days-weeks"},
    supports:["darunavir_boosted_cyp3a_inhibition","darunavir_rifampin_contraindicated","darunavir_simvastatin_contraindicated","darunavir_midazolam_contraindicated"],
    contradicts:[],
    limitations:["Magnitude depends on booster, regimen, resistance history, hepatic function, and whether the victim drug is oral or parenteral."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed HIV enrichment pending infectious-disease/pharmacy review"
  },
  "ev_rilpivirine_acid_cyp3a_qt_label": {
    id:"ev_rilpivirine_acid_cyp3a_qt_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Rilpivirine prescribing information - acid-dependent absorption, CYP3A induction, and QT context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=rilpivirine%20proton%20pump%20inhibitor%20rifampin%20carbamazepine%20QT",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP3A4"],
    quantifiedEffects:{note:"Rilpivirine labeling contraindicates proton pump inhibitors and strong CYP3A inducers such as rifampin/carbamazepine, and describes QT prolongation at supratherapeutic exposure."},
    temporal:{mechanism:"gastric_pH_dependent_absorption_CYP3A4_clearance_and_QT_exposure_context", onset:"same_day", offset:"days-weeks"},
    supports:["rilpivirine_ppi_contraindicated","rilpivirine_strong_inducer_contraindicated","rilpivirine_qt_exposure_context"],
    contradicts:[],
    limitations:["H2 blocker/antacid management uses timing rules; injectable cabotegravir/rilpivirine has different absorption constraints."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed HIV enrichment pending infectious-disease/pharmacy review"
  },
  "ev_bictegravir_cation_induction_label": {
    id:"ev_bictegravir_cation_induction_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Bictegravir/FTC/TAF prescribing information - polyvalent cations and strong induction",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=biktarvy%20bictegravir%20calcium%20iron%20rifampin",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP3A4","UGT1A1"],
    quantifiedEffects:{note:"Bictegravir is cleared by CYP3A and UGT1A1. Labeling warns against rifampin and gives timing/food rules for polyvalent cations such as calcium and iron."},
    temporal:{mechanism:"CYP3A4_UGT1A1_induction_and_integrase_cation_chelation", onset:"same_day_to_days", offset:"days-weeks"},
    supports:["bictegravir_rifampin_contraindicated","bictegravir_polyvalent_cation_absorption_reduction","bictegravir_cyp3a_ugt1a1_substrate"],
    contradicts:[],
    limitations:["Mineral effect depends strongly on fasting/fed state and timing; complete HIV regimen context determines failure risk."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed HIV enrichment pending infectious-disease/pharmacy review"
  },
  "ev_taf_pgp_induction_label": {
    id:"ev_taf_pgp_induction_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Tenofovir alafenamide prescribing information - P-gp/BCRP substrate and inducer exposure loss",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tenofovir%20alafenamide%20P-gp%20rifampin%20carbamazepine",
    studyDesign:"regulatory_label", n:null, phenotypes:["ABCB1","ABCG2"],
    quantifiedEffects:{note:"TAF is a P-gp/BCRP substrate; labeling warns that P-gp inducers can decrease TAF exposure and that boosters/inhibitors can increase exposure."},
    temporal:{mechanism:"Pgp_BCRP_transport_before_intracellular_activation", onset:"days", offset:"days-weeks"},
    supports:["taf_pgp_bcrp_substrate","taf_pgp_inducers_reduce_exposure","taf_prodrug_to_tenofovir_diphosphate"],
    contradicts:[],
    limitations:["Clinical significance depends on full HIV/HBV regimen, adherence, renal function, and whether TAF is used with pharmacokinetic boosters."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed HIV enrichment pending infectious-disease/pharmacy review"
  },
  "ev_lamivudine_renal_transport_label": {
    id:"ev_lamivudine_renal_transport_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Lamivudine prescribing information - renal clearance and trimethoprim exposure increase",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=lamivudine%20trimethoprim%20renal%20clearance",
    studyDesign:"regulatory_label", n:null, phenotypes:["SLC22A2","MATE1"],
    quantifiedEffects:{note:"Lamivudine is primarily renally eliminated unchanged; labeling describes increased lamivudine exposure with trimethoprim/sulfamethoxazole."},
    temporal:{mechanism:"renal_tubular_clearance", onset:"days", offset:"days"},
    supports:["lamivudine_renal_clearance","lamivudine_trimethoprim_exposure_increase"],
    contradicts:[],
    limitations:["Usually manageable at standard doses; renal impairment and high-dose TMP-SMX make the signal more important."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed renal transporter enrichment pending infectious-disease/pharmacy review"
  },
  "ev_flucytosine_amphotericin_label": {
    id:"ev_flucytosine_amphotericin_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Flucytosine prescribing information - renal clearance, concentration toxicity, and amphotericin nephrotoxicity",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=flucytosine%20amphotericin%20renal%20toxicity",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Flucytosine is renally cleared and toxicity is concentration dependent; amphotericin-related renal impairment can increase flucytosine levels."},
    temporal:{mechanism:"renal_clearance_reduction_after_nephrotoxicity", onset:"days", offset:"days-weeks"},
    supports:["flucytosine_renal_clearance","flucytosine_concentration_dependent_toxicity","amphotericin_can_raise_flucytosine_by_nephrotoxicity"],
    contradicts:[],
    limitations:["Therapeutic-drug monitoring and renal adjustment supersede categorical pair scoring."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antifungal enrichment pending infectious-disease/pharmacy review"
  },
  "ev_olaparib_cyp3a_label": {
    id:"ev_olaparib_cyp3a_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Olaparib prescribing information - strong/moderate CYP3A inhibitors and inducers",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=olaparib%20CYP3A%20rifampin%20itraconazole",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP3A4"],
    quantifiedEffects:{note:"Olaparib labeling recommends avoiding strong/moderate CYP3A inhibitors or reducing dose, and avoiding strong/moderate CYP3A inducers because exposure can change substantially."},
    temporal:{mechanism:"CYP3A4_parent_clearance", onset:"days", offset:"days-weeks"},
    supports:["olaparib_cyp3a_substrate","olaparib_cyp3a_inhibitor_dose_reduction","olaparib_avoid_cyp3a_inducers"],
    contradicts:[],
    limitations:["Dose modification depends on formulation, cancer indication, renal/hepatic function, myelosuppression, and alternative anti-infective availability."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed PARP enrichment pending oncology/pharmacy review"
  },
  "ev_rucaparib_cyp_substrate_label": {
    id:"ev_rucaparib_cyp_substrate_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Rucaparib prescribing information - inhibition of CYP1A2, CYP2C9, CYP2C19, and CYP3A substrates",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=rucaparib%20CYP1A2%20CYP2C9%20warfarin",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP1A2","CYP2C9","CYP2C19","CYP3A4"],
    quantifiedEffects:{note:"Rucaparib labeling describes increased exposure of CYP1A2, CYP2C9, CYP2C19, and CYP3A substrates and recommends dose adjustment/monitoring for sensitive substrates."},
    temporal:{mechanism:"multi_CYP_inhibition_by_PARPinhibitor", onset:"days", offset:"days"},
    supports:["rucaparib_inhibits_cyp1a2","rucaparib_inhibits_cyp2c9","rucaparib_sensitive_substrate_monitoring"],
    contradicts:[],
    limitations:["Victim-specific magnitude varies; narrow-index substrates such as warfarin require closer monitoring."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed PARP enrichment pending oncology/pharmacy review"
  },
  "ev_parp_transporter_myelosuppression_label": {
    id:"ev_parp_transporter_myelosuppression_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"PARP inhibitor prescribing information - transporter exposure and myelosuppression context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=talazoparib%20niraparib%20P-gp%20BCRP%20myelosuppression",
    studyDesign:"regulatory_label", n:null, phenotypes:["ABCB1","ABCG2"],
    quantifiedEffects:{note:"Talazoparib is a P-gp/BCRP substrate with dose-modification context for inhibitors; niraparib has less CYP metabolism but prominent myelosuppression and hypertension monitoring."},
    temporal:{mechanism:"Pgp_BCRP_transport_and_class_myelosuppression", onset:"days-weeks", offset:"days-weeks"},
    supports:["talazoparib_pgp_bcrp_substrate","niraparib_low_cyp_burden","parp_myelosuppression_monitoring"],
    contradicts:[],
    limitations:["CBC reserve, renal function, cancer regimen, and prior platinum therapy modify clinical risk."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed PARP enrichment pending oncology/pharmacy review"
  },
  "ev_romidepsin_cyp3a_qt_warfarin_label": {
    id:"ev_romidepsin_cyp3a_qt_warfarin_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Romidepsin prescribing information - CYP3A metabolism, warfarin PT/INR, and ECG monitoring",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=romidepsin%20warfarin%20CYP3A%20QT",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP3A4"],
    quantifiedEffects:{note:"Romidepsin is mainly metabolized by CYP3A4, labeling advises caution with strong CYP3A inhibitors/inducers, notes PT/INR prolongation with warfarin derivatives, and includes ECG/electrolyte monitoring context."},
    temporal:{mechanism:"CYP3A4_clearance_anticoagulation_and_ECG_risk", onset:"days", offset:"days"},
    supports:["romidepsin_cyp3a_substrate","romidepsin_warfarin_inr_monitoring","romidepsin_ecg_monitoring"],
    contradicts:[],
    limitations:["QT signal is multifactorial; potassium/magnesium, cardiac disease, antiemetics, infection, and oncology dosing schedule matter."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed HDAC enrichment pending oncology/pharmacy review"
  },
  "ev_abiraterone_cyp2d6_cyp2c8_label": {
    id:"ev_abiraterone_cyp2d6_cyp2c8_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Abiraterone prescribing information - CYP2D6/CYP2C8 inhibition and mineralocorticoid toxicity",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=abiraterone%20CYP2D6%20CYP2C8%20metoprolol",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2D6","CYP2C8"],
    quantifiedEffects:{note:"Abiraterone inhibits CYP2D6 and CYP2C8 and labeling emphasizes hypertension, hypokalemia, fluid retention, and hepatic monitoring."},
    temporal:{mechanism:"CYP2D6_CYP2C8_inhibition_and_mineralocorticoid_excess", onset:"days-weeks", offset:"days-weeks"},
    supports:["abiraterone_inhibits_cyp2d6","abiraterone_inhibits_cyp2c8","abiraterone_hypokalemia_hypertension_monitoring"],
    contradicts:[],
    limitations:["Prednisone coadministration, cardiac status, potassium, liver function, and oncology indication modify risk."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed oncology endocrine enrichment pending oncology/pharmacy review"
  },
  "ev_clorazepate_nordiazepam_label": {
    id:"ev_clorazepate_nordiazepam_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Clorazepate prescribing information - prodrug conversion to long-lived nordiazepam",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=clorazepate%20nordiazepam",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP2C19","CYP3A4"],
    quantifiedEffects:{note:"Clorazepate is decarboxylated to nordiazepam, a long-lived active benzodiazepine metabolite; sedation/falls depend on the active metabolite rather than parent alone."},
    temporal:{mechanism:"acid_activation_to_nordiazepam_and_oxidative_clearance", onset:"same_day", offset:"days-weeks"},
    supports:["clorazepate_to_nordiazepam","nordiazepam_long_lived_active_metabolite","clorazepate_active_metabolite_sedation"],
    contradicts:[],
    limitations:["Older age, liver disease, alcohol/CNS depressants, and benzodiazepine tolerance often matter more than a single CYP route."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed prodrug enrichment pending psychiatry/pharmacy review"
  },
  "ev_midodrine_desglymidodrine_label": {
    id:"ev_midodrine_desglymidodrine_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Midodrine prescribing information - active desglymidodrine pressor metabolite",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=midodrine%20desglymidodrine%20monoamine%20oxidase",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Midodrine is a prodrug to desglymidodrine, an alpha-1 agonist; labeling emphasizes supine hypertension and caution with vasoconstrictors/pressor agents."},
    temporal:{mechanism:"esterase_activation_to_alpha1_agonist", onset:"hours", offset:"same_day"},
    supports:["midodrine_to_desglymidodrine","midodrine_supine_hypertension","midodrine_additive_pressor_risk"],
    contradicts:[],
    limitations:["Dose timing, supine BP, autonomic failure severity, renal function, and specialist indication determine management."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed autonomic/prodrug enrichment pending cardiology/neurology/pharmacy review"
  },
  "ev_droxidopa_norepinephrine_label": {
    id:"ev_droxidopa_norepinephrine_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Droxidopa prescribing information - conversion to norepinephrine and MAOI/pressor risk",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=droxidopa%20norepinephrine%20monoamine%20oxidase",
    studyDesign:"regulatory_label", n:null, phenotypes:["COMT","MAO-A","MAO-B"],
    quantifiedEffects:{note:"Droxidopa is converted to norepinephrine; labeling emphasizes supine hypertension and cautions with medicines that increase blood pressure or affect catecholamine metabolism."},
    temporal:{mechanism:"DOPA_decarboxylase_activation_to_norepinephrine", onset:"hours", offset:"same_day"},
    supports:["droxidopa_to_norepinephrine","droxidopa_supine_hypertension","droxidopa_maoi_pressor_risk"],
    contradicts:[],
    limitations:["Parkinson/autonomic failure context, carbidopa exposure, baseline BP, renal function, and timing relative to sleep are key."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed autonomic/prodrug enrichment pending neurology/pharmacy review"
  },
  "ev_nitazoxanide_tizoxanide_label": {
    id:"ev_nitazoxanide_tizoxanide_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Nitazoxanide prescribing information - rapid conversion to highly protein-bound tizoxanide",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=nitazoxanide%20tizoxanide%20warfarin",
    studyDesign:"regulatory_label", n:null, phenotypes:["UGT"],
    quantifiedEffects:{note:"Nitazoxanide is rapidly hydrolyzed to active tizoxanide, then glucuronidated; tizoxanide is highly protein bound, so labels caution with other highly protein-bound drugs with narrow therapeutic indices."},
    temporal:{mechanism:"esterase_activation_to_tizoxanide_and_glucuronidation", onset:"same_day", offset:"same_day"},
    supports:["nitazoxanide_to_tizoxanide","tizoxanide_high_protein_binding","nitazoxanide_low_cyp_burden"],
    contradicts:[],
    limitations:["Warfarin interaction is theoretical/precautionary rather than a strong quantified clinical PK signal."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antiparasitic prodrug enrichment pending infectious-disease/pharmacy review"
  },
  "ev_dipyridamole_antiplatelet_label": {
    id:"ev_dipyridamole_antiplatelet_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Dipyridamole prescribing information - antiplatelet effect and additive bleeding context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=dipyridamole%20aspirin%20warfarin%20bleeding",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Dipyridamole has antiplatelet/vasodilator effects and is used in aspirin-containing combinations; additive bleeding or hypotension context matters with other antithrombotics."},
    temporal:{mechanism:"platelet_function_inhibition_and_vasodilation", onset:"same_day", offset:"days"},
    supports:["dipyridamole_antiplatelet_effect","dipyridamole_aspirin_combination_context","dipyridamole_bleeding_context"],
    contradicts:[],
    limitations:["Aspirin/dipyridamole co-use is often intentional; stroke indication and bleed risk determine net benefit."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antiplatelet enrichment pending cardiology/neurology/pharmacy review"
  },
  "ev_artemether_lumefantrine_cyp3a_qt_label": {
    id:"ev_artemether_lumefantrine_cyp3a_qt_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Artemether/lumefantrine prescribing information - CYP3A modifiers, food, and QT context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=artemether%20lumefantrine%20rifampin%20ketoconazole%20QT",
    studyDesign:"regulatory_label", n:null, phenotypes:["CYP3A4"],
    quantifiedEffects:{note:"Artemether/lumefantrine labeling warns that CYP3A inducers can reduce exposure and describes QT-prolongation context plus food-dependent absorption."},
    temporal:{mechanism:"CYP3A4_substrate_exposure_and_QT_context", onset:"same_day_to_days", offset:"days-weeks"},
    supports:["artemether_lumefantrine_cyp3a_substrate","artemether_lumefantrine_rifampin_avoid","artemether_lumefantrine_qt_context","artemether_lumefantrine_take_with_food"],
    contradicts:[],
    limitations:["Malaria severity, vomiting, resistance geography, pregnancy, and species determine actual regimen choice."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed antimalarial enrichment pending infectious-disease/travel-medicine pharmacy review"
  },
  "ev_argatroban_bleeding_label": {
    id:"ev_argatroban_bleeding_label", public:true, type:EVIDENCE_TIER.FDA_LABEL,
    title:"Argatroban prescribing information - additive bleeding and warfarin transition INR context",
    year:2026, source:"FDA / DailyMed", journal:null, pmid:null, doi:null,
    url:"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=argatroban%20warfarin%20aspirin%20clopidogrel%20bleeding",
    studyDesign:"regulatory_label", n:null, phenotypes:[],
    quantifiedEffects:{note:"Argatroban labeling emphasizes bleeding risk with antiplatelet/anticoagulant coadministration and provides specific guidance for transition to warfarin because argatroban prolongs PT/INR."},
    temporal:{mechanism:"direct_thrombin_inhibition_and_INR_assay_effect", onset:"same_day", offset:"hours"},
    supports:["argatroban_bleeding_with_antithrombotics","argatroban_warfarin_transition_inr_interference","argatroban_hepatic_clearance"],
    contradicts:[],
    limitations:["HIT/ACS protocols may intentionally combine or transition therapy; dose, aPTT, hepatic function, platelet count, and procedural timing determine management."],
    verified:false, reviewRequired:true, verifyNote:"Label-backed anticoagulation enrichment pending cardiology/hematology/pharmacy review"
  },

  "ev_icu_sepsis_shock_workflow": {
    id:"ev_icu_sepsis_shock_workflow", public:true, type:EVIDENCE_TIER.GUIDELINE,
    title:"ICU/sepsis/shock medication workflow coverage: resuscitation fluids, vasoactives, sedation, paralysis, broad-spectrum antibiotics, and stress-dose steroids",
    year:2026, source:"SCCM Surviving Sepsis Campaign / PADIS / NMBA guidance / FDA label synthesis", journal:"Guideline and label synthesis", pmid:null, doi:null,
    url:"https://www.sccm.org/Clinical-Resources/Guidelines/Guidelines/Surviving-Sepsis-Guidelines-2021",
    studyDesign:"guideline_label_synthesis", n:null, phenotypes:[],
    quantifiedEffects:{note:"Sepsis/shock workflows emphasize early antimicrobials/source control, balanced crystalloid resuscitation, norepinephrine-first vasopressor support with vasopressin/epinephrine/dobutamine context, corticosteroids in vasopressor-refractory shock, non-benzodiazepine ICU sedation such as propofol or dexmedetomidine, and protocolized neuromuscular blockade only with adequate sedation/monitoring."},
    temporal:{mechanism:"ICU_sepsis_shock_workflow", onset:"minutes_to_hours", offset:"hours_to_days"},
    supports:["sepsis_norepinephrine_first_line","sepsis_vasopressin_epinephrine_dobutamine_context","sepsis_balanced_crystalloid_resuscitation","icu_nonbenzodiazepine_sedation","icu_neuromuscular_blockade_monitoring","sepsis_stress_dose_hydrocortisone_context"],
    contradicts:[],
    limitations:["This is a workflow coverage synthesis, not a patient-specific sepsis protocol. Local antibiograms, infection source, renal/hepatic function, hemodynamics, ventilation strategy, and ICU protocols govern exact use."],
    verified:false, reviewRequired:true, verifyNote:"ICU/sepsis enrichment batch synthesized from guideline/label sources; pending intensivist/pharmacist review"
  },
  "ev_stroke_neurocritical_workflow": {
    id:"ev_stroke_neurocritical_workflow", public:true, type:EVIDENCE_TIER.GUIDELINE,
    title:"Stroke/thrombolysis/neurocritical medication workflow coverage: fibrinolysis, anticoagulant reversal, hemostasis support, seizure loading, and osmotherapy",
    year:2026, source:"AHA/ASA stroke and ICH guidance / Neurocritical Care Society cerebral edema guidance / FDA label synthesis", journal:"Guideline and label synthesis", pmid:null, doi:null,
    url:"https://www.heart.org/en/professional/quality-improvement/stroke",
    studyDesign:"guideline_label_synthesis", n:null, phenotypes:[],
    quantifiedEffects:{note:"Acute stroke and neurocritical workflows require thrombolysis eligibility checks, anticoagulant and antiplatelet bleeding context, urgent reversal options for warfarin/dabigatran/factor Xa inhibitors, sodium/osmolality monitoring for cerebral edema therapy, and seizure-loading choices that avoid parent-drug-only metabolism assumptions."},
    temporal:{mechanism:"stroke_neurocritical_medication_workflow", onset:"minutes_to_hours", offset:"hours_to_days"},
    supports:["acute_stroke_thrombolysis_anticoagulant_screening","ICH_anticoagulant_reversal_workflow","neurocritical_cerebral_edema_osmotherapy_monitoring","desmopressin_hyponatremia_context","fosphenytoin_to_phenytoin_prodrug_context"],
    contradicts:[],
    limitations:["This is a medication coverage synthesis, not an acute stroke protocol. Exact decisions depend on time-last-known-well, imaging, labs, renal function, anticoagulant timing/levels, local stroke-team criteria, and neurocritical care protocols."],
    verified:false, reviewRequired:true, verifyNote:"Stroke/neurocritical enrichment batch synthesized from guideline/label sources; pending neurology/neurocritical-care/pharmacy review"
  },
  "ev_dialysis_advanced_ckd_workflow": {
    id:"ev_dialysis_advanced_ckd_workflow", public:true, type:EVIDENCE_TIER.GUIDELINE,
    title:"Dialysis/advanced CKD medication workflow coverage: binders, potassium management, CKD-MBD, anemia support, renal clearance, and narrow-index monitoring",
    year:2026, source:"KDIGO CKD/CKD-MBD/anemia guidance / FDA label synthesis", journal:"Guideline and label synthesis", pmid:null, doi:null,
    url:"https://kdigo.org/guidelines/",
    studyDesign:"guideline_label_synthesis", n:null, phenotypes:[],
    quantifiedEffects:{note:"Advanced CKD and dialysis workflows often hinge on renal clearance and non-CYP mechanisms: phosphate and potassium binders reducing oral drug absorption, sodium/calcium load, hyperkalemia management while preserving RAAS therapy, CKD-mineral bone calcium/phosphate/PTH balancing, ESA plus iron response, and narrow-index drug monitoring for digoxin, lithium, warfarin, tacrolimus, and antiseizure medicines."},
    temporal:{mechanism:"dialysis_advanced_CKD_medication_workflow", onset:"hours_to_weeks", offset:"hours_to_weeks"},
    supports:["dialysis_phosphate_binder_absorption_interactions","potassium_binder_oral_drug_separation","CKD_MBD_calcium_phosphate_PTH_monitoring","CKD_anemia_ESA_iron_support","advanced_CKD_narrow_index_TDM_context"],
    contradicts:[],
    limitations:["This is a medication coverage synthesis, not a dialysis prescription or CKD protocol. Residual kidney function, dialysis modality/schedule, dialyzability, potassium/phosphate/calcium/PTH values, volume status, transplant status, and local nephrology protocols govern exact decisions."],
    verified:false, reviewRequired:true, verifyNote:"Dialysis/advanced CKD enrichment batch synthesized from guideline/label sources; pending nephrology/pharmacy review"
  },
  "ev_pregnancy_obstetric_workflow": {
    id:"ev_pregnancy_obstetric_workflow", public:true, type:EVIDENCE_TIER.GUIDELINE,
    title:"Pregnancy and obstetric emergency medication workflow coverage: teratogenic exposure flags, hypertensive emergency, magnesium, uterotonics, hemorrhage, Rh prophylaxis, and vaccine timing",
    year:2026, source:"ACOG/SMFM/CDC-FDA label synthesis", journal:"Guideline and label synthesis", pmid:null, doi:null,
    url:"https://www.acog.org/clinical",
    studyDesign:"guideline_label_synthesis", n:null, phenotypes:[],
    quantifiedEffects:{note:"Pregnancy medication review must surface both emergency obstetric therapies and exposure warnings: magnesium sulfate, labetalol/hydralazine/nifedipine, uterotonics, tranexamic acid, antenatal corticosteroids, Rh(D) immune globulin, live-vaccine timing, and high-risk teratogens/fetotoxins including retinoids, methotrexate, mycophenolate, warfarin, valproate, ACE inhibitors, ARBs, and leflunomide/teriflunomide."},
    temporal:{mechanism:"pregnancy_obstetric_medication_workflow", onset:"minutes_to_months", offset:"hours_to_years"},
    supports:["pregnancy_context_teratogenicity_screening","obstetric_hemorrhage_uterotonic_Txa_workflow","preeclampsia_magnesium_antihypertensive_workflow","RhD_immune_globulin_vaccine_timing","retinoid_and_leflunomide_persistent_pregnancy_risk"],
    contradicts:[],
    limitations:["This is a medication coverage synthesis, not obstetric management advice. Gestational age, indication, fetal/maternal status, exposure timing, dose, local protocols, and maternal-fetal medicine consultation determine actual management."],
    verified:false, reviewRequired:true, verifyNote:"Pregnancy/obstetric enrichment batch synthesized from guideline/label sources; pending OB/MFM/pharmacy review"
  },
  "ev_transplant_perioperative_workflow": {
    id:"ev_transplant_perioperative_workflow", public:true, type:EVIDENCE_TIER.GUIDELINE,
    title:"Transplant perioperative and immunosuppression medication workflow coverage: induction biologics, calcineurin/mTOR TDM, infection prophylaxis, CMV therapy, live vaccines, and nephrotoxicity",
    year:2026, source:"KDIGO transplant recipient guidance / AST infectious disease interaction guidance / FDA label synthesis", journal:"Guideline and label synthesis", pmid:null, doi:null,
    url:"https://kdigo.org/guidelines/transplant-recipient/",
    studyDesign:"guideline_label_synthesis", n:null, phenotypes:[],
    quantifiedEffects:{note:"Solid-organ transplant medication review requires trough-guided calcineurin/mTOR inhibitor management, CYP3A/P-gp/OATP interaction checks with azoles, macrolides, boosters, rifamycins, grapefruit, statins, and antivirals; induction/maintenance immunosuppression infection and vaccine context; CMV prophylaxis/treatment marrow and renal toxicity; PJP prophylaxis alternatives; and perioperative nephrotoxin/electrolyte monitoring."},
    temporal:{mechanism:"transplant_perioperative_immunosuppression_workflow", onset:"hours_to_months", offset:"days_to_months"},
    supports:["transplant_CNI_mTOR_TDM_interactions","transplant_azole_macrolide_booster_CYP3A_risk","transplant_live_vaccine_avoidance","transplant_CMV_PJP_prophylaxis_toxicity","transplant_nephrotoxin_electrolyte_monitoring"],
    contradicts:[],
    limitations:["This is a medication coverage synthesis, not a transplant protocol. Organ type, time from transplant, rejection risk, infection risk, trough targets, renal/hepatic function, pharmacogenetics, and transplant-center protocols determine actual management."],
    verified:false, reviewRequired:true, verifyNote:"Transplant enrichment batch synthesized from guideline/label sources; pending transplant medicine/ID/pharmacy review"
  },
  "ev_cabg_perioperative_medications": {
    id:"ev_cabg_perioperative_medications", public:true, type:EVIDENCE_TIER.GUIDELINE,
    title:"CABG/cardiac surgery perioperative medication coverage: antithrombotics, hemostasis, vasoactives, inotropes, and secondary prevention",
    year:2026, source:"ACC/AHA/STS/AATS/FDA label synthesis", journal:"Guideline and label synthesis", pmid:null, doi:null,
    url:"https://www.jacc.org/doi/10.1016/j.jacc.2021.09.006",
    studyDesign:"guideline_label_synthesis", n:null, phenotypes:[],
    quantifiedEffects:{note:"CABG care commonly involves aspirin/P2Y12 and statin/beta-blocker secondary prevention; intraoperative heparin/protamine anticoagulation management; antifibrinolytics such as tranexamic acid or aminocaproic acid for blood conservation; and ICU vasoactive/inotropic support such as norepinephrine, epinephrine, dopamine, dobutamine, milrinone, phenylephrine, and vasopressin."},
    temporal:{mechanism:"perioperative_CABG_medication_context", onset:"minutes_to_days", offset:"minutes_to_weeks"},
    supports:["cabg_antiplatelet_secondary_prevention","cabg_heparin_protamine_reversal","cabg_antifibrinolytic_blood_conservation","cabg_vasoactive_inotrope_support","cabg_electrolyte_and_bp_support"],
    contradicts:[],
    limitations:["This is a coverage and mechanism synthesis, not a patient-specific cardiac surgery protocol. Local surgical, anesthesia, ICU, renal-function, bleeding, and hemodynamic protocols govern exact use."],
    verified:false, reviewRequired:true, verifyNote:"CABG enrichment batch synthesized from guideline/label sources; pending cardiac anesthesiology/cardiology/pharmacy review"
  },
  "ev_cyp3a7_etonogestrel_implant_2019": {
    id:"ev_cyp3a7_etonogestrel_implant_2019", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"Influence of genetic variants on steady-state etonogestrel concentrations among contraceptive implant users",
    year:2019, source:"Etonogestrel implant candidate-gene study", journal:"Obstetrics and Gynecology", pmid:"30870275", doi:"10.1097/AOG.0000000000003189",
    url:"https://pubmed.ncbi.nlm.nih.gov/30870275/",
    studyDesign:"candidate gene pharmacokinetic association study", n:350,
    phenotypes:[GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"CYP3A7*1C carrier status was associated with lower etonogestrel concentrations in the candidate-gene model, but BMI and implant duration were stronger clinical factors and the genetic signal requires replication."},
    temporal:{mechanism:"persistent CYP3A7 expression and progestin clearance", onset:"weeks_to_months", offset:"months"},
    supports:["CYP3A7_1C_etonogestrel_lower_concentration_context","etonogestrel_CYP3A7_review_flag"],
    contradicts:["CYP3A7_is_not_a_standalone_contraceptive_failure_rule"],
    limitations:["Candidate-gene association; not a prescribing guideline. Contraceptive decisions depend on formulation, adherence, implant age, BMI, CYP3A inducers, and reproductive-health clinician review."],
    verified:false, reviewRequired:true, verifyNote:"CYP3A7/etonogestrel enrichment pending reproductive pharmacology review"
  },
  "ev_cyp3a7_1c_dheas_2005": {
    id:"ev_cyp3a7_1c_dheas_2005", public:true, type:EVIDENCE_TIER.CLINICAL_PK,
    title:"A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels",
    year:2005, source:"CYP3A7*1C steroid-hormone association study", journal:"Journal of Clinical Endocrinology and Metabolism", pmid:"15985487", doi:"10.1210/jc.2005-0307",
    url:"https://pubmed.ncbi.nlm.nih.gov/15985487/",
    studyDesign:"population-based steroid hormone association study", n:553,
    phenotypes:[GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"CYP3A7*1C carriers showed persistent adult CYP3A7 activity and substantially lower DHEA-S/estrone context, supporting CYP3A7 as a steroid/endocrine metabolism modifier."},
    temporal:{mechanism:"persistent fetal CYP3A7 expression in adult steroid metabolism", onset:"lifelong", offset:"lifelong"},
    supports:["CYP3A7_1C_persistent_expression_context","CYP3A7_DHEAS_steroid_metabolism_context"],
    contradicts:["CYP3A7_is_not_a_general_adult_CYP3A_dose_rule"],
    limitations:["Endogenous hormone association; does not by itself define medication dosing."],
    verified:false, reviewRequired:true, verifyNote:"CYP3A7 endocrine context pending endocrinology/pharmacology review"
  },
  "ev_cyp3a7_neonatal_review_2019": {
    id:"ev_cyp3a7_neonatal_review_2019", public:true, type:EVIDENCE_TIER.REVIEW,
    title:"Neonatal cytochrome P450 CYP3A7: a comprehensive review of its role in development, disease, and xenobiotic metabolism",
    year:2019, source:"CYP3A7 review", journal:"Archives of Biochemistry and Biophysics", pmid:"31445893", doi:"10.1016/j.abb.2019.108078",
    url:"https://pubmed.ncbi.nlm.nih.gov/31445893/",
    studyDesign:"review", n:null,
    phenotypes:[GENOTYPE_PHENOTYPE.NM, GENOTYPE_PHENOTYPE.UM],
    quantifiedEffects:{note:"Review summarizes CYP3A7 fetal/neonatal expression, DHEA-S and retinoic-acid biology, adult persistence via CYP3A7*1C, and limited xenobiotic/drug-metabolism evidence."},
    temporal:{mechanism:"fetal/neonatal CYP3A biology and adult persistence"},
    supports:["CYP3A7_developmental_expression_context","CYP3A7_xenobiotic_review_context"],
    contradicts:["CYP3A7_has_limited_routine_adult_prescribing_actionability"],
    limitations:["Review-level evidence; most adult CYP3A drug interactions remain CYP3A4/CYP3A5/P-gp driven."],
    verified:false, reviewRequired:true, verifyNote:"CYP3A7 review context pending pharmacology review"
  },
};

// ── Evidence Ingestion Pipeline (Phase 1 Infrastructure) ──
//
// Architecture for AI-assisted + human-reviewed study ingestion.
//
// CRITICAL WARNING: AI hallucinations in pharmacology are dangerous.
// DO NOT auto-publish extracted evidence without pharmacist/physician review.
//
// Pipeline flow:
//   PubMed / FDA / CPIC search
//   → AI extraction → normalized draft (createStudyDraft)
//   → INGESTION_QUEUE (awaiting review)
//   → human review & approval
//   → merge into STUDY_DB
//
// In a future version, this queue will be backed by a server-side review UI.
// For now it persists in memory for within-session use.

const INGESTION_QUEUE = [];   // drafts awaiting review

// createStudyDraft — create a structured evidence draft from raw inputs
// Called by future AI extraction pipeline or manual entry
function createStudyDraft({pmid, doi, title, year, source, journal, type, studyDesign, n,
                           phenotypes, quantifiedEffects, temporal, supports, contradicts, limitations}) {
  const id = `draft_${Date.now()}_${Math.random().toString(36).slice(2,7)}`;
  const draft = {
    id, _status:'pending_review',
    type: type || EVIDENCE_TIER.CLINICAL_PK,
    title: title || '',
    year: year || null,
    source: source || '',
    journal: journal || '',
    pmid: pmid || null,
    doi: doi || null,
    studyDesign: studyDesign || '',
    n: n || null,
    phenotypes: phenotypes || [],
    quantifiedEffects: quantifiedEffects || {},
    temporal: temporal || {},
    supports: supports || [],
    contradicts: contradicts || [],
    limitations: limitations || [],
    verified: false,
    verifyNote:'Auto-extracted draft — requires human pharmacist/physician review before use',
    _createdAt: new Date().toISOString(),
  };
  INGESTION_QUEUE.push(draft);
  return draft;
}

// reviewStudyDraft — approve a draft and merge into runtime STUDY_DB
// In production this would be a server-side operation with audit logging.
// For now it merges into the session-level STUDY_DB and marks as verified.
function reviewStudyDraft(draftId, reviewerNotes, approve) {
  const idx = INGESTION_QUEUE.findIndex(d => d.id === draftId);
  if (idx === -1) return { error: 'Draft not found' };
  const draft = INGESTION_QUEUE[idx];
  if (!approve) {
    draft._status = 'rejected';
    draft._reviewerNotes = reviewerNotes;
    return { status: 'rejected' };
  }
  const published = { ...draft, _status:'approved', verified:true,
    verifyNote: reviewerNotes || 'Human reviewed', _approvedAt: new Date().toISOString() };
  delete published._createdAt;
  STUDY_DB[published.id] = published;
  INGESTION_QUEUE.splice(idx, 1);
  invalidateGraph();  // graph must rebuild to pick up new evidence
  return { status:'published', id:published.id };
}

// getIngestionQueueStatus — returns summary for display
function getIngestionQueueStatus() {
  return {
    pending: INGESTION_QUEUE.filter(d => d._status === 'pending_review').length,
    rejected: INGESTION_QUEUE.filter(d => d._status === 'rejected').length,
    total: INGESTION_QUEUE.length,
  };
}

// Usage: getTemporalProfile(actorId) → { onset, offset, mechanism, reversible }
